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General introduction 

Chapter 1 
HistolT and classification of influenza viruses 
Influenza viruses are the causative agents of outbreaks of acute respiratory 
disease, known as influenza or ,sh011Iy, 'flu' which has afflicted humans 
since ancient times, Although the earliest report of an outbreak of 
respiratory disease by Hippocrates dates back to 412 BC, the first recorded 
epidemic with characteristics of influenza occured in 1173-1174 while the 
first recognized influenza pandemic occured in 158062,123, In 1933, the first 
influenza virus, later classified as influenza virus A, was isolated from a 
human followed in 1940 and 1947 with influenza virus Band C, 
respecti velyl7 ,94,155,'62, 
Influenza viruses are classified as members of the family Ortholllyxovil'idae 
and are divided into two genera: influenza virus A and B, and influenza 
virus C, Influenza virus A, Band C can be distinguished on the basis of 
antigenic differences between their nucleoprotein (NP) and matrix (M) 
protein, Influenza A viruses are further divided into subtypes based on 
antigenic differences in their surface glycoproteins haemagglutinin (HA) 
and neuraminidase (NA), At present, 15 different HA (designated HI to 
HIS) and 9 different NA (designated Nl to N9) can be distinguished, This 
introduction mainly focusses on influenza A viruses, 
Virus morphology 
Influenza A viruses, in general, have a spherical morphology and are 80 to 
120 nm in diameter"''', The lipid membrane, or envelope, of influenza 
viruses is derived from the host cell in which the virus replicated70, Within 
the envelope are two membrane-spanning proteins, the glycoproteins HA 
and NA, which project outward and appear as rod-shaped and mushl'oom-
shaped spikes, respectively" (Figure I), Approximately 500 HA and 100 
NA spikes cover the envelope with the HA molecules anchored in the 
membrane as trimers and the NA molecules as tetramersI07 ,'71"",I8],185, A 
third integral membrane protein, the matrix protein M2, is found in only a 
few copies per virus84,192, Underneath the lipid membrane a shell of matrix 
MI protein, the most abundant protein, can be found'4,]9,110,114,'46, Inside the 
virus, ribonucleoprotein (RNP) complexes are found consisting of viral 
RNA segments, NP and the polymerase proteins PB2, PB 1 and P A which 
appear as rods",55,76,I2', The NP is relatively abundant in the virus while the 
polymerase proteins are present in 30 to 60 copies per virus66,,,, Finally, the 
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nonstructural NS2 protein is found within the virus. Approximately 130 to 
200 molecules are present that associate with the MI protein I28.I'9. 
Figure 1. Schematic representation of influenza A vims, 
(Reproduced with pennission fi'om Fields Virology, Third Edition, 1996, Lippincott 
Williams and Wilkins, Philadelphia) 
Genome organization and protein function 
The genome of influenza A viruses is composed of eight separate single-
stranded RNA molecules with negative polarity which together encode a 
total of 10 proteins (Table I). The RNA strands vary in length between 2341 
and 890 nucleotides and are numbered I to 8 starting from the longest 
strand. Except for strand 7 and 8, each RNA strand encodes only one 
protein. RNA strand 1 encodes the PB2 polymerase protein which functions 
in the initiation of transcription by binding 5' cap structures and subsequent 
cleavage from host cell mRNAs which are then used as primers for viral 
mRNA synthesisI2.16.150,l6S. Strand 2 encodes the PBI polymerase protein 
which is responsible for elongation of primed nascent viral mRNA and also 
for complementary and viral RNA synthesis in the process of 
replicationI6.I35.16'. Strand 3 encodes the PA polymerase protein whose role 
in transcription and replication is not completely clear yet, but is at least 
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required for viral RNA synthesis108. The envelope glycoprotein HA is 
encoded by strand 4. HA is responsible both for binding of the virus to the 
host cell receptors and, after endocytosis, for fusion of the viral membrane 
with the membrane of the endosomel8l • HA undergoes extensive post-
translational processing with the final step being its cleavage into HA I and 
HA2 which remain connected by disulfide linkages. Cleavage is required for 
the virus to be infectious". RNA strand 5 encodes NP which encapsidates 
viral RNA to form RNP complexes to which the three polymerase proteins 
(PB2, PB I and P A) associate. NP is believed to playa role in the switching 
of viral RNA polymerase activity from mRNA synthesis to complementary 
and viral RNA synthesis. The second envelope glycoprotein, NA, is 
encoded by strand 6. NA functions as a receptor destroying enzyme by 
cleavage of terminal sialic acid residues from the receptor and thereby 
facilitates the release and spread of progeny viruses away from the infected 
ceW4. RNA strand 7 encodes two matrix proteins, MI and M2, the latter 
arising by splicing of the MI transcript6].67.83,l59. MI forms a shell 
surrounding the virus RNPs underneath the virus envelope which provides 
structure to the virus and interacts with the cytoplasmic tails of HA, NA and 
M2, and with the RNPs. M2 is anchored in the membranes as tetramers 
forming an ion channel allowing flow of ions from endosomes to the virus 
interior which is of importance in the process of replication20,6],115,118,159.1GS 
(see below). Finally, strand 8 encodes two nonstructural proteins designated 
NSI and NS2, Like M2, NS2 is a splicing product ofNSl. Both proteins are 
abundant in the infected cell but only the NS2 protein is found in progeny 
viruses where it associates with the MI proteinI28.189, NSI regulates nuclear 
export of mRNA and inhibits pre-mRNA splicingJ,9,35,9J,I24,I25. The function 
ofNS2 is at present not known. 
Replication cycle 
An influenza virus particle binds to the cells of the respiratory tract via 
interaction between the receptor-binding site of HAl and a terminal sialic 
acid residue of a cell surface receptor followed by endocytosis (receptor-
mediated endocytosis) (Figure 2). The low pH in endosomes permits the 
flow of ions from the endosomes to the virus interior through the M2 
proteins to disrupt protein-protein interactions and to free the RNPs from the 
M I protein56.95 • In addition, it triggers a conformational change in the HA 
which facilitates inseliion of the hydrophobic N-terminus of HA2 into the 
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membrane of the endosome leading to fusion between this membrane and 
the viral membrane and subsequent release of the RNPs in the cytoplasm of 
the infected cellI53.184. 
RNA segment Gene product Molecules per virus 
(Nucleotides) (Amino acids) 
1.(2341) polymerase PB2 (759) 30-60 
2.(2341) polymerase PB I (757) 30-60 
3. (2233) polymerase PA (716) 30-60 
4. (l778) haemagglutinin HA (566) 500 
5. {I 565) nucleocapsid protein NP (498) 1000 
6. (l413) neuraminidase NA (454) 100 
7. {I 027) matrix protein MI (252) 3000 
matrix protein M2 (97) 20-60 
8. (890) non structural protein NS I (230) 
non structural protein NS2 (121) 130-200 
TABLE 1. Influenza virus A gene segments and encoded proteins. 
During influenza virus infection, a dramatic switch from cellular to viral 
protein synthesis occurs"·87.151.152. The RNPs migrate to the host cell nucleus 
and their associated polymerase proteins begin primary transcription of 
mRNAs52 • The synthesis of viral mRNA requires initiation by capped host 
cell primers which are generated from host cell mRNAs by a viral cap-
dependent endonucleaseI5.77.119.12O. After primary transcription, 
complementary RNAs (cRNAs) are transcribed from all the viral RNAs 
(vRNAs) at equimolar amounts followed by selective transcription of 
cRNAs to vRNAs with the NP and NS vRNAs being the most abundant. 
Newly synthesized vRNAs then function as templates for secondary 
transcription of viral mRNAs. Since synthesis of vRNAs, mRNAs and viral 
proteins are coupled in the early phase, the NP and NS mRNAs and proteins 
are synthesized early52.147.154. NP is synthesized early because it is needed for 
cRNA and vRNA synthesis while NS I is synthesized early because it 
regulates nuclear expott of mRNA and inhibits pre-mRNA 
splicing3.9.35.93.124.125,l48. During the late phase, synthesis of vRNAs, mRNAs 
and proteins is no longer coupled. Viral proteins are synthesized at high 
rates during the late phase, especially MI and HA which are poorly 
synthesized in the early phase. Synthesis of MI is delayed since it stops 
14 
Chapter I 
transcription of vRNA into mRNA and mediates transport of vRNA 
(enclosed in RNPs) from the nucleus to the cytoplasm96"", 
endosome 
endoplasmIc reticulum .A' 
synthesis and glycosyJaUon 
of envelope proteIns 
'completion of glycosylaUon 
of envelope proteins 
Figure 2. Schematic representation of replication cycle of influenza viruses. 
(Reproduced with permission fi'om Fields Virology, Third Edition, 1996, Lippincott 
Williams and Wilkins, Philadelphia) 
Newly synthesized NP, PB2, PBI and PA, which contain karyophilic 
signals, migrate to the nucleus where new RNPs are assembled which 
associate with MI protein to facilitate transport out of the nucleus to the 
cytoplasm96, Here, they become encased in a shell of MI proteins, The 
surface glycoproteins HA and NA and the M2 protein, after passaging the 
ER and Golgi apparatus for modification and folding, are transported to the 
apical surface of cells where they are expressed at the cell surface, Progeny 
viruses are assembled at the apical surface and bud outward through the cell 
membrane 132 , Release of progeny viruses away from the infected cell is 
facilitated by NA24 , New viruses then can infect other cells or being 
transmitted to another individual. 
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Host range and interspecies transmission 
Influenza virus Band C are almost exclusively isolated from humans. 
Influenza virus C has also been isolated from pigs and, recently, influenza 
virus B has been isolated from seals"·74.113. In contrast, influenza A viruses 
infect a wide range of mammalian species including humans, pigs, horses 
and aquatic mammals". Of the HA subtypes, HI, H2 and H3 (and incidently 
H5 and H9, see below) viruses are found in humans, HI and H3 in pigs and 
H3 and H7 in horses. In contrast, all known HA subtypes are found in 
aquatic birds, most notably ducks, which are considered a natural reservoir 
of influenza A viruses from which all influenza A viruses originate58.60•177 . 
This means that influenza A viruses can cross species barriers and can be 
transmitted from one species to another, either directly, or indirectly via an 
intermediate host. 
Examples of direct transmission from the aquatic reservoir to pigs, horses, 
mink, domestic poultry and aquatic mammals which caused infections 
varying in severity from asymptomatic to major disease outbreaks have 
been described'9.lo.61.75.141.176.177. 
Transmission of influenza A viruses from pigs to humans occurs relatively 
frequently. WIJ.ile most of these transmissions do not cause disease in 
humans, exceptions have been reported"·I37·I6J.IJ9.18o. In addition, it is not 
unlikely that pigs played a role in the emergence of vil1lses causing the 
pandemics of the 20th century (see below). Pigs are supposed to play an 
important role in interspecies transmission as they can act as an intermediate 
host between the avian virus reservoir and humans72.144.178. Since they can be 
infected with influenza A viruses of avian and human origin they also may 
create avian-human reassottant viruses with pandemic potential (see below). 
Occasionally, influenza A viruses of avian origin are directly transmitted to 
humans"·193. A recent example of direct transmission from clJ.ickens to 
humans is the H5NI virus that was isolated in 1997 in Hong Kong from 
humans'I.69.1". The virus that was isolated closely resembled a H5NI virus 
that had been shown responsible for an outbreak in chicken fanus where it 
caused high mottality. Eighteen humans were shown to be infected of which 
6 died. In addition, two cases have been reported of infection of humans 
with a H9N2 virus of avian origin 116. 
The receptor specificity of HA, which differs between influenza A viruses, 
is considered to be an important determinant in host range restriction 
although a putative role of the NP has also been suggested40.133.134.I42. 
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However, also other influenza virus proteins and/or other yet unknown 
factors may playa role in host range restriction. 
Epidemics and pandemics 
Both influenza A and B viruses continuous undergo gradual changes of their 
surface glycoproteins HA and NA which is caused by the accumulation of 
point mutations, a process referred to as antigenic drift. In addition, 
influenza A viruses occasionally undergo more dramatic changes of their 
surface glycoproteins by replacing one or both for completely new ones, a 
process referred to as antigenic shift. Both processes, antigenic shift being 
the most dramatic, allow influenza viruses to evade pre-existing il11ll1unity 
in the human population. While antigenic drift is the mechanism behind 
recurrent influenza epidemics, antigenic shift has been the cause of three 
pandemics recorded the last century. 
In 1918, the 'Spanish flu', estimated to cause 40-50 million deaths 
worldwide, resulted from the introduction ofa novel influenza virus, HINI, 
in the human population. This virus most probably was transmitted from 
pigs to humans. Sequencing of parts of four gene segments of an influenza 
virus isolated from a lung sample of a soldier who died in 1918 revealed 
that this virus was genetically similar to swine influenza virusesl6O • In 1957, 
the HINI virus was replaced by a H2N2 virus (,Asian flu') which in turn 
was replaced by a H3N2 virus ('Hong Kong flu') in 1968. The viruses 
causing these pandemics, like the one of 1918, most likely originated from 
pigs. 
Since pigs are susceptible to both avian and human influenza A viruses and 
because the genome of influenza viruses is segmented, influenza virus gene 
segments may be exchanged upon dual infection of pigs with viruses of 
avian and human origin, a process referred to as genetic reassOliment. If 
pigs become infected with avian and human influenza A viruses of different 
subtypes, then genetic reassortment may create a new (reassOliant) influenza 
virus that has surface glycoproteins of avian origin against which limited or 
no immunity exists in the human population (antigenic shift). If such a virus 
is subsequently transmitted from pigs to humans and spreads in the human 
population it may initiate a pandemic. Thus, pigs have been implicated as 
'mixing vessels' for the generation of pandemic influenza A viruses 143.!"'. It 
is now generally believed that the pandemics of 1957 and 1968 resulted 
from avian-human reassortant viruses transmitted from pigs,,·14o.I?4. The 
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H2N2 influenza virus of 1957 acquired the HA, NA and PB 1 gene segment 
from an avian virus and kept the other five gene segments from the strain 
circulating in humans at that time, while in the H3N2 virus of 1968 the HA 
and PB 1 gene segments were of avian origin and the remaining six gene 
segments derived from the virus circulating in humans'! (Figure 3). 
~ ~, 
-;;;- .,.,. 
" i E m ft ;p .. • iii I;i 
HINI H2N2 ",m 
~ ~ 1Ci 
Figure 3. Origin of pandemic influenza A vil1lses. 
(Reproduced with permission from Fields Virology, Third Edition, 1996, Lippincott 
Williams and Wilkins, Philadelphia) 
In 1977, HINI viruses were re-introduced in the human population. The 
origin of this virus remains a mystery. Since this virus did not differ 
significantly from influenza A HINI viruses isolated in 1950, it most likely 
represents an escape from a laboratoryI09. Currently, both HINI and H3N2 
influenza A viruses and influenza virus B circulate in the human population. 
In contrast to pandemics, which are unpredictable, epidemics occur vhtually 
evelY year in the winter months (October to April in the northern 
hemisphere and in May to September in the southern hemisphere). 
Epidemics are less common in tropical countries. 
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Pathogenesis 
Influenza virus is transmitted from one individual to another by aerosols or 
direct contact. Infection starts in the tracheobronchial epithelium and then 
spreads; virus replication may occur throughout the entire respiratory tract 
but is usually confined to the upper respiratory tract. Infection can be 
asymptomatic or accompanied with clinical symptoms typical of influenza 
like malaise, fever, chills, headache, dizziness, myalgia, arthralgia, lassitude, 
anorexia, rhinorrhea, sneezing, cough and sore throat. Symptoms appear 
within few days and usually persist for 3-4 days, but cough, lassitude and 
malaise may persist for 1-2 weeks. The clinical outcome may vary and is 
influenced by factors including prior influenza virus infections, intrinsic 
properties of the virus and health status. With regard to the latter, influenza 
risk groups are recognized which include people aged 65 or older, diabetics, 
people with chronic hemi or lung diseases (e.g. asthma, cystic fibrosis) and 
people suffering from renal failure, infection with staphylococcus or a 
malfunction of the immune system (e.g. transplant recipients, HIV -infected 
patients). Influenza may be accompanied with complications which usually 
are respiratory (e.g. primary viral or secondary bacterial pneumonia) but 
may also involve other organ systems. Complications are more conmlon in 
risk groups and may result in death. Because influenza-associated morbidity 
and mortality are highest among people of risk groups, they are 
recommended to receive mmual vaccination against influenza. In general, 
influenza virus A and B infection cannot be distinguished from each other 
on the basis of clinical symptoms while influenza virus C infection usually 
causes less severe symptomatic illness. 
In other mammals, influenza viruses also replicate in cells lining the 
respiratory tract, causing localized infection, and symptoms of infection can 
be compared to those in humans. In contrast, most avian influenza viruses 
are non-pathogenic to birds. Exceptions are H5 and H7 viruses which can be 
highly pathogenic to domestic poultry (chickens and turkeys). Infection with 
these viruses may be systemic, involving all organ systems rather than the 
respiratory tract only, and often has a lethal outcome. In ducks, in which 
influenza viruses preferentially replicate in cells lining the intestinal tract, 
infection is usually asymptomatic175. 
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Immune responses 
Both non-specific and specific humoral and cellular immune responses are 
induced following influenza virus infectionl. Usually these responses are 
sufficient to clear infection and establish long-lived immunity against the 
infecting virus36.38.41.1 1 1.122. However, as discussed above, influenza viruses 
continuously change in the process of antigenic drift and, concomittantly, 
new virus variants emerge. While immunity against a patiicular influenza 
virus usually will protect against re-infection with the same or a closely 
related virus, it will be less protective or absent when a more distant virus is 
encountered. In other words, immunity to influenza wanes over time and 
largely depends on the extent of antigenic drift of the virus. In the case of 
antigenic shift, a new influenza virus A subtype is introduced in the human 
popUlation to which little, if any, immunity exist. This has become clear 
during influenza pandemics of the last century. The fact that hetero-subtypic 
protective immunity appears weak in humans indicates that immunity 
against influenza is primarily mediated by responses to the surface 
glycoproteins and it is generally believed that protection against influenza is 
mediated by antibodies directed against these surface glycoproteins. In 
contrast, clearance of infection is supposed to be largely mediated by 
cellular responses1.?26.1'9.156. 
During influenza virus infection, antibodies are most prominently raised 
against the HA, NA, NP and M proteins27•122 • Neutralizing antibodies against 
the HA and NA of influenza virus are associated with resistance to infection 
andlor illness, whereas antibodies to NP and M proteins are not'.6.23.32.103.157. 
Functionally, antibodies against HA are believed to prevent virus from 
attaching to cells and thus inhibit initiation of infection. Antibodies against 
NA are believed to inhibit NA enzymatic activity and to cross-link viruses 
budding from cells thereby inhibiting virus release. Following primary 
infection, local (mucosal) antibodies of the IgA, IgG and IgM isotype 
directed against HA can be detected in nasal washes5.26.105.106.1J6. Since 
secretory IgA antibodies react with the virus at the site of entry, these 
antibodies are believed to be an important first line of defence against 
infection and have been shown to confer protection against 
infection22 ,23.91.126.127. Serum antibodies of the same isotypes are also detected 
in primary infections, while IgA en IgG antibodies predominate in 
subsequent infectionsI7.19.106.188. Levels of serum antibodies correlate with 
resistance to illness23•26.103 . 
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Influenza virus-specific T helper (Th) cells are induced upon influenza virus 
infection, Th cells contribute to clear virus infection primarily by 
stimulating antibody production and proliferation of cytotoxic T 
lymphocytes (CTL) and by production of cytokines79,81,19I, It has been 
repolied that Th cells specific for NP or M proteins can stimulate B-cells 
specific for HA79,8o,m, Although a subset of CD4+ cells has been shown to 
have a cytotoxic effect on cells infected with influenza virus, adoptive 
transfer experiments in mice demonstrated that Th cells by their own are 
unable to clear virus infectionl39,I64,19I, 
CTL directed against influenza virus antigens can be isolated from 
previously infected individualsJO,68, CTL contribute to clearance of virus 
from the respiratory tract and accelerate recovery from infectionJO,97,JOo, CTL 
epitopes are less abundant when compared to Band Th cell epitopes and are 
mainly concentrated in the more conserved influenza virus proteins, like the 
Np ll ,44,99,IOI,166,190, CTL directed against conserved influenza virus A antigens 
usually are cross-reactive and will lyse cells infected with any subtype while 
CTL directed against the surface glycoproteins are largely subtype-
specific34 ,166,19o,191,195, The former have been shown to confer protection 
against heterosubtypic influenza A viruses90,145,166,I90, In addition, numerous 
experiments with vaccinated or infected mice, including adoptive transfer 
experiments, have demonstrated that CTL are capable of clearing virus 
infection and do protect against challenge infection in the absence of Band 
Th cells2,13,33,45,92,J02,16I,167,186,J87, However, despite the fact that heterosubtypic 
CTL are induced following infection, they do not confer long-lived 
immunity against influenza virus A infections in humans9', It has been 
suggested that this may be due to the limited life-span of memory CTL. The 
discrepancy with the animal studies may reflect the relatively short duration 
of these studies, i.e, the time span between vaccination and challenge 
infection, 
Non-specific immune responses induced following influenza virus infection 
include the production of cytokines, most notably interferons, and the 
activation of natural killer (NK) cells3I ,46,57,89,lo4,I29, NK cells may limit 
replication and spread of the virus, but NK cells on their own are not 
sufficient for viral clearance, Interferons are produced early in infection and 
may reduce viral spread by inducing an antiviral state in host cells and by 
activation of CTL and NK cells, thereby contributing to recovery from 
infection, 
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Vaccines and antivirals 
Influenza vaccines currently in use consist of inactivated whole or disrupted 
(split) virus or purified preparations containing the surface glycoproteins 
HA and NA (Table 2). These vaccines are trivalent, i.e. they contain 
representatives of both influenza A viruses (HINI and H3N2) and influenza 
virus B. The composition of the vaccine is reconsidered each year by the 
WHO which is advised by influenza centers all over the world which 
monitor circulating viruses. Representative viruses are selected as vaccine 
strains and propagated in the allantoic cavity of embryonated chicken eggs. 
Usually, 'high-growth' reassOliant viruses are used as vaccine strains, unless 
the selected virus itself has a high-growth phenotype. High-growth 
reassoliant viruses are obtained after dual infection of embryonated chicken 
eggs with a vaccine strain and a high growth virus (a virus adapted to 
replicate to high titers in eggs). ReassOliant viruses containing the surface 
glycoproteins HA and NA of the vaccine strain which inherited the high-
growth phenotype (by exchanging some or all of the remaining gene 
segments) of the high-growth virus are selected for vaccine production. The 
currently used vaccines usually confer protection against infection andlor 
illness and are recommended for people at risk (see above). 
Antivirals can be used prophylactically or after infection has been 
established and reduce influenza-associated illness. The antiviral 
amantadine and its analogue rimantadine are effective against all subtypes 
of influenza A viruses, but not against influenza B viruses l7o. Both agents 
inhibit virus replication by blocking the M2 ion chmmel, thereby preventing 
transport of RNPs to the nucleus and, consequently, RNA transcription and 
replication,o.53.I7J. Analogues of the neuraminidase substrate N-
acetylneuraminic acid (sialic acid) constitute a second group of antivirals. 
Two neuraminidase inhibitors, zanamivir and oseltamivir have been 
approved for human use and both drugs have been shown effective against 
both influenza virus A and 8 8,18,47,51,54.73,88,\72, Although antivirals may be 
used prophylactically or therapeutically for individuals that have not been 
vaccinated or in case vaccination was inadequate, vaccination will remain 
the major means to control influenza11 '. 
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Vaccine 
Whole virus 
(in-activated) 
Split virus 
Purified 
proteins 
MF59' 
Live attenuatedb 
Liposomes/ 
Virosomcsa 
ISCOM' 
Recombinant 
vaccinjad 
DNA' 
Mode of action 
Primarily induction of 
serum antibody responses 
Same as above 
Same as above 
Same as above 
Induction of sennn and 
secretory antibody and 
cellular responses 
Induction of senun 
antibody and cellular 
responses 
Same as above 
Same as above 
Same as above 
TABLE 2. Vaccines and antivirals. 
Antiviral 
Amantadine 
Rimantadine 
Zanamivir 
Oseltamivir 
Chaplel' l 
Mode of action 
Inhibiton of M2 ion 
channel 
Same as above 
Neuraminidase 
inhibitor 
Same as above 
aLiccllsed in some countries; bNot (yet) licensed; ~Phase III trials, licensed for use in 
horses; dNat expected to become licensed soon. 
New developments 
An alternative to the currently used vaccines are the live-attenuated virus 
vaccines, e.g. cold-adapted virus vaccines. One advantage of these vaccines 
is that, when administered intranasally, they mimic natural infection and 
may thus induce local immune responses (involving secretory IgA) as well 
as CTL responses in addition to serum antibody responses. Thus, in contrast 
to the current vaccines which mainly aim at the induction of virus-
neutralizing serum antibodies, live-attenuated vaccines challenge the entire 
immune system. Another (economical) advantage would be that more doses 
of vaccine can be obtained per embryonated chicken egg. Live-attenuated 
virus vaccines have already been extensively tested in humans but are still 
not licensed. A disadvantage of these vaccines is that it can not be excluded 
that they lose their attenuated phenotype and reverse to wild type virus. 
Other vaccines that have been, and still are, evaluated in humans include 
liposome/virosome and ISCOM (Immune Stimulating COMplex)-based 
vaccines42 .43,117,13o.131.169. In liposome/virosomc based vaccines, the surface 
glycoproteins HA and NA are associated with phospholipids, e.g. 
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phosphatidylcholine, to form vesicles, while in ISCOMs the surface 
glycoproteins are incorporated into a structure composed of phospholipids, 
cholesterol and the adjuvant Quil A. Like live-attenuated virus vaccines, 
these vaccines induce cellular immune responses in addition to humoral 
responses and have been shown to confer protective immunity in animal 
models. Virosome-based influenza vaccines have been licensed for use in 
humans in some countries and ISCOM-based vaccines are currently being 
tested in clinical phase III trials. One other adjuvant that has been tested and 
is already licensed in some countries is MF59, consisting of squaleen, 
polysorbate 80 and sorbitan trioleaat. Vaccines which thus far have been 
tested experimentally in animal models only, include recombinant vaccina 
virus-based vaccines and DNA vaccines. Although promising results have 
been obtained with these vaccines they are not expected to become available 
for use in humans within the near future. In addition to the development and 
analysis of novel influenza vaccines using different adjuvant formulations 
and antigen presentation forms, also attempts are made to improve the 
current influenza vaccine production procedure. Since the use of 
embryonated chicken eggs has major disadvantages, the lack of flexibility 
(and hence the necessity of long-term planning) being the most important 
one, the use of continuous cell lines as a source to propagate influenza virus 
is being evaluated. 
Laboratory diagnosis of influenza 
There are numerous tests available for the diagnosis of influenza virus 
infection. These tests either detect viral antigens, viral nucleic acids or 
influenza virus induced antibodies. For rapid diagnosis of influenza virus 
infection, direct iml11unofluorescense (DIF) on patient material (nasal wash 
samples) is usually performed. DIF is usually based on the detection of 
influenza virus NP in infected cells. Another rapid method is the detection 
of influenza virus RNA by RT-PCR of a selected gene segment. While rapid 
diagnosis is an advantage of these tests, which in a hospital setting is of 
major importance, they usually only provide information about the type of 
influenza virus (A or B) but not about influenza virus A subtypes and 
antigenic properties of the virus, which is of importance for influenza 
surveillance. For this purpose, influenza virus is isolated after passaging 
patient material in embryonated chicken eggs or susceptible cells (e.g. MK 
or MDCK cells). The isolated virus then is antigenic ally characterized III 
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haemagglutination inhibition (HI) assays using a panel of sera raised against 
a series of antigenically distinct influenza viruses. The HI assay can be used 
to discriminate between different subtypes of influenza A viruses and 
antigenic variants of influenza virus A subtypes and influenza B viruses. In 
addition to the HI assay, also virus neutralization (VN) assays can be used 
to discriminate between antigenic ally distinct viruses. Serological assays for 
detection of antibodies or antibody titer rises induced after influenza virus 
infection include the complement fixation (CF) assay, the HI assay and 
enzyme-linked immunosorbent assays (ELISA). Since most influenza virus-
infected patients have encountered influenza virus in the past, the HI assay 
requires paired serum samples to be able to measure antibody responses, i.e. 
titer rises, which may be difficult to obtain. However, the HI assay is 
pmiicularly important in clinical trials for the evaluation of antibody 
responses induced upon vaccination where, in contrast to infection, paired 
serum samples can be obtained easily. 
Aims and outline of this thesis 
The studies described in this thesis have multiple objectives: development 
of ELISAs for measuring NP-specific antibody responses; evaluation of the 
usefulness of a continuous cell line for generation and propagation of 
reassortant influenza A viruses; evaluation of an ISCOM-based vaccine with 
respect to activation of CTL; and studying MHC class I processing and 
presentation of influenza virus antigen. 
After summarizing the most impOliant aspects of influenza viruses in this 
chapter, chapter 2 discusses the advantages and disadvantages of the use of 
a continuous cell line for the generation of reassortant influenza A viruses 
for vaccine production as a possible alternative to the current use of 
embryonated chicken eggs. Reassortant influenza A HINI and H3N2 
viruses were generated in MDCK-SFI cells, a continuous cell line adapted 
to grow without serum, and their genetic make-up as well as their growth 
properties in this cell line were studied. While chapter 2 focusses on 
improvement of the current vaccine production procedure, chapter 3 deals 
with some aspects ofISCOM, an antigen presentation form that may be the 
basis for future influenza vaccines. The potential of ISCOM to facilitate 
MHC class I processing and presentation of the influenza virus A matrix MI 
protein to specific CTL was evaluated in Vi/I'D. The necessity of a 
membrane-spanning region and incorporation of the MI protein into the 
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ISCOM structure was studied. The study of MHC class I processing of 
influenza virus antigen for presentation to CTL is continued in chapters 4 
and 5. Chapter 4 describes MHC class I presentation of recombinant NP-
derived peptides by B-lymphoblastoid cell lines (B-LCL). Possible 
pathways for processing of this exogenous antigen are discussed. Chapter 5 
describes the consequences of mutations in CTL epitopes with respect to 
MHC class I presentation and recognition of influenza virus-infected cells 
by specific CTL. The introduction of mutations in CTL epitopes as a 
possible mechanism to escape CTL-mediated immunity is discussed. In 
chapter 6, the development and evaluation of ELISAs for measuring 
influenza virus A or B-induced NP-specific antibodies of the IgA and IgG 
isotypes in influenza virus-infected patients is described. Finally, chapter 7 
summarizes and discusses the results of the studies described in this thesis. 
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Chapter 2 
SUMMARY 
In the present study reassot1ant influenza A viruses of both the HINI and 
H3N2 type were generated in Madin Darby Canine Kidney cells grown in 
the absence of fetal bovine serum (MDCK-SFI cells). To this end, MDCK-
SF I cells were simultaneously infected with one of the high-growth 
laboratory strains AlPuel10 Rico/8/34 (HINI) or AlHong Kong/2/68 
(H3N2) and recent I-I3N2 and HINI vaccine strains, respectively. 
Reassortant viruses obtained from these mixed infections were genetically 
characterized by RT-PCR and restriction enzyme analysis and their growth 
propel1ies were compared to those of the corresponding field strains. 
Reassot1ant H3N2 viruses inherited the matrix and polymerase pa gene 
whilst HINI reassot1ant viruses inherited the matrix and polymerase pbl 
gene of the high-growth parent. Reassot1ant viruses generally gave higher 
viral yields, as measured by a haemagglutination assay, than their wild type 
counterparts. The procedure followed, results in the generation of high-
growth reassot1ant viruses in weeks. The use of MDCK-SFI cells together 
with these reassortants for generating influenza virus antigens can signifi-
cantly speed up the vaccine production procedure. 
INTRODUCTION 
Influenza viruses, members of the family Ortholllyxoviridae, are the causative 
agents of annual epidemics of acute respiratoty disease. Influenza epidemics 
are associated with considerable morbidity and mortality, especially in people 
at risk, i.e. people suffering from heart or lung diseases, diabetics or a 
malfimction of the immune system. Vaccination is the most effective way to 
prevent the often fatal complications in these patients during influenza virus 
outbreaks. 
Influenza vaccines contain the surface glycoproteins (haemagglutinin and 
neuraminidase) of the influenza viruses expected to circulate in the human 
population in the upcoming season. Currently, trivalent influenza vaccines 
are used that contain representative strains of influenza A (HIN I and 
H3N2) and influenza B viruses. Due to antigenic drift, the antigenic 
epitopes of the surface glycoproteins continuously change which necessi-
tates yearly adjustments of the vaccine. These changes are monitored by 
over a hundred National Influenza Centres worldwide. Based on the 
information collected, the World Health Organization (WHO) in Geneva 
yearly recommends the composition of the influenza vaccine, usually in 
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February. Tllis leaves the vaccine manufacturers approximately six months 
to produce and register the vaccine for use in the NOl1hern hemisphere. Vac-
cine production requires embryonated chicken eggs to propagate the 
influenza virus antigens. In case of an urgent worldwide demand for large 
quantities of vaccine, for example with the emergence of a novel subtype of 
influenza A virus (due to an antigenic shift), vaccine production may be 
hampered by the limited availability of eggs. Recentl~, an influenza A virus 
of the H5NI subtype was isolated from humans. Fortunately, human 
infections with this virus appeared to be restricted to 18 hospitalized cases. 
If, however, this virus would have managed to spread in the human 
population, it could have hlitiated a new influenza pandemic4. In that case it 
would have been difficult, if not impossible, to obtain sufficient 
embryonated eggs for rapid production of a new vaccine. The availability of 
embryonated eggs also can become a problem when flocks of chickens 
supplying the eggs become the victim of avian diseases or when the 
embryo's themselves are sensitive to the influenza virus used. The time 
limits on the one hand and the use of eggs on the other hand render 
influenza vaccine production unflexible and requires long-term plmming by 
vaccine manufacturers. 
The use of continuous cell Ihles like Madin Darby Cmline Kidney (MDCK) 
cells for influenza virus antigen production can be considered an attractive 
alternative to emblyonated chicken eggs for several reasons. Firstly, cell 
cultures are mahltained easily and can be expanded in a relatively shOl1 time 
and therefore will allow initiaton and scaling up of antigen production at any 
thue. Secondly, human viruses propagated in MDCK cells usually resemble 
the original human isolate more closely than do viruses propagated in eggs l4 . 
Also, egg-derived vacchle strains often constitute a heterogenous population 
of influenza vh·uses6,15,20. Due to adaptation to avian cells, these viruses 
undergo mutations in their surface glycoproteins which can render the ultimate 
vaccine less effectiveI 1,l3.18. Thirdly, the use of MDCK cell derived influenza 
vaccines would overcome allergic reactions in vaccinated individuals sensitive 
to egg proteins and, finally, liOlU all etllical point of view, it would reduce the 
amount of animals used for the benefit of human medicin. 
A major draw-back in the use of MDCK cells has been the requirement to 
grow the cells hl the presence of fetal bovine serum. The use of fetal bovine 
serum not only interferes with the activity of trypsin, necessmy for propa-
gation of most influenza A viruses, but its biological variation also 
complicates standardization of the culture conditions. Recently, a MDCK cell 
line (MDCK-SFI) that overcomes this draw-back has been developed as these 
cells grow in medium devoid of fetal bovine senlm l ,2. MDCK-SF! cell 
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derived vaccines already have been extensively tested and shown to be equally 
"" . d . d . 12 ellectIve as egg- enve vacCllles . 
Important factors in the production of an influenza vaccine are the growth 
properties of the virus and the amount of viral antigens (haemagglutinin and 
neuraminidase) that can be produced per unit of volume. Ideally, viruses 
should replicate to high titre in a short period of time and yield high amounts 
of viral antigens at the end of the process. Influenza A virus field strains, 
selected to be included in egg-based antigen production, are usually being 
genetically modified to generate a virus containing the genes encoding 
haemagglutinin and neuraminidase of the field strain while a high-growth 
phenotype is derived from a laboratOlY strain. Dual infection of embryonated 
chicken eggs with repression of replication of the laboratOlY strain results in a 
selective advantage of so called high-growth reassOliants with the appropriate 
surface glycoproteins. Tllis reassOliment procedure, made possible by the 
segmented genome of influenza viruses, is currently carried out routinely for 
the egg-derived influenza vaccine viruses. 
Here we describe the application of this approach for the generation of high-
growth reassortant influenza A viruses that can be used for viral antigen 
production in MDCK -SF I cells. Also, methods to characterize reassOliant 
vimses are described. 
MATERIALS AND METHODS 
Viruses, ccJls and sera 
The HINI vimses A1Puerto Rico/8/34 (PR 34), A/Taiwanll/86 (TW 86), A/Johannes-
burg/82/96 (JB 96) and A/Shenzhen1227/95 (SZ 95) as well as the H3N2 viruses A/Hong 
Kong/2/68 (HK 68), A1Wuhan/359/95 (\'lH 95), AlNanehang/933/95 (NC 95) and 
A/Johannesburg/33/94 (JB 94) were obtained ITom the repositOlY of the Dutch National 
Influenza Centre. Most of these vaccine strains were primarily obtained from the National 
Institute for Biological Standards and Control (NTBSC), Potters Bar, United Kingdom. All 
vil1lses were passaged several times on MDKC-SFI cells before the stal1 of the experiments. 
MOCK-SF I cells were obtained fi'om Solvay Phannaceuticals, Weesp, TIle Netherlands. The 
cells were cultured in EpiSerf medium (Gibco-BRL) supplemented with antibiotics (penicillin 
10 IU/ml, streptamycin 50 fIg/mI). For propagation of the vimses, ltypsin (5 flg/ml) was added. 
PR 34 and HK 68-specific antisera were raised in rabbits injected with sucrose gradient 
purified virus and TW 86, JB 96, SZ 95, NC 95 and JB 94-specific antisera were obtained li'Olil 
ferrets after intranasal infection. 
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Dual infections and isolation ofvi .. uses 
MDCK-SFI cells were grown in 96-wells plates until confluency and infected either with a 
single virus or with a mixture of a HINt and a H3N2 vims in 100 ~d culture mediulll. Mixed 
infections were caJTied out with the HINI virns PR 34 and one of the H3N2 vimses \vH 95, 
NC 95 or JB 94, or with the H3N2 virus HK 68 and one of the !-lINI vimses T\v 86, JB 96 or 
SZ 95. Infections were performed at various multiplicities of infection (moi's) ranging from 
0.001 to 1. After one hour of incubation at 37'C, the inoculum was removed, cells were 
washed with culture medium, 200 ~I fresh medium was added and the cells were fmiher 
cultured for three days. At day 3, 20 ~I of the supematant was transferred to new MDCK-SFI 
cells which were fmiher cultured for another !lu'ee days in the presence of PR 34 or HK 68-
specific polyclonal rabbit antisenllll (I: 1000) in 200 It! culture medium. One round of plaque 
purifications were performed in 6-wells plates in the presence of antisenlln (I: I 000) and 
agarose (1%) added to the clllture medium. 
Hacmagglutina tion assay 
To 50 It! of two-fold diluted vims solutions (in Phosphate Buffered Saline; PBS), 25 III PBS 
and 25 I" of a 1% turkey erythrocyte suspension in PBS was added and incubated for one hour 
at 4"C. TI,en the haemagglutination pattem was examined and expressed in haemagglutinating 
units (HAU). TIle amount of HAU corresponded to the reciprocal value of the highest vims 
dilution that showed full haemagglutination. 
Haemaggilltination inhibition assay 
One volume of vims-specific antisenUll (raised in felTets or rabbits) was incubated with five 
volumes of cholera filtrate at 37'C for approximately 16 hours, followed by one hour 
incubation at 56"C. To 50 It! of two-fold dilution series of semm (in PBS), 25 III of a vims 
solution of 4 haemagglutinating units (HAU) was added and incubated for 30 minutes at 37'C. 
Then, 25 III of a I % turkey erythrocyte suspension in PBS was added followed by one hour 
incubation at 4°C. Subsequently the haemagglutination pattem was examined and expressed as 
the reciprocal value of the highest semm dilution inhibiting haemagglutination. 
RNA isolation, RT -PCR and restriction enzyme analysis 
Viral RNA was extracted as previously described'. RT-PCR was perfOlllled as follows. To 10 
I" of viral RNA 2 I" fOlward primer (10 pmol/l") was added and incubated at 80"C for 2 
minntes followed by a short incnbation on ice. Then, cDNA was synthesized fi'om the viral 
RNA by adding dNTP's (0.5 mM each), DTT (10 mM), RNasin (40 units) and MMLV-RT 
(200 nnits) in a total volnme of25 III Ix reverse transcriptase buffer and incubation at 42"C for 
45 minutes. The reaction was stopped by heating the mixture to 95'C for three minutes. The 
PCR mixture contained cDNA, 2 III fOlWaJ'd and 2 I" reverse primer (both 10 pmol/ll\), 
dNTP's (0.2 mM each), MgCI2 (1.5 mM) and Taq polymerase (2.5 units) in a total volume of 
100 III Ix Taq buffer. TIle PCR cycles consisted of I minute 94'C, 2 minutes 40"C and 3 
minutes n'c for a total of 40 cycles. PCR products were ethanol precipitated and dissolved hI 
50 I" H20. 8 I" of a PCR product was incubated with a paJiicular restriction enzyme for one 
hour at 37°C and subsequently nm on a 1% agarose gel containing ethidium bromide. 
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Comparison of wild type and reassortant viruses 
MDCK-SF! cells were grown in 24 wells plates and infected with 100 fl! reassortant virus or 
the cOlTesponding field strahl at a broad range of moi's (1.10" to 1.10'3 pfirlcell ). After one 
hour incubation at 37°C, the inocululll was removed and 2 1111 fresh culture medium was added. 
The amount of HAU in the culhlre supernatant was measured in a haemaggiutinatioll assay 
fi'Om day! to day 6 post infection. TIle experiment was pelfol1ued twice in duplicate and the 
average HAU values were calculated from both experiments. 
RESULTS 
Dual infections 
For generation ofH3N2 and HINI reassottant influenza A vil1lses, PR 34 and 
HK 68 were chosen as high-growth parents, respectively, because on compari-
son with a series of other vil1lses, PR 34 and HK 68 yielded the highest 
amounts of haemagglutinating units (HAU) when propagated in MDCK-SFI 
cells. Replication of these viruses was completely inhibited by their respective 
antisera since no haemagglutinating units (HAU) could be measured in 
supematants of cells infected with PR 34 or HK 68 only. The supernatants of 
cells infected with H3N2 or HINI field strains and cultured in the presence of 
PR 34 or HK 68-specific antiserum, respectively, caused haemagglutination of 
turkey erythrocytes indicating that the antisera did not inhibit these field 
strains. Viruses derived fi·otn dual infections which escaped the antiserum 
pressure (positive supernatants) were subjected to plaque purification. Of each 
dual infection, t1ll'ee randomly selected plaque purified viruses were characte-
rized to detennine whether they represented wild type (field strain) or 
reassottant viruses. 
Determination of the type of surface glycoproteins 
To check the subtype of haemagglutinin of the plaque purified viruses grown 
in the presence of antiserum, haemagglutination inhibition assays using 
antisera raised against PR 34, HK 68 and the field strains were ca11'ied out. 
From table I it is clear that the plaque purified viruses obtained from dual 
infections with PR 34 contained H3 haemagglutinin while those obtained from 
dual infection with HK 68 contained HI haemagglutinin. The neuraminidase 
subtype of the plaque purified vimses was detennined by RT-PCR using 
neuraminidase NI and N2-specific primer sets. RT-PCR's with RNA isolated 
from the plaque purified viruses obtained from dual infection with PR 34 were 
only positive using the N2 primer set, whereas the plaque purified vil1lses 
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obtained from dual infection with HK 68 were only positive when the NI 
primer set was used. Thus, all plaque purified vimses were of the same 
subtype as their conesponding field strains. 
Virusfl Antiscl'aD Virus Antiscra 
NC95 JB94 PR34 TW86 J1J96 8Z95 HK68 
(H3N2) (H3N2) (HINI) (HINI) (HINI) (HINI) (H3N2) 
WH95 640' nt <IOd TW86 2560 nt nt <10 
WHxPRI 640 nt <10 TWxHKI 2560 nl nt <10 
WHxPR2 640 nt <10 TWxHK2 2560 nt nt <10 
WHxPR3 640 nt <10 TWxHK3 2560 nt nt <10 
NC95 2560 nt <10 JB 96 nt 2560 nt <10 
NCxPRI 2560 nt <10 JBxHKI nt 2560 nt <10 
NCxPR2 2560 nt <10 JBxHK2 nt 2560 nt <10 
NCxPRJ 2560 nt <10 JBxHK3 nt 2560 nt <10 
JB 94 Nt 2560 <10 SZ95 nt nt 5120 <10 
JBxPRI Nt 2560 <10 SZxHKI nt nt 5120 <10 
JBxPR2 Nt 2560 <10 SZxHK2 nt nt 5120 <10 
JBxPR3 Nt 2560 <10 SZxHK3 nt nt 5120 <10 
PR34 <10 <10 >20480 HK68 <10 <10 <10 >20480 
TABLE 1. Haemagglutination inhibition titers for field strains and reassortant influenza 
vimses. 
'Vimses are abbreviated as follows: WH 95 (AlWuhanl359/95), NC 95 
(AINanchangl933/95), JB 94 (AiJohaimesburgl33/94), PR 34 (AiPuerto Rico/8/34), 
WHxPRI-3, NCxPRI-3 or JBxPRI-3 reassOltant vimses obtained from mixed infections of 
PR 34 with WH 95, NC 95 or JB 94 respectively), TW 86 (AlTaiwanIl/86), JB 96 
(AiJohannesburgl82/96), SZ 95 (AiShenzhen/227/95), HK 68 (A/Hong Kongl2/68), 
TWxHKI-3, JBxHKI-3 or SZxHKI-3 (reassOItant viruses obtained fi'om mixed infections of 
HK 68 with TW 86, JB 96 or SZ 95 respeclively); "PR 34 and HK 68-specific antisera were 
derived fi'om immunized rabbits; other sera were derived fi'om infected ferrets; 'WH 95 and 
the reassortant viruses WHxPRI-3 were measured against NC 95 antiserum as WH 95 
antiserum was not available (nt: not tested); dA liter <10 corresponded to no detectable 
inhibition of haemagglutination. 
Determination of the origin of the other gene segments 
The results of the haemagglutination inhibition assays and neuraminidase RT-
peR's do not discriminate between wild-type viruses (field strains) and 
reassortant viruses. To establish whether the plaque purified viruses derived 
from the dual infections were actually reassOliant viruses, the origin of the 
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remaining six gene segments encoding the intemal viral proteins (PB2, PB 1, 
PA, NP, MA and NS) was determined. RT-PCR followed by restriction 
enzyme analysis has previously been found to be a suitable method1o•17. Primer 
sequences were selected for amplification of the six gene segments in regions 
conserved within HINI and H3N2 vil1lses. However, different recognition 
sequences for restriction endonucleases were present within the amplified 
region to distinguish gene segments derived from HINI or H3N2 viruses 
(Table 2). An example of a plaque purified vil1ls obtained from mixed 
infection with PR 34 and WH 95 is shown in figure I. Tllis figure clearly 
demonstrates that all gene segments encoding the internal viral proteins of the 
plaque purified virus originated from PR 34. Therefore, tllis virus is the result 
of genetic reassortment between PR 34 and WH 95. The origin of the gene 
segments of other plaque purified vil1lses was determined as well and all these 
viruses proved to be reassortant viruses. Table 3 shows the genonlic 
composition of the reassortant viruses derived fi'om three different mixed 
infections with PR 34 or HK 68. All reassOliant viruses contained the matrix 
gene of the lligh-growth laboratOlY strain. In addition to the matrix gene, also 
the gene segment encoding polymerase P A originated from the PR 34 strain in 
all H3N2 reassOliant vimses. Four out of nine reassOliant H3N2 viruses 
contained a complete PR 34 background; in these reassOliant viruses all gene 
segments, except the ones encoding the surface glycoproteins, were of PR 34 
origin. 
Gene Amplified region Restriction enzyme(sY' 
PB2 1-764 BglIJ (HINI) 01' PvuII (H3N2) 
PBI 1-623 RsaI (HINI) 
PA 1132-1790 BamHI (H I N I) 01' BglIl (H3N2) 
NP 46-1542 BamHl (both)" 01' Pvull (H3N2) 
MA 26-784 BglIl (H3N2) 
NS 1-574 HindIII (HINI) 
TABLE 2. Restriction enzymes used to determine the origin of gene segments encoding 
internal viral proteins. 
aThe type of vil1ls whose gene segment contains the recognition sequence for a particular 
restriction enzyme is shown in brackets; bBall/HI cuts the NP peR product of HINI viruses 
once and that of AlHong Kong!2168 (H3N2) twice. 
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PB2 
8gl11 
8amHI 
PB1 
Rsal 
8gl11 
PA 
8gl11 
Hind 11/ 
Figure 1. RT-PCR and restriction enzyme analysis of the gene segments encoding the 
internal viral proteins of AlPlIerto Rico/8/34 (HINI), a H3N2 reassortant (WHxPR) alld 
AlWuhan/359/95 (H3N2). 
The HIN I reassortant viruses shared the gene segments encoding polymerase 
PB I and the matrix proteins of HK 68. The gene segments encoding the 
nucleoprotein and the nonstructural proteins were ofHINI origin in all HINI 
reassmiants and consequently none of the BINI reassortant vilUses contained 
a complete HK 68 background. 
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Gene WHxPR NCxPR JBxPR TWxHK JBxHK SZxHK 
I 2 3 I 2 3 I 2 3 I 2 3 I 2 3 I 2 3 
PBI P P P P P N P P P H H T H H H S S H 
PB2 P P P P N N J P J H H H H H H H H H 
PA P P P P P P P P P T T T B B B H H H 
HA W W W N N N J J J T T T B B B S S S 
NP P P P N N N P P P T T T B B B S S S 
NA W W W N N N J J J T T T B B B S S S 
MA P P P P P P P P P H H H H H H H H H 
NS P P P N N N P P P T T T B B B S S S 
TABLE 3. Genomic composition of influenza A H3N2 and H1NI reassortant vimses. 
'A one letter code is used to depict the origin of each of the gene segments: P (AiPuerto 
Rico/8/34), W (A/Wuhan/359/95), N (AlNanchang/933/95), J (A/Johannesburg/33/94), H 
(AlHong Kong/2/68), T (AiTaiwan/1/86), B (A/Johalmesburg/82/96) and S 
(A/Shenzhen/227/95). 
Comparison of growth characteristics of the 
reassortant vil'Uses and field strains 
The viral yield, expressed as haemagglutinating units (HAll) of reassortant 
viruses resulting from each dual infection was compared with that of the 
corresponding field strain for different m.o.i.'s. Most vimses, both wild type 
and reassortant viruses, reached a maximum yield of HAU within three to four 
days post infection (Figures 2 and 3). In general, the reassortant viruses 
showed higher yields than the wild type viruses. Of the H3N2 reassotiant 
viruses, the yields produced by the WH 95 reassotiant (WHxPR2) were at 
least twofold higher than the yields produced by wild type WH 95 at allmoi's 
tested. The NC 95 reassortant (NCxPRl) showed higher yields than wild type 
NC 95 at l110i= 0.001 and 0.0001, and the JB 94 reassortant (JBxPRI) showed 
higher yields than wild type JB 94 at l110i= 0.001 and 0.000001. Of the I-IINI 
reassortants, the SZ 95 reassoliant (SZxHKI) yielded at least two times the 
amount ofHAU of wild type SZ 95 itl'espective of the moi. The JB 96 reassor-
tant (JBxHK2) yielded at least twice the amount ofHAU of wild type JB 96 at 
three of the four moi' tested. The difference between the TW 86 reassortant 
(TWxHKI) and wild type TW 86 was most pronounced at velY low moi's 
(0.00001 and 0.000001). 
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Figure 2. Kinetics of virus propagation measured in haemagglutinating units (HAU) from 
day I to 6 after infection of MDCK-SFI cells at four different multiplicities of infection 
(moi). Average values of four similar experiments with H3N2 field strains A/Wuhan/359/-
95, AINanchangl933/95 and A/Johannesburg/33194 (open circles) and their corresponding 
reassortant vimses WHxPR2, NCxPRI and JBxPRI (solid circles) are shown. 
DISCUSSION 
MDCK-SF! cells, a newly developed MDCK cell line, can be considered a 
serious candidate for production of tissue culture grown vaccines. In the 
present study it was shown that these cells allow genetic reassortment to take 
place after mixed infection resulting in potential vaccine seed strains with a 
high-growth phenotype. 
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Figure 3. See legend to figure 2. Open circles represent the HI N I field strains 
AlTaiwan/l/86, AlJohanllesburg/82/96 and AIShenzhen1227/95 and solid circles represent 
the corresponding reassortant viruses TWxHKI, JBxHK2 and SZxHKl. 
The reassottant H3N2 and HINI influenza A viruses all contained the gene 
segment encoding the matrix proteins from the high-growth laboratory 
strains PR 34 or HK 68, respectively. In other studies it was shown that a 
high-growth phenotype of reassottant viruses correlates with the uptake of 
the matrix encoding gene of the high-growth parent virusI9.21-23. Therefore, 
the improvement of the viral yield of the reassortant viruses (expressed in 
HAU) observed in the present study most likely can be attributed to the 
matrix protein of PR 34 or HK 68. However, the H3N2 reassortant viruses 
also shared the gene segment encoding polymerase P A of PR 34 while the 
HINI reassortant viruses shared the gene segment encoding polymerase 
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PB I of HK 68, indicating that the matrix protein may be not the only 
important factor. The polymerase proteins PA and PB I in the H3N2 and 
HINI reassot1ant viruses, respectively, could have contributed to the high-
growth phenotype of these viruses as well. 
The WH 9S reassortant (WHxPR2) contained a complete PR 34 background 
and tlus H3N2 reassot1ant virus consistently produced lugher yields than wild 
type WH 9S. The WH 9S strain was selected as the H3N2 vaccine strain in 
199611997 but was replaced by the NC 95 strain that revealed better growth 
properties. For this strain, the reassot1ment procedure in MDCK-SFI cells 
seems superior to embryonated chicken eggs as the WH 9S reassortant showed 
excellent growth properties. Although the WH 9S reassortant was found 
superior to the wild type strain, a complete PR 34 background does not 
necessarily result in the best growth characteristics. One reassot1ant vil1ls 
(JBxPR2) contained the complete set of gene segments encoding the intemal 
proteins of PR 34, but its yield did not differ from JBxPRI (data not shovm). 
Moreover, none of the HINI reassot1ant viruses contained a complete HK 68 
background although a clear improvement in viral yield was measured. Taken 
together, the results show that the set of genes of a high-growth parent that 
confers a high-growth phenotype to a certain reassortant virus, do not 
necessarily benefit another type of reassortant virus and that it is not a 
prerequisite to inherit all gene segments of a lugh-growth parent to obtain a 
high yield. Apparently, the genonuc constellation of reassot1ant viruses as a 
whole, rather than the inheritance of defined gene segments, determines their 
growth characteristics. 
This statement is suppot1ed by the genetic characterization of the reassortant 
viruses. The genomic make-up of the three reassot1ant viruses isolated for 
each dual infection did not differ significantly from each other. The WH 95 
reassot1ant viruses were identical to each other as were the JB 96 reassortant 
viruses. The reassot1ant viruses obtained from the other dual infections 
differed only fi'Om each other with respect to the origin of one or two gene 
segments encoding the polymerase proteins. Although we only characterized 
tlll'ee reassot1ant viruses per dual infection, it seems that there is a restriction 
towards the random combination of gene segments. Tlus is in agreement with 
other studies showing that the number of combinations of the six gene 
segments encoding the intemal viral proteins (of wluch there are 64 
possibilities) is limited5•9•16,21. 
The use of heterologous hlgh-growth HINI and H3N2 virus for generation of 
H3N2 and HINI reassot1ant viruses, respectively, makes it easy to fully 
suppress reproduction of the lugh-growth parent virus, without affecting 
reproduction of desired reassot1ant viruses. In addition, it is velY helpful to 
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determine the genetic make up of reassottant viruses. After a single passage of 
a mixed yield in the presence of the appropriate antiserum, the high-growth 
parent is neutralized and in subsequent plaque purifications the reassottant 
virus can be separated and cloned. This complete procedure, including the 
genetic characterization takes only 3-4 weeks. 
The MDCK-SFI cell line we used differs from the original MDCK cell line by 
its ability to be cultured in the absence of fetal bovine serum. TIlerefore, 
MDCK -SF I cells do not need washing and replacement of culture medium so 
they can be directly infected with influenza viruses. TIJis can be considered a 
great advantage in large-scale virus productions. Moreover, as shown in this 
study, high yields of virus in MDCK-SFI cells can be obtained at low m.o.i. 
and a maximum amount of HAU usually is reached within three to four days. 
Obviously, in the scaling up of the procedure, the optinlalm.o.i. will have to 
be reconsidered and detemuned for every new vaccine strain. 
Although the use of MDCK-SFI cells is likely to offer numerous advantages 
over emblyonated c1ucken eggs in viral antigen production, two remarks must 
be made. First, influenza field strains may be contaminated with other viruses 
that also replicate in MDCK cells. TIJerefore, for safety reasons, an llutial 
passage in emblyonated chicken eggs will still be required to elimllJate 
potential contamination of the ultimate influenza vaccllle with adventitious 
human viruses. Second, the tumourigenic character of continous cell lines has 
withheld the use of these cells for viral antigen production so far as it was 
thought that residual cellular DNA present in the vaccine might be able to 
induce tumours. However, the purification procedures for the viral antigens 
will reduce the presence of residual cellular DNA to undetectable amounts and 
it has already become clear by safety studies that induction of tumours by 
residual cellular DNA is highly unlikelyl,7. 
Within the next few years, influenza vaccllles based on MDCK -grown 
antigens are likely to become available. By then, integration of the procedure 
described in this paper will be of lllterest. The flexibility of using cell lines, the 
ease of makillg reassottant viruses together with the increased yield that can be 
obtained using these reassottants, make MDCK -SF I cells an attractive 
alternative to emblyonated c1ucken eggs. 
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SUMMARY 
The gene encoding the influenza virus A matrix (MA) protein was cloned 
into the bacterial expression vector pMalC with and without the sequence 
encoding the transmembrane region of the haemagglutinin (HA). With the 
resulting recombinant proteins, im1l1unestimulating complexes (ISCOM) 
were prepared. The MA protein with the hydrophobic anchor region 
(rMAHA) associated more efficiently with ISCOM than the UlllllOdified 
MA protein (rMA). A B-Iymphoblastoid cell line (B-LCL) was lysed by an 
autologous CD8+ cytotoxic T lymphocyte (CTL) clone specific for the MA 
protein after incubation with rMAHA-ISCOM but not after incubation with 
rMA, rMAHA, rMA-ISCOM or empty ISCOM. The B-LCL was also lysed 
by the CTL clone after incubation with empty ISCOM mixed with the 
respective MA proteins. Incubation of ISCOM with the rMAHA protein 
proved to be the most efficient in this respect. Addition of the proteasome 
inhibitors lactacystin or clasto-Iactacystin ~-Iactone to the B-LCL incubated 
with rMAHA-ISCOM or the MA proteins mixed with empty ISCOM 
dramatically decreased the lysis by the CD8+ CTL clone. These results 
indicate that the addition of a hydrophobic anchor to hydrophilic proteins in 
combination with ISCOM facilitates their entry in the MHC class I 
processing and presentation pathway. TIlls may be an attractive approach 
for the development of subunit vaccines aiming at the induction of CTL-
mediated i1l11l1Ulllty. 
INTRODUCTION 
The immunestimulating complex (IS COM), a hydrophilic structure held 
together by hydrophobic interactions and composed of amphipatlllc and 
hydrophobic constituents, the adjuvant Qui! A, cholesterol and 
phospholipids, was originally developed as an antigen presentation form for 
viral membrane proteins and proved to be a potent inducer of humoral and 
cell-mediated immunity, including cytotoxic T lymphocyte (CTL) 
immunity'S,23. In the process ofISCOM preparation, the hydrophobic nature 
of the membrane-spanning region of such proteins allows their spontaneous 
incorporation into ISCOM. In contrast, the incorporation of hydrophilic 
non-transmembrane proteins is usually less efficient. Increasing the 
efficiency of incorporation of these proteins can be achieved by coupling 
them to hydrophobic carrier molecules, like bacterial lipopolysaccharide or 
fatty acids2o.3o.37. However, these procedures are usually cumbersome to 
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perform, lack universal applicability and may result in conformational 
changes. A universal approach that would enable the incorporation of 
hydrophilic proteins into ISCOM would allow a wider application of the 
ISCOM technology in the field of vaccine development. 
The use of ISCOM is especially of interest when vaccination aims at the 
induction of specific CTL responses. For influenza, currently used vaccines 
are mainly based on the use of the membrane glycoproteins of the virus, the 
haemagglutinin (HA) and neuraminidase (NA). The HA of influenza viruses 
shows a high degree of variation due to the accumulation of mutations in the 
antigenic determinants, which necessitates the regular adjustment of the 
vaccine. Although ISCOM-based vaccines prepared with the influenza HA 
and NA have been shown to induce strong humoral as well as cellular 
immune responses, conferring protective immunity to vaccinated animals, 
also ISCOM-based influenza vaccines would have to be adjusted on a 
regular basis7,9,15.24.26,28. The internal influenza virus proteins, like the 
nucleoprotein (NP) and matrix protein (MA), are well conserved amongst 
different influenza virus strains and are major targets for CTL 16,27. However, 
the role of CTL directed against these proteins in protection or recovery 
from infection is still controversial22. Some studies have shown protection 
against infection conferred by (vaccine-induced) CTL, while others have 
shown that CTL only contribute marginally to vaccine-induced protective 
immunity2,8,lo,14,19,33.35. Nevet1heless, by killing virus-infected cells, CTL do 
contribute to viral clearance. The induction of CTL-mediated immunity by 
vaccination largely depends on the nature of the vaccineI7,22. For a vaccine 
to induce CTL it is imp0l1ant that the antigen would be delivered into the 
cytosol of cells where it enters the endogenous route of antigen processing. 
This leads to the expression of antigenic peptides associated with MHC 
class I molecules on the surface of the cell. It has been shown that ISCOM-
b d · ff!" . d . CTL 3 12 IJ 32 ase vaccll1es are e IClent 111 111 uCll1g responses"'. 
Here, we describe the preparation of ISCOM with recombinant influenza 
virus MA protein modified by extending the C-tenllinus with the 
transmembrane region of the influenza HA by recombinant DNA 
tecimology, a method used previously for incorporation of malaria antigen 
into ISCOMI. The antigen processing of several MA protein ISCOM 
preparations and the presentation to a MA protein-specific CTL clone were 
evaluated in vitro. 
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MATERIALS AND METHODS 
Cloning, production and purification of recombinant MA proteins 
The MA protein encoding gene (RNA segment 7) of influenza vims AlNetheriandslO 18/94 
(H3N2) was cloned into pBluescript after introduction of an EcaRI restriction endonuclease 
recognition site at the 5' end of the MA gene and a Sail site at the 3' end by RT-PCR using 
the primers 5'CAGGAA TTCCTCGAGACGCGTA TGAGCCTTCTAACCGAGGTCG 
and 5'GCGGTCGACTCGCGATCAGTTAACCTTGAA TCGTTGCA TCTGCACC 
(restriction sites underlined, start and stop codon in bold). A HpaI site was introduced 
upstream of the stop codon of the MA gene. The transmembrane and cytoplasmic tail 
encoding region (aa 530-566) of the HA gene (RNA segment 4) of the same influenza virus 
was amplified by RT-PCR using the primers 5'GTCGTTAACTGGATC-
CTGTGGA TTTCCTTTGCC and 5'TCGGTCGACTCGCGATCAAATGCAAATGTT-
GCACCTAATG, which ino'oduced a HpaI site at the 5' end and a Sail site at the 3' end, 
and subsequently subcloned into the pBluescript construct as a HpaI-SaII fi'agment. To 
minimize the mutation error rate, Pfu polymerase (Stratagene, La Jolla, USA) was lIsed in 
the PCR reactions. Both constmcts (the MA gene and the MA gene extended with the 
transmembrane and cytoplasmic tail region of HA) were subcloned as EcaRl-SaII 
fragments into the bacterial expression vector pMalC (New England Biolabs, Hertfordshire, 
UK) in frame with the maltose binding protein encoding gene (MBP) to yield recombinant 
fusion proteins consisting of MBP and the MA protein with or without the C- terminal 
region of HA, referred to as rMAHA and rMA, respectively. RNA isolation, RT-PCR, 
cloning, production and purification of the recombinant proteins were performed by 
methods described previously". 
Analysis of recombinant MA proteins 
Recombinant MA proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SOS-PAGE) and Western blotting according to standard procedures". 
Nitrocellulose membranes were incubated with blocking buffer (2% nonfat milk powder, 
0.05% Tween 20 in phosphate buffered saline (PBS)) for I h, followed by I h of incubation 
with I: I 000 diluted mouse monoclonal antibody directed against influenza virus MA 
protein (kindly provided by Dr. W. Gerhard of the Wi star Institute of Anatomy & Biology, 
Philadelphia). After washing the blot with PBS, the blot was incubated for I h with I: 1000 
diluted horseradish peroxidase (HRP)-Iabeled rabbit anti-mouse IgG antibodies (Oako, 
Glostmp, Denmark). Then, the blot was washed with PBS followed by incubation in 
diaminobellzidine-H,O, in PBS (250 J.lg of diamillobellzidine/ml, 0.002% H,O,). The 
reaction was stopped with H,O after protein bands became visible. 
Preparation of immunestimulating complexes (IS COM) 
ISCOM were prepared by adding I mg phosphatidylcholine, I mg cholesterol and 5 mg 
semi purified saponins of the tree Quillaja sapanaria (Iscoprep 703, kindly provided by Dr. 
B. Sundquist of ISCOTEC, Uppsala, Sweden) to I mg recombinant protein in a total 
volume of 2 ml aqua bidest. containing 2% decanoyl N-methyl-glucamide (Mega-IO, 
Sigma, St. Louis, USA). ISCOM without recombinant protein were also prepared and 
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referred to as empty ISCOM. The mixture was sonicated for 30 minutes and transferred to a 
dialysis cassette (Pierce, Rockford, USA). After 30 Ins dialysis against PBS, the ISCOM 
preparations were harvested from the cassette and stored at _20°C until use. In parallel, 
ISCOM were prepared in the presence of 'H-Iabeled cholesterol (2.5 [ICi/[II) for analytical 
purposes. These ISCOM were loaded on 10-60% discontinuous sucrose gradients and 
centrifuged at 35,000 rpm (Beckmann Ultracentrifuge, SW41 rotor) and 16'C for 16 hrs. 
Subsequently, I ml fractions were collected and analyzed for 'H, as a measure for ISCOM 
formation, by measuring radioactivity in a scintillation counter (expressed as CPM). The 
protein content of these fractions was determined by measuring the optical density at a 
wavelength of 620nm (OD620) after the addition of Bradford reagent'. MA protein content 
was analyzed by an innnuno dot blot assay. 20 [t1 of each fl'action was blotted onto 
nitrocellulose and the blot was further processed as described for the Western Blot. 
Isolation of MA protein-specific HLA-A2-l'estl'icted CTL clones 
In round bottom microtiter plates, 1000 peripheral blood mononuclear cells (PBMCs) of a 
HLA-A2 positive donor were stimulated twice, with an interval of one week, with 2,5 x 104 
gamma irradiated (30 minutes 3000 rd) autologous PHA-stimulated PBMCs pulsed with 
the peptide GILGFVFTL (a HLA-A2-l'estricted CTL epitope of the influenza vims A MA 
protein (aa 5S-66)). The cells were cultured in RPM! 1640 medium containing L-glutamine 
(2 mM), penicillin (100 lU/ml), streptamycin (100 [Ig/ml), 2-mercaptoethanol (2 x 10-' M), 
IL-2 (50 U/ml) and 10% human pool serum at 37'C and 5% CO2• One week after the 
second stimulation, expanding cells were analyzed for peptide-specific CTL activity. Cells 
from wells sholVing CTL activity were cloned by limiting dilution (0,3 , I and 3 cells per 
well) and stimulated non-specifically by adding 3 x 10' APD B-LCL (B-Iymphoblastoid 
cell line), 3 x 10' BSM B-LCL and 6 x 10' allogeneic PBMCs (which were all gamma 
irradiated), I ~g PHA and 50 U IL-2 per mill. After an incubation of two weeks, clones 
showing CTL activity were stimulated specifically with gamma irradiated peptide-pulsed 
autologous PBMCs. After incubating the clones for twelve days they were stimulated non-
specifically as described above in 75 cm2 flasks. After two weeks, cells were harvested, 
aliquoted and stored at -135'C until use. The CD3+ CDS+ CD4- phenotype was confirmed 
by FACS analysis, after staining for CD3, CD4 and CDS, and their MA protein-specificity 
and HLA-A2 restriction was confirmed in CTL assays. To this end, I x 10' autologous and 
mismatched EBV-transformed B-LCL were incubated with the peptide GILGFYFTL (10 
[1M) or infected with a recombinant vaccinia virus expressing the MA protein of influenza 
virus AlNetherlands/0IS/94 (generated essentially as previously described"), a control 
vaccinia vin.s (YSC65), both at a multiplicity of infection of 10, or infected with 5 x 10' 
TCID,o/ml influenza vims AlNanchang/933/95 (kindly provided by Dr. J. Bates, CSL, 
Sydney, Australia) in I ml RPMI 1640 medium for one hour at 37'C and 5% CO2 , Cells 
were washed with complete RPMI 1640 medium (RPMI 1640 medium containing L-
glutamine (2 mM), penicillin (100 IV/ml), streptamycin (100 Jlg/ml) and 10% fetal bovine 
serum) and either directly used as target cells in CTL assays (peptide-pulsed cells) or after a 
further incubation in this medium for 16 hrs (vaccinia and influenza virus-infected cells). 
Preparation of target cells for studying processing of antigen preparations 
I X 10' autologous EBY-transfonned B-LCL were incubated with different antigen 
preparations in I ml complete RPM! 1640 mediulll at 37'C and 5% CO,. The antigen 
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preparations included rMA protein, rMAHA protein, rMA-ISCOM, rMAHA-ISCOM, 
rMA and rMAHA protein mixed with empty ISCOM and empty ISCOM only. B-LCL were 
also incubated with empty ISCOM for I h, washed with medium and subsequently 
incubated with rMA or rMAHA protein. The antigen preparations were added to the B-
LCL to a final concentration of 7,5 I'g protein per ml. All ISCOM were prepared with 
identical amounts of Qui! A, cholesterol and phospholipids and gave similar profiles when 
analysed by sucrose gradient centrifugation. The amount of protein in the preparations 
containing empty ISCOM mixed with protein was adjusted to the amount of protein present 
in ISCOM prepared with protein. Untreated B-LCL served as a negative control. 24 hrs 
after the addition of the antigen preparations, cells were washed with medium and used as 
target cells in CTL assays. In order to study proteasome involvement in antigen processing, 
the highly specific proteasome inhibitors lactacystin or clasto-Iactacystin 13-lactone 
(Affinity Research Products, Mamhead Castle, UK) were added to a final concentration of 
311M. 
CTL assays 
Target cells (B-LCL) were labeled for I h with 100 IICi Na,[" Cr]04 in RPMI 1640 
medium. Cells were washed three times in complete RPM! 1640 medium and resuspended 
in this medium to a concentration of 104 cells / 50 III. Effector cells (CTL) were suspended 
in this medium to a concentration of 10' cells /100 III. 50 It! Target cells were incubated 
either with 100 It! medium (spontaneous release), with 100 III 10% Triton X-IOO 
(maximum release) or with 100 III effector cells (experimental release; effector to target 
ratio ~ 10) for 4 hrs at 37' C. For other effector to target ratios, the concentration of effector 
cells was adjusted. Supematants were harvested and radioactivity was measured by gamma 
counting. The percentage specific lysis was calculated as: 100 x [experimental release -
spontaneous release] / [maximum release - spontaneous release]. All CTL assays were 
perfollned with ten replicates per target per experiment. Experiments were performed twice 
for B-LCL incubated with rMA or rMAHA protein mixed with empty ISCOM and three 
times for control B-LCL and B-LCL incubated with rMA protein, rMAHA protein, rMA-
ISCOM, rMAHA-ISCOM or empty ISCOM. Mean values +/- S.E.M. were calculated. 
Statistical analysis was performed using the Student T test. 
RESULTS 
Recombinant MA proteins rMA and rMARA 
Highly purified recombinant fusion proteins consisting of MBP and 
influenza virus MA protein were produced using the pMalC expression 
system with an estimated purity of 90% for both the rMA and rMAHA 
proteins (Figure lA). The lllolecular lllass of rMA protein was 
approximately 70 kD which correlates with the calculated molecular mass 
of the fusion protein (40 kD for MBP and 30 kD for the MA protein). The 
molecular mass of rMAHA protein proved to be slightly higher probably 
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due to the addition of the C terminal region of the HA. Besides a major band 
at 70 kD, minor bands of smaller molecular masses were observed. These 
bands are likely to be the result of some degradation by bacterial proteases 
or may represent incomplete translation products. The identity of both 
proteins was confirmed by Western blot analysis using mouse monoclonal 
antibodies, directed against the MA protein, which showed equal reactivity 
with both recombinant proteins (Figure I B). 
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Figure I. Analysis of rMA and rMAHA protein by SDS-PAGE and Westem Blotting. 
rMAHA (lane I) and rMA (lane 2) were separated on a SDS-IO% polyaelylamide gel and 
stained with eoomassie brilliant blue (A) or transferred to a nitrocellulose membrane which 
was incubated with mouse monoclonal antibodies specific for influenza vims A MA protein 
(B) as described in materials and methods. 
Analysis of sucrose gradient fractionated ISCOM preparations 
Sucrose gradient fractions of rMA-ISCOM and rMAHA-ISCOM were 
analyzed for 3H-labeled cholesterol and protein content. As shown in figure 
2, ISCOM were formed since they typically migrated at a density of 40-45% 
sucrose which coincides with the fraction containing the highest amount of 
64 
Chapter 3 
cholesterol (fraction 7). This was confirmed by analysis of these fractions 
by negative contrast electron microscopy which revealed the typical cage-
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Figure 2. Analysis of rMA and rMARA-ISCOM. ISCOM were prepared in the presence 
ofrMA (A) or rMARA (B) protein and loaded onto a 10-60 dicontinuous sucrose gradient. 
16 Fractions (from bottom to top) were collected and analyzed for total protein content, 
expressed as the optical density at a wavelength of 620 Illn (circles), and 3H-Iabeled 
cholesterol, expressed as CPM (triangles). Fractions 3 to 14 were also analyzed for the 
presence of MA protein in an immuno dot blot assay using mOllse monoclonal antibodies 
directed against influenza vims MA protein. Reactivities of the individual fractions are 
shown at the bottom of each graph. 
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like structure of the ISCOM (data not shown). The rMAHA protein 
comigrated with the 3H-labeled cholesterol whereas the rMA protein 
showed a wider distribution. Although equal amounts of soluble rMA- and 
rMAHA protein were used in the preparation ofISCOM, the total amount of 
rMAHA protein retrieved after ISCOM formation, centrifugation and 
fractionation was lower compared to rMA protein. It is possible that part of 
the rMAHA has become insoluble during the preparation process and 
subsequently was not incorporated into ISCOM. Nevertheless, the fact that 
the distribution of rMAHA protein in the gradient exactly followed the 
distribution of ISCOM and that rMA protein was also detected in fractions 
devoid of any ISCOM material may indicate a more efficient incorporation 
of rMAHA protein into ISCOM. Inmmno dot blot analysis confirmed the 
identity of the proteins present in the ISCOM fractions. 
Analysis of MA protein-specific, HLA-A2-restricted, CTL clones 
In order to study MHC class I-restricted recognition of MA protein, CTL 
clones were isolated after stimulating PBMCs of a HLA-A2 donor with the 
known A2 peptide GILGFVFTL. From one cloning event, five clones were 
isolated. The results with one representative clone are shown in figure 3. It 
was shown that the CTL clone lysed peptide-pulsed target cells but not 
control target cells. It lysed target cells infected with influenza virus or a 
recombinant vaccinia virus expressing the influenza virus MA protein but 
failed to lyse target cells infected with a control vaccinia virus or 
mismatched target cells. This confirmed that the CTL clone recognized 
naturally liberated peptides from the MA protein in a HLA-A2-restricted 
fashion. FACS analysis confirmed that the clones were all CD3+ CDS+ CD4-
(not shown). 
Processing ofMA protein and MHC class I 
antigen presentation by ISCOM 
To measure MHC class I presentation of the peptide derived from the 
influenza virus MA protein, the recognition of the MHC class I peptide 
complex by the CTL clone was analyzed in CTL assays using autologous B-
LCL as target cells. As shown in figure 4A, control B-LCL or B-LCL 
incubated with empty ISCOM were not recognized by the MA protein-
specific CTL clone. Also B-LCL incubated with the soluble recombinant 
proteins with or without the addition of the transmembrane region of HA 
were poorly recognized by the CTL clone. B-LCL incubated with ISCOM 
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prepared with the rMA protein did not significantly differ in their 
recognition by the CTL clone from B-LCL incubated with the soluble rMA 
protein. In contrast, the specific lysis observed with B-LCL incubated with 
rMAHA-ISCOM was significantly higher (p<O.005) than that observed after 
incubation with soluble rMAHA protein or rMA-ISCOM. Interestingly, 
target cells simultaneously incubated with empty ISCOM and recombinant 
proteins rMA or rMAHA were lysed significantly more efficient by the 
CTL clone (p<O.OOOI) than B-LCL incubated with rMA-ISCOM or 
rMAHA-ISCOM. The specific lysis of B-LCL incubated with empty 
ISCOM and rMAHA protein was significantly higher than that of B-LCL 
incubated with empty ISCOM and rMA protein (p<O.OOO I). To assess 
whether this observation was due to association of the proteins with empty 
ISCOM, or the result of protein entry into the B-LCL after being sensitized 
by ISCOM, B-LCL were incubated with empty ISCOM and, after washing, 
subsequently incubated with rMA or rMAHA protein. No lysis of these 
target cells was observed (data not shown). To confirm that the MA protein 
was processed in the endogenous route of antigen processing, B-LCL were 
incubated with the respective antigen preparations in the presence of the 
proteasome inhibitors lactacystin or clasto-lactacystin 13-lactone6. The 
results obtained with B-LCL incubated with empty ISCOM and IMAHA 
protein are shown in figure 4B. Addition of 3 flM of the proteasome 
inhibitors dramatically decreased the specific lysis of these target cells by 
the CTL clone, demonstrating that presentation was dependend on 
proteasome activity. Similar results were obtained with target cells 
incubated with empty ISCOM and rMA protein or target cells incubated 
with rMAHA-ISCOM (data not shown). Full inhibition could not be 
demonstrated as the concentration of these agents necessary to completely 
block proteasome activity (> I 0 flM) is toxic for B-LCL5. 
DISCUSSION 
Since ISCOM were first described as an antigen presentation form for viral 
membrane proteins, their potential as candidate vaccines against a variety of 
viruses has been demonstrated 18,23. One of the limitations of the ISCOM 
tedmology is that only proteins with highly hydrophobic regions such as 
envelope glycoproteins, can efficiently be incorporated into ISCOM, 
whereas hydrophilic proteins, such as most of the internal proteins of 
enveloped viruses, are incorporated poorly or not at all. Incorporation of 
such proteins was only observed after chemical modification or conjugation 
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to hydrophobic carrier molecules2o,3o,37. Here, we describe an alternative 
approach taking advantage of the transmembrane region of influenza virus 
A HA which has been shown to facilitate efficient incorporation of this 
protein into ISCOM. The sequence encoding the transmembrane region of 
HA was cloned into the 3' end of the influenza virus MA protein encoding 
gene, which was subsequently expressed as a recombinant fusion protein. 
The transmembrane region of the HA indeed facilitated the incorporation of 
the MA protein into ISCOM. To investigate whether the MA protein 
containing ISCOM were processed by the endogenous antigen processing 
pathway resulting in MHC class I presentation of the MA protein-derived 
peptide GILGFVFTL, the recognition of antigen-pulsed target cells by a 
HLA-A2-restricted CDS+ CTL clone specific for tlils peptide was studied in 
CTL assays. It was shown that target cells incubated with rMAHA-ISCOM 
were lysed by the MA protein-specific CTL clone, whereas target cells 
incubated with ISCOM prepared with the MA protein lacking the 
hydrophobic extension or soluble rMA or rMAHA protein were not 
recognized. From these data it was concluded that the addition of the 
transmembrane region of HA facilitated incorporation into the ISCOM 
structure and that this was necessary for entry into the endogenous route of 
antigen processing. 
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Figure 3. Confirmation of influenza virus MA protein-specificity and HLA-A2 restriction 
of one CTL clone. B-LCL of a HLA-A2 positive (A) and a HLA-A2 negative (B) donor 
were incubated with peptide GILGFVFTL (solid circles), infected with recombinant 
vaccinia virus expressing the influenza virus MA protein (solid squares), control vaccinia 
virus (open squares) or influenza virus (triangles) and used as target cells in CTL assays 
with the CTL clone as effector cells. Untreated B-LCL (open circles) served as a negative 
control. 
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Figure 4. MHC class I presentation of influenza virus MA protein and influence of 
proteasome inhibitors. B-LCL were incubated with empty ISCOM, rMA protein, rMARA 
protein, rMA-ISCOM, rMAHA-ISCOM, rMA protein and empty ISCOM, rMAHA protein 
and empty ISCOM or left untreated (A). In another experiment, B-LCL were incubated 
with rMAHA protein and empty ISCOM in nonnalmedium or in medium containing 3 ~M 
of the proteasome inhibitor lactacystin or clasto-Iactacystin Jl-Iactone (B). The B-LCL were 
used as target cells in CTL assays with a MA protein-specific CTL clone as effector cells. 
CTL assays were performed with ten replicates per target per experiment at an effector to 
target ratio of 10. Mean percentages specific lysis +/- S.E.M. are shown for one (B) or two 
similar experiments (A). 
Interestingly, autologous B-LCL incubated with empty ISCOM together 
with the recombinant proteins rMA or rMAHA also resulted in the specific 
lysis of these cells by the MA protein-specific CTL clone. These target cells 
were lysed significantly more efficiently than the target cells incubated with 
rMA- or rMAHA-ISCOM. It can not be excluded, however, that possible 
differences in the composition of the respective ISCOM preparations had an 
influence on the level of antigen presentation. This finding conflicts with 
data obtained in previous studies showing that the measles virus fusion (F) 
protein was only processed for MHC class I presentation by B-LCL after 
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incorporation into ISCOM and not when it was administered in the presence 
of empty ISCOM3. The processing and presentation we observed after 
mixing empty ISCOM with proteins indicate that the proteins can associate 
with the ISCOM through hydrophobic interactions. Indeed, the MA protein 
contains hydrophobic domains which are most likely involved in 
interactions with the lipid membrane of the virus31 ,38. The finding that the 
addition of the hydrophobic transmembrane region of HA improves 
presentation of the MA peptide is in agreement with this hypothesis. 
FUlihennore it was shown that the physical interaction between empty 
ISCOM and protein is required for MHC class I processing and presentation 
of the MA protein since pre-incubation of the target cells with empty 
ISCOM followed by an incubation with protein did not result in recognition 
of the target cells by the CTL clone. The bacterial fusion part, MBP, did not 
appear to play a direct role in incorporation into ISCOM or entry of 
recombinant proteins into the endogenous processing pathway since rMA-
ISCOM and soluble rMA- or rMAHA failed to sensitize B-LCL for 
recognition by the CTL clone. 
Recognition of the target cells incubated with rMAHA-ISCOM or empty 
ISCOM together with rMA or rMAHA protein by the CTL clone showed to 
be influenced by the proteasome inhibitors lactacystin and clasto-lactacystin 
~-lactone. This indicates that processing was dependend on proteasome 
activity, which is impOliant for cytosolic protein degradation typical for 
endogenous processing, and that the antigenic peptides were liberated from 
ISCOM-delivered MA protein in the cytosolic compartment rather than in 
lysosomes from which they could have leaked into the cytosol. 
In conclusion, we have demonstrated that ISCOM facilitate the entry of 
influenza virus MA protein into the endogenous processing pathway leading 
to MHC class I presentation of a HLA-A2-restricted CTL epitope. This was 
improved after its co-expression with the transmembrane region of 
influenza HA. The introduction of a hydrophobic region into hydrophilic 
proteins by way of recombinant DNA technology would in principle be 
universally applicable and could therefore be exploited for the development 
of ISCOM vaccines for a variety of virus infections against which CTL-
mediated immunity plays a role. 
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SUMMARY 
In general, exogenous proteins are processed by APC in the endosomes for 
MHC class II presentation to CD4+ T cells, while proteins synthesized 
endogenously are processed in the cytoplasm for MHC class I presentation 
to CD8+ T cells. However, it is recognized that exogenous proteins can be 
processed for MHC class I presentation also and evidence in favour of 
alternatives to the conventional MHC class I processing and presentation 
pathway is accumulating. Here, we show that exogenous recombinant 
influenza A virus nucleoprotein (rNP) is processed for MHC class I 
presentation to CD8+ CTL by EBV -transformed B-Iymphoblastoid cell lines 
(B-LCL). The presentation of the HLA-A3-restricted peptide ILRGSVAHK 
(aa 265-273) was found to be less efficient than that of the HLA-B27-
restricted peptide SRYWAIRTR (aa 383-391), since approximately hundred 
times more rNP or peptide was required to sensitize B-LCL cells for 
recognition by HLA-A3-restricted CTL. Processing of rNP for HLA-B27-
associated presentation seemed to follow the conventional MHC class I 
pathway predominantly, since presentation was diminished in the presence 
of lactacystin (inhibiting proteasome activity) and brefeldin A (inhibiting 
transpOli from the endoplasmic reticulum) but was less sensitive to 
chloroquine and NH4CI (both inhibiting proteolysis in endosomes). HLA-
B27-associated presentation was also observed using cells lacking a 
functional TAP, suggesting that alternative pathways may be exploited for 
processing ofrNP. 
INTRODUCTION 
In vhus-infected cells, antigenic peptides are liberated in the cytoplasm 
from endogenously synthesized proteins and are presented to CD8+ CTL by 
MHC class I molecules. These proteins are degraded by a multi-enzyme 
complex, the proteasome, which generates peptides 9-12 amino acids long 
that are subsequently transported to the endoplasmic reticulum (ER) by 
TAP. In the ER, the peptides associate with MHC class I molecules and the 
resulting complex traverses the Golgi apparatus to be presented at the 
surface of the cell for recognition by specific CTL13.15.23.24.47. 
Although proteins synthesized in the cytoplasm of infected cells are the 
main substrate for the conventional (endogenous) MHC class I processing 
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and presentation pathway, it has become evident that peptides liberated from 
exogenous proteins can be presented in a MHC class I -restricted fashion 
also and evidence in favour of alternatives to the conventional MHC class I 
pathway is accumulating",3o,46, Indeed, it has been shown that macrophages, 
as well as other APC, can process a vast diversity of exogenous antigens, 
including particulate antigens like bacteria, bead-coupled antigens, cell 
debris, inactivated viruses, and antigens associated with or incorporated into 
virosomes, liposomes or immune stimulating complexes (iscoms) for MHC 
class I presentation46, Recently, it was shown that MHC class I presentation 
of exogenous antigens may be necessmy for the induction of CTL responses 
whereby APC function as messengers for infected non-lymphoid cells (by 
taking up viral proteins or virus-infected cells) which would otherwise be 
difficult to target by specific CTL 35,J6. 
Several mechanisms for processing of exogenous proteins and MHC class I 
presentation have been proposed. The results of several studies suggest a 
model in which endocytosed exogenous proteins gain access to the 
cytoplasm either by leakage from endosomal compartments or by a yet 
unknown transpOlt mechanism, and subsequently follow the conventional 
MHC class I pathways,20,25,JI,J3, Results of other shldies suggest an alternative 
mechanism in which endocytosed exogenous proteins are degraded in an 
endosomal compmiment and subsequently loaded onto MHC class I 
molecules3,14,22)4,38. This could take place either extracellularly following 
regurgitation, or in the endosomal compartment itself following 
internalization of MHC class I molecules from the cell surface. 
Processing of exogenous proteins for MHC class I presentation has been 
demonstrated almost exclusively for macrophages and dendritic cells46. B-
lymphocytes usually process exogenous antigen for MHC class II 
presentation by means of inte111alization of antigen bound to surface Ig 
(receptor-mediated endocytose). It has been demonstrated that B-
lymphocytes can present exogenous antigen in association with MHC class I 
molecules also, but only if the antigen matches the surface Ig6,17. 
Here, we describe MHC class I presentation of exogenous recombinant 
influenza A virus nucleoprotein (rNP) by EBV -transformed B-
Iymphoblastoid cell lines (B-LCL). MHC class I processing and 
presentation of rNP-derived peptides were studied using CTL clones 
specific for the HLA-A3-restricted peptide ILRGSVAHK (aa 265-273) and 
the HLA-B27-restricted peptide SRYWAIRTR (aa 383-391). 
78 
Chapter 4 
MATERIALS AND METHODS 
Pmduction of rNP 
rNP of influenza virus AlHongKong/2/68;H3N2 (AIHKI2/68), AlNetherlandsll8/94;H3N2 
(AlNeth/18/94), and B/Harbinl7l94 (B/HarI7194) was produced as described previously". 
In brief, the nucleoprotein (NP)-encoding genes were cloned at the 3' end of the maltose 
binding protein (MBP)-encoding gene using the bacterial expression vector pMalC (New 
England Biolabs) to yield fusion proteins consisting of MBP at the N-tenllinus and NP at 
the C-terminus. Recombinant MBP alone (rMBP) was generated from the empty vector as 
a control. The resulting recombinant proteins were purified by affinity chromatography 
using amylose resin columns (New England Biolabs). 
Isolation and analysis of NP-specific CTL clones 
A HLA-B27-restricted CTL clone, designated NP/B27, with specificity for the influenza A 
vims NP epitope SRYWAIRTR (aa 383-391) was isolated as previously described41 . A 
HLA-A3-restricted CTL clone, designated NP/A3, specific for the influenza A virus NP 
epitope ILRGSV AHK (aa 265-273) was kindly provided by Dr. W. Biddison, NIH, 
Bethesda, MD. Phenotype, specificity and HLA restriction of both CTL clones were 
confinned as described41 . 
CTL assays 
IxlO' B-LCL cells ofa HLA-A3 and -B27 positive donor were incubated with rNP derived 
from A1HKI2/68, AINethll8/94 or B/HarI7l94, or rMBP (0-50 Ilg/ml), or were incubated 
with the peptide ILRGSVAHK or SRYWAIRTR (0-10 ~M) in I ml RPMI 1640 medium 
containing L-glutamin (2mM), penicillin (100 IUlml), streptomycin (100 ~g/ml) and 10% 
FBS (culture medium) at 37'C and 5% CO,. In addition, B-LCL cells were infected with 
influenza virus (Rcsvir-9; a H3N2 reassortant influenza vims obtained from 
AlNatlchang/933195;H3N2 and AlPuerto Rico/8/34;HINI) at a multiplicity of infection 
(m.oj.) of 0.1. Infections were performed for I h in I ml RPM! 1640 medium without 
FBS, washed with cuiture medium and further cultured iu I ml of this medium. Also, I x I 0' 
BM28.7 and BM36.1 cells, both transfectant cell lines expressing HLA-B27 with the 
BM36.1 cell line differing from BM28.7 in a 2 bp deletion in TAP2 leading to a 
nonfunctional TAP lIT AP2 complex1', were incubated with rNP derived from AlHKl2/68 
(0-5 ~g/ml), the peptide SRYWAIRTR (0-10 nM) or infected with influenza VinlS (m.oj. ~ 
0.1) as described above. The BM28.7 and BM36.1 cell lines were cultured in the presence 
of 300 Ilg/ml geneticin. In selected experiments, cells were cultured in the continuous 
presence of lactacystin (311M) or brefeldin A (50 11M). After an incubation of I h 
(peptide-pulsed cells) or 16 Ius (rNP-incubated or influenza virus-infected cells), target 
cells were washed with culhlre medium to remove excess peptide, antigen, lactacystin and 
brefeldin A and labeled for I h with 75 IICi Na,[,l Crj04' After washing three times with 
culture medium, 104 target cells were incubated with 10' cells of the NP/A3 or NP/B27 
CTL clone (E:T ratio ~ 10) in a total volume of 150 ~I for 4 Ius at 37'C. Since the BM28.7 
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and BM36.1 ceHlines are HLA-A3 negative, only NPIB27 CTL were used as effector ceHs 
in experiments with these ceH lines. Target cells were also incubated in culture medium 
(spontaneous release) or in 10% Triton X-IOO (maximum release). Supernatants were 
harvested and radioactivity was measured by gamma coullting. The percentage specific 
lysis was calculated as: 100 x [experimental release - spontaneous release] / [maximum 
release - spontaneous release]. CTL assays were performed at least in tenfold. Statistical 
analysis was performed using Student-T tests. 
Lymphocyte Stimulation Test (LST) 
IxIO' B-LCL ceHs were incubated with rNP derived from AlHK/2/68 (50-100 Ilg/mI) or 
infected with influenza virus (m.o.L ~ 0.1) as described above, and cultured in the presence 
or absence of lactacystin (3 ~M), brefeldin A (50 11M), chloroquine (50 11M) or NH,CI (20 
mM). Also, I x I 0' BM28.7 and BM36.1 ceHs were incubated with rNP derived from 
AlHKl2/68 (100 Ilg/ml) and cultured in the presence or absence of these inhibitors. Culture 
conditions were as described above. After an incubation of 1611IS, cells were washed twice 
with PBS to remove antigen and inhibitors, fixed with parafonnaldehyde (1.5%), and 
resuspended in RPMI 1640 medium containing L-glutamin (2mM), penicillin (100 nJ/ml), 
streptomycin (l00 ~g/ml), 2-mercapto-ethanol (5xlO" M) and 10% human pool sernm. 
5xlO' of these stimulator cells were incubated with 5xlO' cells of the NP/A3 or NP/B27 
CTL clone in a total volume of200 ~I at 37'C and 5% CO,. After 3 days, 10 ~llH-labeled 
thymidine (50 ~CilmI) was added and after an incubation of 16 IlIS cells were harvested 
and thymidine incorporation was measured using a O-plate reader (LKB Wallac). The 
stimulation index was calculated as: radioactivity sample/radioactivity negative control 
(medium). LST were perfonned in triplicate. 
Radio Immuno Precipitation Assay (RIPA) 
6x10' B-LCL cells were washed in PBS and resuspended in 3 ml RPMI 1640 medium 
without L-methionin and L-cystin, supplemented with L-glutamin (2mM), penicillin (100 
IV/ml), streptomycin (100 IIg/mI), 5% dialysed FBS, and incubated at 37"C and 5% CO,. 
After 30 minutes, 300 IICi ofa mixture of"S-labeled L-methionin and L-cystin was added 
and incubated for 15 minutes. Cells were pelleted and resuspended in 2 ml ice cold RIP A 
buffer (10 mM Tris pH 7.8,150 mM NaCI, 600 mM KCI, 4 mM EDTA, 2% Triton X-IOO, 
2.5 mM iodocetamide and protease inhibitor (Complete, Boehringer Mamlheim). After 
incubation on ice for 10 minutes, the lysate was centrifuged and the supernatant used for 
immuno-precipitation. 1% of the volume (20 III), diluted in 300 III PBS, was incubated 
with 50 ~I of a 20% suspension of protein A beads and I 0 ~I control mouse ascites fluid 
for I h at 4'C. Beads were pelleted and the supernatant was incubated with 50 III protein A 
beads and 5 It! normal mouse sennn for I h at 4"C. Again, beads were peHeted and the pre-
cleared supernatant was used for specific precipitation with monoclonal antibodies directed 
against HLA-A3 or -B27 (Biotest). 50% of the lysate was incubated with 100 It! protein A 
beads and 50 It! anti HLA-A3 antibody or anti HLA-B27 antibody and incubated for I hat 
4"C. Beads were pelleted and resuspended in SDS-PAGE sample buffer to a final volume 
of 150 III. The supernatant was subjected to a second round of precipitation with the 
respective monoclonal antibodies after which the beads were resuspended in SDS-PAGE 
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sample buffer to a final volume of 150 pI. Samples were boiled for 3 minutes and 50 ~t1 
was loaded onto a 15% polyacrylamide gel. After electrophoresis, gels were incubated in a 
solution of 40% methanol and 10% acetic acid for I h, followed by incubation in distilled 
H20 for 30 minutes. Then, the gels were incubated with amplify solution (Phannacia 
Amersham) for 30 minutes, dried under vacuum at 80'C for 2 hrs and exposed to X-ray 
film. 
RESULTS 
MHC class I presentation of rNP 
B-LCL cells of a HLA-A3 and -B27 positive donor were incubated with 
various concentrations of rNP derived from AlHKJ2/68 and used as target 
cells in CTL assays (Figure lA). B-LCL cells incubated with as little as 0.2 
~lg rNP were recognized by NP/B27 CTL. The percentage of specific lysis 
by these CTL increased with increasing concentrations of rNP. The B-LCL 
cells were also recognized and lysed by NPI A3 CTL, but only after 
incubation with rNP at the highest concentration tested (50 !Jg/ml). The 
recognition of the rNP-derived peptides ILRGSVAHK (aa 265-273) and 
SRYWAIRTR (aa 383-391) by NP/A3 and NP/B27 CTL respectively, was 
also studied with B-LCL from other donors which were either HLA-A3, 
HLA-B27 or HLA-A3 and -B27 positive, but with mismatching other HLA-
A and -B alleles. With these B-LCL, comparable results were obtained (data 
not shown). Using peptide-pulsed cells it was found that at saturating 
. concentrations of peptide, the B-LCL cells were lysed equally well by 
NP/A3 and NP/B27 CTL whereas at low concentrations of peptide (below 
0.01 ,lM) only NPIB27 CTL specifically lysed the B-LCL cells (Figure IB). 
Thus, HLA-B27 requires approximately 100-fold less rNP or peptide for 
efficient lysis by NP/B27 CTL. Fmihermore, in LST, proliferation of 
NPIB27 CTL was observed after stimulation with B-LCL cells incubated 
with rNP (Figure 4B) while NP/A3 CTL failed to respond (data not shown). 
In order to fmiher address the observed differences in recognition by NP/A3 
and NPIB27 CTL, the expression levels of HLA-A3 and HLA-B27 
molecules in the B-LCL cells was studied. In a RIPA it was shown that the 
expression levels of HLA-A3 and HLA-B27 in the B-LCL cells used were 
comparable (Figure 2). 
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Figure 1. MHC class I presentation of rNP. B-LCL cells of a HLA-A3 and -B27 positive 
donor were incubated with various concentrations of rNP derived from AlHK/2/68 (A) or 
various concentrations of the HLA-A3-restricted peptide ILRGSV AHK (B, left panel) or 
the HLA-B27-restricted peptide SRYWAIRTR (B, right panel) and used as target cells in 
CTL assays with NPI A3 and NP/B27 CTL as effector cells. CTL assays were performed in 
tenfold. Mean percentages of specific lysis at an E:T ratio of 10: I are shown. 
To confirm that the recognition of the B-LCL cells incubated with rNP by 
NP/ A3 and NPIB27 CTL was specific for the epitopes ILRGSV ARK and 
SRYWAIRTR, respectively, B-LCL cells were incubated with rNP derived 
from AIHKI2/68, AlNethl18/94 (containing an amino acid mutation in the 
HLA-B27-restricted epitope), BlHarl7/94, or rMBP (both of which do not 
contain the HLA-A3 and HLA-B27-restricted epitopes and served as 
negative controls) (Figure 3A). B-LCL cells were lysed by NPIB27 CTL 
after incubation with 0.5 /lg rNP derived from AlHKl2/68 but not after 
incubation with the same amount ofrMBP or rNP derived from B/Harl7/94 
or A/NethI18/94 which contains a R384G mutation in the SRYWAIRTR 
epitope. This mutation has been associated with the loss of recognition by 
CTL specific for this epitope41 • B-LCL cells incubated with 50 /lg rNP 
(required to measure specific lysis by NP/A3 CTL; see figure lA) derived 
from AlHKl2/68 or AlNethl18/94 (which both contain the ILRGSV AHK 
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epitope) were recognized by NP/A3 CTL. Like NPIB27 CTL, NPlA3 CTL 
did not lyse B-LCL cells incubated with the same amount of rNP of 
B/Har/7/94 or rMBP. 
MW(kD) 
220 
97.4 
66 
46 
30 
21.5 
14.3 
HLA-A3 HLA-B27 
precipitation I 2 I 2 
Figure 2. Analysis of expression levels of HLA-A3 and HLA-B27 in B-LCL cells. B-LCL 
cells incubated with "S-labeled cysteine and methionine were lysed and the pre-cleared 
lysate was subjected to two rounds of specific precipitation using HLA-A3 and HLA-B27-
specific monoclonal antibodies. Lanes I: first precipitation, lanes 2: second precipitation. 
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Figure 3. MHC class I presentation of rNP derived from several influenza vintses and the 
effect of lactacystin and brefeldin A. B-LCL cells of a HLA-A3 and -B27 positive donor 
were incubated with 50 (left panel) or 0.5 ~Ig (right panel) rNP derived from AIHKI2I68, 
AINethll8194 or BIHarI7l94, with rMBP or left untreated (A), or incubated with 50 (left 
panel) or 0.5 fig (right panel) rNP derived from AIHKI2168 or infected with influenza vims 
(m.o.L ~ 0.1) in the presence or absence of lactacystin or brefeldin A (B). Cells were used 
as target cells in CTL assays with NPI A3 and NPIB27 CTL as effector cells. CTL assays 
were performed in tenfold. Mean percentages of specific lysis at an E:T ratio of 10: I are 
shown. 
Effect of lactacystin and brefeldill A on 
MHC class I presentation of rNP 
In order to study the route of processing of rNP, B-LCL cells were 
incubated with rNP derived from AlHKl2/68 in the continuous presence of 
the MHC class I pathway inhibitor lactacystin, which inhibits proteasome 
activity, or brefeldin A, which blocks transport from the ER (Figure 3B). As 
a control, B-LCL cells infected with influenza virus Resvir-9 (of which the 
NP contains both the HLA-A3 and I-ILA-B27-restricted epitopes) were 
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included. Both NP/A3 and NPIB27 CTL lysed virus-infected target cells. As 
expected, recognition of virus-infected cells by these CTL was sensitive to 
the action of lactacystin and brefeldin A (p<O.OO I). The recognition of B-
LCL cells incubated with rNP in the presence of these inhibitors was also 
reduced (p<O.OOI) suggesting that the conventional MHC class I pathway is 
of importance for processing and presentation of rNP in these cells. The 
results obtained with the CTL assays were confirmed in a LST: proliferation 
of NP/A3 and NP/B27 CTL was reduced after stimulation with influenza 
virus-infected B-LCL cells which had been cultured in the presence of 
lactacystin or brefeldin A (Figure 4A). Likewise, proliferation of NPIB27 
CTL was reduced when B-LCL cells had been incubated with rNP derived 
from A/HK!2/68 in the presence of these inhibitors (Figure 4B). 
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Figure 4. Effect of inhibitors of the conventional MHC class I pathway and endosomal 
antigen processing on MHC class I presentation of rNP. B-LCL cells of a HLA-A3 and -
B27 positive donor were infected with inflnenza virus (m.o.i. ~ 0.1) in the presence or 
absence of lactacystin, brefeldin A, chloroquine or NH,CI and used as stimulator cells in 
LST with NPfA3 and NPfB27 CTL (A). B-LCL cells were also incubated with 100 ~lg rNP 
derived from AfHKf2f68 in the presence or absence of these inhibitors and used as 
stimulator cells in LST with NPfB27 CTL (B). LST were performed in triplicate. Mean 
stimulation indices are shown. 
85 
lHHC class j presentation of exogenous influenza nucleoprotein 
Effect of chloroquine and NH,CI on MHC class I presentation of rNP 
A possible role for endosomal processing was studied using chloroquine and 
NH,CI which prevent acidification of endosomes and, consequently, 
proteolysis. The effect ofthese inhibitors was not tested in CTL assays since 
the required continuous presence of these agents affected CTL activity. 
Therefore, paraformaldehyde fixed B-LCL cells which had been infected 
with influenza virus Resvir-9 or incubated with rNP derived from 
AlHKl2/68 in the presence or absence of these inhibitors were used as 
stimulator cells in LST. Proliferation of NP/A3 and NPIB27 CTL was 
reduced after stimulation with infected B-LCL cells which had been 
cultured in the presence of chloroquine or NH,CI as compared to CTL 
stimulated with untreated infected B-LCL cells (Figure 4A). This is 
explained by the fact that a low pH in the endosomes is essential for 
conformational changes in the haemagglutinin allowing fusion of the viral 
melnbrane with the membrane of endosomes and subsequent release of viral 
antigens into the cytoplasm. In contrast, no significant difference in 
proliferation of NP/B27 CTL was observed upon stimulation with B-LCL 
cells incubated with 100 pg rNP in the presence or absence of these 
inhibitors (Figure 4B). When B-LCL cells were incubated with a lower 
amount of rNP (50 fIg) only a limited reduction in proliferation of NPIB27 
CTL was observed (data not shown). 
MHC class I presentation of rNP in the absence of TAP 
To study the role of TAP in the processing of rNP, BM28.7 and TAP-
deficient BM36.1 cells were used. The recognition of virus-infected 
BM36.1 cells by NPIB27 CTL was significantly reduced (p<O.OOl) 
compared to the recognition of the corresponding TAP-competent BM28.7 
cells (Figure SA). This difference could not be attributed to differences in 
the infection rates of the respective cell lines since both cell lines were 
infected equally well as demonstrated by immunofluorescense using a NP-
specific monoclonal antibody (data not shown). Surprisingly, the opposite 
was found for rNP derived from AlHKl2/68. BM36.1 cells incubated with 
rNP were lysed more efficiently by NPIB27 CTL than BM28.7 cells 
(p<O.OOl). To rule out that the observed differences between the BM28.7 
and BM36.1 cells are the result of differences in the expression of peptide-
receptive HLA-B27 molecules, the recognition of these cells by NP/B27 
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CTL was studied after incubation with limiting amounts of peptide (Figure 
SB). 
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Figure 5. MHC class I presentation of rNP in the absence of TAP and the effect of 
inhibitors of the conventional MHC class I pathway and endosomal antigen processing. 
BM28.7 and BM36.1 cells were incubated with 0.5 or 5 fIg rNP derived fi'om AIHKl2/68 
or infected with influenza virus (m.o.i. ~ 0.1) (A), incubated with various concentrations 
of the HLA-B27-restricted peptide SRYWAIRTR (B), or incubated with 5 fIg rNP derived 
from A/HKl2/68 in the presence of lactacystin or brefeldin A (C). Cells were used as target 
cells in CTL assays with the NP/B27 CTL as effector cells. CTL assays were performed in 
tenfold. Mean percentages of specific lysis at an E:T ratio of 10: I are shown. BM28.7 and 
BM36.1 cells incubated with 100 fIg rNP derived from A1HK12/68 in the presence or 
absence of lactacystin, brefeldin A, chloroquine or NH,CI were used as stimulator cells in 
LST with the NP/B27 CTL (D). LST were performed in triplicate. Mean stimulation 
indices are shown. 
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Both cell lines were recognized equally well by the NP/B27 CTL under 
these conditions indicating that I-ILA -B27 was expressed at comparable 
levels in both cell lines. In contrast to the CTL assay, no differences in 
proliferation of NP/B27 CTL stimulated with BM36.1 or BM28.7 cells 
incubated with rNP were observed (Figure 5D). 
The effect of the MHC class I pathway inhibitors lactacystin and brefeldin 
A, as well as inhibitors of endosomal processing (chloroquine and NH4Cl) 
was also studied for BM28.7 and BM36.1 cells incubated with rNP derived 
from AlHKl2/68 (Figure 5C and D). Specific lysis by NP/B27 CTL was 
reduced when cells had been incubated with rNP in the presence of either 
lactacystin or brefeldin A (Figure 5C). Similarly, proliferation of NPlB27 
CTL was reduced under these circumstances (Figure 5D). Although 
proliferation ofNP/B27 CTL stimulated with BM28.7 cells which had been 
incubated with rNP in the presence of chloroquine was reduced, no 
reduction was observed when BM28.7 cells had been incubated with rNP in 
the presence of NH4Cl. In contrast, proliferation of NPIB27 CTL was 
severely reduced when TAP-deficient BM36.1 cells had been incubated 
with rNP in the presence of chloroquine or NH4Cl (Figure 5D). 
DISCUSSION 
Although exogenous proteins are usually processed for MHC class II 
presentation to CD4+ Th cells, it has been shown that some APC (e.g. 
macrophages and dendritic cells) are capable of processing these proteins 
for MHC class I presentation to CD8+ CTL as well (8). With the exception 
of proteins that are delivered into the cytosol mtificially (e.g. proteins 
associated with iscoms), or proteins that are internalized by receptor-
mediated endocytosis, MHC class I presentation of exogenous protein by B-
lymphocytes thus far has not been demonstrated'·'·17·19,21,32,)).4'. Here, we 
show MHC class I presentation of the HLA-A3-restricted peptide 
ILRGSV AHK (aa 265-273) and the HLA-B27-restricted peptide 
SRYWAIRTR (aa 383-391) derived fi-om exogenous rNP by B-LCL. 
The NPIB27 CTL recognized B-LCL cells which had been incubated with 
rNP at a concentration of 200 ng/ml, while approximately 100 times higher 
concentrations of rNP were required to sensitize B-LCL cells for lysis by 
NP/A3 CTL. Since the expression levels of I-ILA-A3 and HLA-B27 in the 
B-LCL cells were virtually identical, the differences observed between 
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HLA-A3 and HLA-B27-associated presentation should result from 
differences in the efficiency of processing or presentation of the respective 
epitopes, or intrinsic differences between both CTL. Recently, it has been 
demonstrated that HLA-B27-restricted peptides have higher affinity for 
TAP than HLA-A3-restricted peptides9 and, using peptides, we have shown 
that B-LCL cells could be sensitized for lysis by NPIB27 CTL at peptide 
concentrations much lower than needed for measuring HLA-A3-associated 
presentation. Peptides with higher affinities for their MHC class I molecule 
andlor TAP may be presented more efficiently than peptides possessing low 
affinity. The efficient presentation by HLA-B27 molecules may also be 
related to some unique features of these MHC class I molecules including 
their ability to bind peptides without associating with TAP or tapasin, the 
ability to bind peptides longer than nonamers and to form peptide binding 
homodimers '·26•39• 
The mode of processing of exogenous proteins for MHC class I-restricted 
presentation is not fully clear. MHC class I presentation of the HLA-A3 and 
HLA-B27-restricted peptides derived frohl exogenous rNP, like presentation 
of these peptides derived from de novo synthesized NP by virus-infected 
cells, was found to depend on proteasome activity and to be sensitive to 
brefeldin A. This suggests that rNP gained access to the cytoplasm, 
following endocytosis and subsequent leakage from endosomes, and that 
processing and presentation followed the conventional MHC class I 
pathway. It is unlikely that endocytsosis was receptor-mediated since the B-
LCL cells did not express NP or MBP-specific Ig (data not shown). 
Previously, we have shown that influenza virus Ml protein fused to MEP 
only sensitized B-LCL cells for recognition by CTL specific for the Ml 
protein, HLA-A2-restricted, epitope GILGFVFTL (58-66) when the protein 
was associated with iscoms42. In addition, B-LCL cells incubated with high 
doses (100 ~lg) of this recombinant Ml protein (without iscoms) were not 
recognized by specific CTL (unpublished data). These results rule out a 
direct role of MBP in entry of rNP into the MHC class I pathway. 
HLA-B27-associated presentation by B-LCL cells was shown to be 
insensitive to chloroquine and NH4Cl at a high concentration of rNP, while 
at a lower concentration limited sensitivity to these agents was observed. 
This suggests that, in addition to the conventional MHC class I pathway, 
endosomal processing may be exploited by these cells to a limited extent. It 
is possible that in the endosomal compartments of B-LCL cells peptides 
were generated from rNP by proteolysis and subsequently loaded onto 
89 
kfHC class 1 presentation of exogenous influenza Jlucleoprotein 
peptide-receptive internalized MHC class I molecules, which are known to 
recycle through endosomal compmimentsli ,28, This process could then be 
followed by presentation to specific CTL. While this mechanism may have 
contributed to the observed MHC class I presentation of rNP, it is most 
probably not the major route, Indeed, inhibition of presentation by 
chloroquine and NH,Cl was less pronounced than by inhibitors of the 
conventional MHC class I pathway, 
Surprisingly, HLA-B27-associated presentation of rNP also occured in the 
TAP-deficient cell line BM36, 1. Since in cells lacking a functional TAP the 
conventional MHC class I pathway is hampered, as demonstrated by the fact 
that recognition of influenza virus-infected BM36,1 cells by NPIB27 CTL 
was reduced, processing and presentation of rNP in these cells must have 
followed alternative routes, TAP-independent MHC class I-restricted 
presentation has been described for peptides liberated from N-tenllinal 
signal sequences of proteins that enter the ER via translocation2",IO,I2,16,37,4J,45, 
In addition, it has been suggested that entry of proteins or peptides in the ER 
of TAP-deficient cells may take place by (unknown) mechanisms other than 
translocation37, Since the influenza virus NP does not contain a signal 
sequence and because it was cloned C-terminal of the MBP, translocation-
mediated entry in the ER is unlikely, MHC class I presentation of rNP by 
BM36,1 cells, but not BM28,7 cells, was found to be severely inhibited by 
chloroquine and NH,CI indicating that the endosomal route is involved in 
the processing of rNP in these cells, These results are in agreement with a 
study showing that processing and presentation of an ovalbumin epitope 
(257 -264), contained within an ovalbumin fusion protein, was sensitive to 
chloroquine in TAP-deficient macrophages, but not 111 normal 
macrophages44 , 
The observed MHC class I presentation of rNP by BM36.1 cells was also 
found to be sensitive to brefeldin A indicating that antigenic peptides were 
loaded onto MHC class I molecules prior to their transpoti to the cell 
surface, In addition to inhibition of transport of MHC class I molecules from 
the ER to the cell surface, brefeldin A is known to inhibit transpoti of MHC 
class II molecules from the endosomes to the cell surface", It may be 
speculated that brefeldin A could also affect transport of internalized MH C 
class I molecules, loaded with peptide in the endosomes, back to the cell 
surface, Alternatively, brefeldin A treatment could have resulted in a 
reduced availability ofMHC class I molecules for recycling in endosomes, 
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Interestingly, the processing of rNP in BM36.1 cells was sensItive to 
lactacystin implying that, at least in pmi, the peptides that were presented to 
the NPIB27 CTL were liberated by proteasome activity. Since BM36.1 cells 
are unable to transpoli these peptides in the ER by TAP, they were probably 
loaded onto MHC class I molecules through alternative, yet unkown, routes 
which may involve endosomes, the ER or a post ER compartment. 
Collectively, the data presented show MHC class I presentation of 
exogenous rNP by B-LCL cells. Wllile in normal cells the conventional 
MHC class I pathway seems to predominate, in TAP-deficient cells 
alternative pathways, including endosomal processing, may operate for 
HLA-B27-associated presentation. The results of this study also show that 
care should be taken in drawing conclusions with respect to the steps 
involved in processing and presentation of exogenous proteins. 
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SUMMARY 
Viruses exploit different strategies to escape immune surveillance, including 
the introduction of mutations in cytotoxic T-Iymphocyte (CTL) epitopes. 
The sequence of these epitopes is critical for their binding to major 
histocompatibility complex (MHC) class I molecules and recognition by 
specific CTLs, both of which interactions may be lost by mutation. 
Sequence analysis of the nucleoprotein gene of influenza A viruses (H3N2) 
isolated in The Netherlands from 1989 to 1999 revealed two independent 
amino acid mutations at the anchor residue of the HLA-B27-specific CTL 
epitope SRYWAIRTR (383 to 391). A R384K mutation was found in 
influenza A viruses isolated during the influenza season 1989-1990 but not 
in subsequent seasons. In the influenza season 1993-1994, a novel mutation 
in the same CTL epitope at the same position was introduced. This R384G 
mutation proved to be conserved in all influenza A viruses isolated from 
1993 onwards. Both mutations R384K and R384G abrogated MHC class-I 
presentation and allowed escape from recognition by specific CTLs. 
INTRODUCTION 
Cytotoxic T lymphocytes (CTLs) of the CD8+ phenotype control viral 
infections by recognizing antigenic peptides of viral proteins presented by 
infected cells in association with major histocompatibility complex (MI-IC) 
class I molecules. The interaction of specific CTLs with these complexes 
may lead to the elimination of infected cells. Viruses exploit several 
strategies to escape from immune surveillance by CTLs21 ,32. One strategy 
involves the introduction of amino acid mutations within CTL epitopes or in 
sequences flanking these epitopes, The flanking sequences are important for 
cytosolic processing of the viral proteins to yield the CTL epitopes, usually 
9-mer peptides, while the epitope sequences themselves are critical both for 
association with MHC class I molecules and recognition by virus-specific 
CTLs. Mutations within or in close proximity of CTL epitopes, therefore, 
may be accompanied by loss of CTL-mediated lysis of target cells I5 ,46. In 
addition, mutations in CTL epitopes may generate peptides that antagonize 
CTL function2,IO,18,20,38. Mutations that affect CTL epitopes, resulting in 
escape from immune surveillance by specific CTLs, have been described for 
several viruses causing persistent infections, includinf. lymphocytic 
choriomeningitis virus2 ,35, Epstein-Barr virus l , ,6,7, human 
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immunodeficiency virus8,13,21,27,34,37, hepatitis B virus3, and hepatitis C 
. 45 
VllUS • 
Influenza A viruses, causing acute infections, continuously escape from 
recognition by virus-neutralizing antibodies as a result of accumulation of 
mutations in their surface glycoproteins hemagglutinin and neuraminidase 
(antigenic drift) or by introduction of new subtypes of these glycoproteins 
(antigenic shift). The more conserved internal proteins of influenza viruses, 
such as the nucleoprotein (NP) and the matrix protein are impotlant targets 
for CTLs 12,25. Mutations in these proteins, which occur less frequently than 
in the surface glycoproteins, potentially could affect CTL-mediated immune 
surveillance. 
Here we show that mutations at the anchor residue of the HLA-B27-
restricted CTL epitope SRYWAIRTR (383-391), found in the NP of 
influenza A (H3N2) viruses isolated between 1989 and 1999 in The 
Netherlands, abrogate MHC class I presentation and recognition by specific 
CTLs. 
MATERIALS AND METHODS 
RNA isolation, RT-PCR and sequencing 
RNA of 59 influenza A (H3N2) vimses of the influenza season 1989-1990, 16 of the 
season 1991-1992, 16 of the season 1992-1993,56 of the season 1993-1994, and 15 of the 
season 1998-1999 (arbitrarily chosen) obtained from the Dutch National Influenza Centre 
originating from geographically distinct areas in The Netherlands, was isolated using a 
high-pure RNA isolation kit (Boehringer Mannheim) and dissolved in 50 It! 
diethylpyrocarbonaat-treated H20. The RNA was used as template to mUltiply all eight 
gene segments in a reverse transeriptase PCR (RT-PCR) using a single primer set. The RT-
PCR reaction mixture contained 5 )II of RNA, 10 pmol of Ml3-unil2 primer 
(CAGGAAACAGCTATGACCAGCAAAAGCAGG), 10 pmol of Ml3-unil3 primer 
(TGTAAAACGACGGCCAGTAGTAGAAACAAGG), 0.01 M DTT, 0.25 mM 
deoxynucleoside triphosphates (dNTPs), 10 U of Rnasin (promega), 8 U of avian 
myeloblastosis virus RT (Promega), and 1.25 U of Pfh polymerase (Stratagene) in a total of 
25 )11 I x Pfit polymerase buffer. The mixture was incubated for 60 min at 42°C followed 
by 4 min at 95°C, 2 min at 37°C, and 3 min at 72°C and 19 cycles of incubation for 1 min at 
95°C, I min at 50°C, and 3 min at nOc. The resulting cDNAs were used as template in a 
NP-specific PCR (nucleotides [nt] 696 to 1243). One microliter of template was added to 
25 I" of reaction mixture containing 5 pmol of NP696 primer (TGCTTATGA-
GAGAATGTGCAA), 5 pmol of NPI243 primer (TCTGTTGGTTGGTGTTTCCTCC), 
1.5 mM MgCI2, 20 11M dNTPs, and 2.5 U of Taq polymerase (Promega) in a total of 25 It! 
I x Taq polymerase buffer. The mixture was incubated for 2 min at 95°C followed by I min 
at 50°C, and 3 min at noc and 29 cycles of incubation for I min at 95°C, 30 s at 50°C, and 
3 min at nOc. Amplified DNA was diluted 1:5, and 10 I" was added to 10 )11 of 
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sequencing reaction mixture (DYEnamic ET terminator cycle sequencing premix kit; 
Amersham Pharmacia Biotech, Inc.) containing 10 pmol of NP696 primer. The resulting 
mixture was incubated for 30 s at 95'C, 15 s at 45'C, and 2 min at 60'C for a total of 30 
cycles. Then, 2 fll of 3M NaAc pH 4.S and SO pi of absolute ethanol were added followed 
by incubation on ice for 15 min and centrifugation at 2,400 x g for 30 min. Pellets were 
resuspended in 3 III of sample buffer, and O.S fll was loaded on a sequence gel followed by 
automatic sequencing (ABI sequencer). Phylogenetic analysis was performed using 
DNAML software (Phylip version 3.5). 
Isolation and analysis of NP-specific CTL clones 
In round-bottomed microtiter plates, 1,000 peripheral blood mononuclear cells (PBMCs) of 
a selected donor (HLA-AOI, A03, B07, B2705, Cw02, Cw07) were stimulated twice, with 
an interval of one week, with 2.5 x 104 gamma-irradiated (30 min, 3,000 rads) autologous 
phytohemagglutinin-stimulated PBMCs pulsed with the peptide SRYWAIRTR (an HLA-
B27-reso'icted CTL epitope of the influenza A virus NP [amino acids (aa) 3S3 to 391]). The 
cells were cultured in RPMI 1640 medium containing L-glutamine (2 mM), streptomycin 
(100 pg/ml), penicillin (100 IU/ml), 2-mercaptoethanol (2 x 10" M), interleukin-2 (50 
U/ml), and 10% pooled human senun at 37'C and 5% CO,. One week after the second 
stimulation, expanded cells were analyzed for peptide-specific CTL activity. Cells from 
wells showing CTL activity were cloned by limitin¥ dilution (0.3 , I and 3 cells per well) 
and stimulated non-specifically by adding 3 x 10 APD B-Iymphoblastoid cell line (B-
LCL) cells, 3 x 104 BSM B-LCL cells, and 6 x 10' allogeneic PBMCs (which were all 
gamma irradiated); I fIg of phytohemagglutinin and 50 U of interleukin-2 per ml". After 
incubation for 2 weeks, clones showing CTL activity were stimulated specifically with 
gamma-irradiated peptide-pulsed autologous PBMCs. After incubating the clones for 12 
days, they were stimulated nonspecifically as described above in 75-cm' flasks. After 2 
weeks, cells were harvested, aliquoted, and stored at -135'C until use. These CTLs will be 
referred to as the NP/B27 CTL clone. An HLA-A3-restricted CTL clone specific for the 
influenza A virus NP epitope ILRGSV AHK (aa 265 to 273) was kindly provided by W. 
Biddison, National Institutes of Health (NIH), Bethesda, Md., and will be referred to as the 
NPI A3 CTL clone. The phenotype of both CTL clones was determined by f1uorescence-
activated cell SOtting (FACS) analysis using monoclonal antibodies specific for CD3, CD4, 
and CDS, and their specificity and HLA restriction was confmned in CTL assays. To this 
end, I x 106 cells of an Epstein-Barr virus transfonned B-LCL of an HLA-A3- and -B27 
positive donor and mismatched (HLA-A3- and -B27 negative) B-LCL cells were incubated 
with the peptide ILRGSVAHK or SRYWAIRTR (10 11M) for one h at 37'C and used as 
target cells in CTL assays with the respective CTL clones as effectors. 
P"cparation of target cells 
B-LCL cells (106) of one donor (HLA-A3- and -B27 positive) were incubated with the 
peptide ILRSGVAHK (HLA-A3), SRYWAIRTR (HLA-B27), or SKYWAIRTR or 
SGYWAIRTR (HLA-B27 mutant peptide) at a concentration giving the highest specific 
lysis (10 IlM for the ILRGSVAHK peptide and I flM for the SRYWAIRTR and mutant 
peptides). In addition, the same B-LCL cells were infected with recombinant vaccinia 
viruses (RVV) expressing the NP of influenza vims A/Plle,to Rico/S/34;HINI (AIPR/S/34) 
(kindly provided by B. Moss, NIH), AlNetherlands/0IS/94;H3N2 (AlNethI1S/94) 
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(generated essentially as previously described"), or a control vaccinia virus (VSC65), each 
at a multiplicity of infection of 10. Also, B-LCL cells were infected with the influenza A 
viruses AlPR/8/34; AlNetherlands/651/89;H3N2 (AlNeth/651/89), having an R384K 
mutation; or AlNeth/18/94, having an R384G mutation in the NP gene. Cells were cultured 
in RPM! 1640 medium containing L-glutamine (2mM), streptomycin (lOa flg/ml), 
penicillin (l00 IV/ml) and 10% fetal bovine sennn at 37'C and 5% CO,. After 16 h of 
incubation, cells were washed and used as target cells in CTL assays with the NP/ A3 and 
NP/B27 CTL clones as effector cells. 
CTL assays 
Target cells (B-LCL cells) were labeled for I h with 75 [lCi Na,[S! CrjO" in RPM! 1640 
medium. Cells were washed three times in culture mediulll (see above) and resuspended in 
this medium at a concentration of 10' cells / 50 fll. Effector cells (CTLs) were suspended in 
this medium at a concentration of2.5 x 10',5 x 10' or I x 10'cells /100 ftl (effector-to-
target [E:T) ratios, 2,5: I, 5: I and 10: I). Fifty microliters of target cells was incubated either 
with 100 [II of medium (spontaneous release), with 100 ftl of 10% Triton X-IOO 
(maximum release), or with 100 ftl of effector cells (experimental release) for 4 h at 37' C. 
Supernatants were hmvested, and radioactivity was measured by gamma counting. The 
percentage of specific lysis was calculated as: 100 x (experimental release - spontaneous 
release) / (maximum release - spontaneolls release). CTL assays were performed in 
triplicate per target per E:T ratio. 
Functional analysis of wild type and mutant NP 
The NP coding sequences of influenza virus AlHong Kong/2/68;H3N2 (A/HKl2/68), 
representing wild type vims, and AlNeth/18/94 (R384G mutant) were amplified by PCR 
using pBluescript plasm ids containing the NP genes of both viruses as templates with a 
Noll-folward primer, CAGCGGCCGCATGGCGTCCCAAGGC, and an Xhol-reverse 
primer, CACTCGAGTTAA TIGTCGTACTCCTCTGC (restriction endonuclease 
recognition sequences are underlined, and start and stop codons of the NP gene are in 
boldface). PCRs were performed with 10 ng of plasmid DNA, 10 pmol of each of the 
primers, 1.5 mM MgCI" 20 flM dNTPs and 5 U of Pfil polymerase in a total of 100 ftllx 
Pfil polymerase buffer. This mixture was heated for 3 min at 94°C followed by a total of20 
cycles consisting of I min at 94°C, 2 min at 50°C, and 4 min at nOc. The PCR products 
were cloned as No/I-X/1OI fragments in a modified version of the eukaryotic expression 
plasmid pcDNA3 (Invitrogen) followed by large-scale production of plasmid DNA and 
purification by esc I gradient cenh'ifugation according to standard methods. 
The respective plasmids were used for transfection into 293T cells. Plasmid DNA (1.5 [lg) 
was mixed with equal amounts of the plasm ids pHMG-PBI, pHMG-PB2 and pHMG-PA 
(encoding the polymerase proteins PBI, PB2, and PA, respectively; kindly provided by P. 
Palese, Mount Sinai School of Medicine, New York, Ny36) and 0.5 fIg of plasmid RF419 
(constructed essentially as described previousl)"o), from which the green fluorescent 
protein (GFP) gene flanked with the influenza A virus noncoding region of the NS gene 
segment is transcribed in a negative orientation. This plasmid mixture was transfected into 
293T cells as described previously". One day after transfection, cells were subjected to 
FACS analysis. Cells transfected with plasmid pcDNA3 without cloned NP sequences 
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served as a negative control, while cells transfected with plasmid pEGFP-NI (encoding 
enhanced GFP; Clontech) served as a positive control. 
Nucleotide sequence accession Illimbers 
Nucleotide sequences have been submitted to GenBank and can be retrieved by the 
following accession numbers: AF225709-AF225764 (influenza season 1993-1994), 
AF225765-AF225823 (influenza season 1989-1990), AF225824-AF225839 (influenza 
season 1991-1992), AF225840-AF225855 (influenza season 1992-1993), AF225856-
AF225869 and AF226872 (influenza season 1998-1999). 
RESULTS 
NP gene sequences of influenza A (H3N2) viruses 
Sequence analysis of the NP genes of influenza A (H3N2) viruses isolated 
in The Netherlands from 1989 to 1999 was performed. The region of the NP 
genes sequenced encompasses aa 240 to 391 (or nt 720 to 1175) and 
harbours four previously described CTL epitopes: aa 265 to 273, aa 338 to 
347, aa 380 to 388, and aa 383 to 391 presented, by HLA-A3, -B37, -B8, 
and -B27 molecules, respectively9.16,26,43. As shown in table 1; differences in 
the nucleotide sequences of viruses isolated in the same season were 
observed. Overall, 46 different nucleotide sequences were identified in 162 
viruses isolated from 1989 to 1999. Nevertheless, within one season viruses 
were closely related, as is shown in the maximum likelyhood tree in figure 
1. The amino acid sequences found in the influenza A viruses isolated in the 
respective influenza seasons are shown in figure 2, and nucleotide mutations 
underlying differences in these amino acid sequences are shown in table 2. 
Eleven different amino acid sequences were identified, and phylogenetic 
analysis based on these amino acid sequences revealed essentially the same 
distances between the recent influenza virus isolates (1993-1998) and older 
isolates (Figure 1). In the influenza season 1989-1990, 13 out of 59 isolated 
viruses had a R384K mutation affecting both the HLA-B8 and HLA-B27 
epitopes (Figure 2). In fact, R384 is the anchor residue of the HLA-B27 
epitope and critical for association with MHC class I molecules. This 
R384K mutation was not found in subsequent seasons. However, in the 
season 1993-1994, a novel mutation at the same position in these CTL 
epitopes was found. This R384G mutation was present in all 56 viruses 
tested of this season, and maintained in all viruses tested of the season 1998-
1999 (Figure 2). In all mutant viruses, the G at position 384 was coded for 
by the same codon (Table 2). The abrupt introduction of the R384G 
103 
Antigenic drift and CTL escape IIIl1tants 
mutation in 1993-1994 was accompanied with two other amino acid 
mutations in the sequenced NP region, S259L and E375G. These mutations 
are located in close proximity to the HLA-A3 and the HLA-B8 and HLA-
B27 epitopes, respectively (Figure 2). We also sequenced several viruses 
isolated between 1994 and 1998 which all showed the R384G, S259L, and 
E375G mutations (data not shown). In contrast to the overlapping HLA-B8 
and HLA-B27 epitopes, the HLA-A3 epitope ILRGSVAHK (aa 265 to 273) 
proved to be conserved. Only three silent mutations were found in this 
epitope in 3 out of the 162 viruses tested (data not shown). Likewise, no 
mutations were found that affected the HLA-B37 epitope (338 to 347). 
Season Variane N° Season Variant N Season Variant N 
1989-1990 I 18 1991-1992 15 8 1993-1994 27 35 
IF59 2 14 n=16 16 3 n=56 28 3 
3 8 17 3 29 2 
4 7 18 30 2 
5 3 19 31 2 
6 32 
7 1992-1993 20 7 33 
8 n=16 21 4 34 
9 22 35 
10 23 36 
II 24 37 
12 25 38 
13 I 26 39 
14 40 
1998-1999 44 II 41 
n=15 45 3 42 
46 43 
TABLE 1. Virus variants and number of each variant observed per influenza season. 
The nucleotide sequence of the NP gene (Ilt 720-1175) of each virus of a particular season 
was compared to the consensus sequence of that season. aVariant numbers cotTespond with 
the numbers shown in figure 1; ~umber of each variant. 
Recognition of influenza A virus NP by specific CTL clones 
An HLA-B27-restricted CTL clone, designated NP/B27, with specificity for 
the NP epitope SRYWAIRTR (aa 383 to 391), was generated. This CTL 
clone lysed matched target cells, pulsed with peptide SRYWAIRTR (Figure 
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3B and D). As a control, an HLA-A3-restricted CTL clone, designated 
NP/A3, with specificity for the conserved NP epitope ILRGSVAHK (aa 265 
to 273) was used. As shown in figure 3A and C, this CTL clone lysed 
matched target cells pulsed with the corresponding peptide. The phenotype 
of both CTL clones as determined by FACS analysis was CD3+,CD4-,CDS+ 
(data not shown). 
-" 92/93 25 ~ 
91/92 
17 
tL-----
.)~~ 
"" 
93/94 30 
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Figure 1. Maximum likelyhood h'ee based on nucleotide sequences of the NP gene. Pmt of the 
NP genes (nt 720-1175) of 162 influenza A (H3N2) vimses isolated from 1989 until 1999 was 
sequenced and sUbjected to phylogenetic analysis. Included in the figure are the influenza 
vimses Affexas/1177, A/Memphis/5/80 and AlBeijing/353/89. TIle numbers shown in the 
figure conespond to the numbers shown in table 1. The insert represents a protein distance h-ee 
(protdist, Fitch) based on the NP sequence of the representative influenza vims strains. TIle 
lettercode used for tlle respective amino acid sequences corresponds to that of figure 2. 
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GFEKEGYSLV GIDPFKLLQN SQVYSLIRPN ENPAHKSQLV \'JHACHSAAFE DLRLLSFIRG 
DFEKEGYSLV GIDPFKLLQN SQVYSLIRPN ENPAHKSQLV WHACHSAAFE DLRLLSFIRG 
DFEKEGYSLL GIDPFKLLQN SQVYSLIRPN ENPAHKSQLV m1ACHSAAFE DLRLLSFIRG 
DFEKEGYSLV GIDPFKLLQN SQVYSLIRPN ENPAHKSQLV WNACHSAAFE DLRLLSFIRG 
DFEKEGYSLV GIDPFKLLQN SQVYSLIRPN ENPAHKSQLV I'lNACHSAAFE DLRLLSFIRG 
DFEKEGYSLV GIDPFKLLQN SQVYSLIRPN ENPAHKSQLV WNACHSAAFE DLRLLSFIRG 
HLA B37 
Figure 2. Continued on next page, 
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Figure 2. Amino acid sequences of the NP (aa 240 to 391) of influenza A (H3N2) viruses 
isolated from 1989 until 1999. 111e consensus sequence of each season is shown in the upper 
rows whereas variant sequences are shown in the lower rows. CTL epitopes are underlined and 
shown in bold. Amino acid differences between seasons are shown in bold while differences 
within a season are shown in bold/italic. All mutations are marked with an arrow. The number 
in brackets refers to the number of isolates showing that sequence. 
The effect of the R384K and R384G mutations in the HLA-B27-specific NP 
epitope SRYWAIRTR on CTL-mediated lysis was first studied with 
synthetic peptides. The NP/B27 CTL clone lysed target cells pulsed with the 
peptide SRYWAIRTR, whereas control untreated target cells or cells pulsed 
with the mutant peptides SKYWAIRTR or SGYW AIRTR were not 
recognized by this CTL clone (Figure 4B). Next, cells infected with 
influenza A viruses having the respective mutations in the NP were used as 
target cells. Target cells infected with influenza virus A/PRl8/34, 
AINeth/651!89 or AlNethl18/94 were all recognized by the NPI A3 CTL 
clone (Figure 4E). However, the NPIB27 CTL clone lysed only target cells 
infected with influenza virus A/PRl8/34, which had the non mutated 
epitope, and failed to recognize target cells infected with influenza virus 
AINeth/651!89 or AlNethl18/94 which had the R384K or the R384G 
mutation, respectively (Figure 4F). These data were further confirmed using 
RVV expressing the NP of A/PRl8/34 (non mutated epitope) or 
AINethl18/94 (R384G mutant epitope). The NPlA3 CTL clone recognized 
target cells infected with RVV expressing NP of A/PRl8/34 or 
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AlNethll8/94 equally well and failed to recognize target cells infected with 
a control vaccinia virus (Figure 4C). The NPIB27 CTL clone, however, 
recognized target cells infected with RVV expressing NP of AlPRl8/34 but 
failed to recognize target cells infected with RVV expressing NP of 
A/Neth/18/94 (Figure 4D). 
Season Amino acid Nucleotide mutation N' 
1989-1990 K293R AAA-->AGA I 
T350S ACC-->TCC 8 
M374! ATG-->ATA I 
E375G GAA-->GGA I 
R384K AGG-->AAG 13 
1991-1992 N287S AAT-->AGT 4 
G290D GGC-->GAC 4 
1992-1993 S287N AGT-->AAT 2 
D290G GAC-->GGC 2 
1993-1994 V299L GTG-->TTG 2 
R36!T AGA-->ACA 2 
R384G AGG-->GGGb 56 
1998-1999 R384G AGG-->GGGb 15 
R389T AGG-->ACG I 
TABLE 2. Amino acid mutations in the influenza NP and the corresponding nucleotide 
mutations. 
lINumber of villlses containing the mutation; see also figure 2; bSince all viruses from the 
influenza season 1993-1994 onwards contained the R384G mutation, the codon encoding 
the original R384 in the NP of influenza viruses of the previous season (1992-1993) lVas 
taken for comparison. 
Functional analysis of NP sequences 
In order to detel1lline whether the R384G mutation affected the function of the 
NP, a eukaryotic expression plasmid encoding the NP of AlHK!2/68 (having 
an R at position 384) or the NP of A/NethlI8/94 (having a G at position 384) 
was cotransfected with expression plasmids encoding the tlU'ee polymerase 
proteins of influenza A virus (PBI, PB2 and PA) and a plasmid expressing 
GFP RNA in the context of an influenza A vims NS gene segment. Others 
have shown previously that such negative-sense RNA molecules can serve as 
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templates for production of cRNA and mRNA in the presence of fimctional 
NP and polymerase proteins, ultimately resulting in synthesis of the encoded 
protein (29). GFP synthesis was measured by FACS analysis (Table 3). The 
percentage of positive cells and mean fluorescense did not differ significantly 
between cells transfected with the NP gene of AlHKl2/68 and those 
transfected with the NP gene of AlNeth118/94, indicating that both NPs were 
equally fimctional. Furthermore, influenza viruses AlHKl2/68 and 
AlNeth/18/94 yielded comparable virus titers in MDCK cells, indicating that 
both viruses replicated equally well (data not shown). 
NP/A3 CTL clone NP/B27 CTL clone 
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Figure 3. Confmnation of specificity and HLA restriction of CTL clones. HLA-A3 and -
B27 positive (A and B) and HLA-A3 and -B27 negative (C and D) 8-LCL were incubated 
with the HLA-A3-specific peptide ILRGSVAHK (solid circles), the HLA-827-specific 
peptide SRYWAIRTR (solid triangles) or left untreated (open circles and triangles) 
followed by incubation with the NP/A3 (A and C) or NP/827 (8 and D) CTL clone. CTL 
assays were performed in triplicate at three E:T ratios. Mean percentages of specific lysis 
are shown. 
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Figure 4. Effect of mutations in the HLA-B27 epitope on CTL-mediated lysis of target 
cells. HLA-A3 and -B27 positive B-LCL of one donor were incubated with the HLA-A3-
specific peptide ILRGSV AHK (solid circles), the HLA-B27-specific peptide 
SRYWAIRTR (solid squares), the HLA-B27 mutant peptides SGYWAIRTR (open 
squares) or SKYWAIRTR (open hexagon) or left untreated (open circles) and used as 
targets in CTL assays with the NP/A3 (A) or NPIB27 (B) CTL clone as effector. The same 
B-LCL were infected with a control vaccinia vims (open triangle pointing downward), a 
vaccinia virus expressing the NP of A/PRl8/34 (solid triangle) or a vaccinia vims 
expressing NP of AINeth/18/94 (open triaugle) followed by incubation with the NP/A3 (C) 
or NPIB27 (D) CTL clone. Also, B-LCL were infected with influenza virus A/PRl8/34 
(solid diamond), A/Neth1l8/94 (open diamond), AINeth/651189 (open hexagon) or left 
untreated (open circles) followed by incubation with the NP/A3 (E) or NP/B27 (F) CTL 
clone. CTL assays were performed in triplicate at three E:T ratios. Mean percentages of 
specific lysis are shown. 
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NP 
negative control 
AlHKl2/68 
AINeth/18/94 
positive control 
% Positive cells 
0.3 
26.4 
23.3 
95.0 
Mean fluorescensc 
433 
2002 
1944 
6383 
TABLE 3. Functional analysis of wild type and mntant NP. 
Chapter 5 
293T cells were transfected with a mixture of plasmids including pHMG-PBl, pHMG-PB2, 
pHMG-PA, RF419 and a plasmid encoding NP of A1HK12/68 or AlNeth1l8/94. Cells 
transfected with plasmid pcDNA3 served as a negative conu'ol while cells transfected with 
plasmid pEGFP-NI were used as a positive conu·o/. Percentage cells showing GFP expression 
and mean fluorescense of 293T cells were measured by F ACS analysis. Results of a 
representative experiment are shown. 
DISCUSSION 
In the present paper, we show that a R384K or R384G mutation in the 
I-ILA-B27-specific epitope SRYWAIRTR (383-391) of influenza A virus 
NP abrogates MHC class I presentation and recognition by specific CTLs. 
In peptides that associate with HLA-B27, the second residue is often au 
arginine (R) and this so-called anchor residue is critical for binding to HLA-
B27 molecules I9,23,24,41,44. Mutations at tillS position are accompanied by 
loss of binding to HLA-B27 and hence loss of the activity of specific CTLs. 
TIlls has previously been demonstrated for the CTL epitope KRWIILGLNK 
(263-272) in the mV-1 Gag protein: exchanging R264 for K or G 
diminished binding to HLA-B27 and lysis of peptide pulsed target cells, 
with the R264G mutation having the greatest effece l . We here show that 
cells pulsed with mutant peptides, having identical mutations at tile anchor 
residue of the epitope SRYWAIRTR of the influenza A virus NP (see Table 
4 for comparison), were not lysed by HLA-B27-restricted CTLs. In 
addition, we show that cells infected either with influenza A viruses or with 
vaccinia virus expressing mutant NP were no longer recognized by specific 
CTLs. 
The R384K mutation was found in several isolates of tile influenza season 
1989-1990, but not in later seasons. This mutation was previously found in 
two viruses isolated in 1971 and 197242. In contrast, the R384G mutation was 
found in all influenza A virus isolates from the influenza season 1993-1994 
onwards. A search in the influenza virus sequence data-base (Los Alamos 
National LaboratolY) and in the literature revealed that from the introduction 
ofH3N2 viruses in 1968 until the 1993 epidemics, all virus isolates (except for 
the R384K mutant viruses mentioned above) had the nomnutated HLA-B27 
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epitope SRYW AlRTR. Since most viruses have been selected for sequencing 
based on antigenic propel1ies of their haemagglutinin, we assume that the NP 
sequences of influenza viruses in this data base are random with regard to CTL 
epitopes. Of note, the R384G mutation has never been found in HINI and 
H2N2 viruses. Since we sequenced influenza viruses that were isolated 11'0111 
patients living in geographically distinct areas in The Netherlands, it is 
unlikely that all viruses originated from a single source. Moreover, in the 
region of the NP that was sequenced (representing 152 aa) differences were 
found between viruses isolated within a single season. Interestingly, the 
R384G mutation has also been found in influenza A (H3N2) viruses isolated 
in Japan after 1993, although vi11lses lacking the R384G mutation co circulated 
in this area after 199322. 
HLA-B27 epitope 
HIV-I gag (263-272) 
HlV -I gag mutant I 
HIV-I gag mutant 2 
Influenza NP (383-391) 
Influenza NP mutant I 
Influenza NP lllutant 2 
Amino acid sequence:} 
KRWIILGLNK 
KKWIILGLNK 
KGWIILGLNK 
SRYWAIRTR 
SKYWAIRTR 
SGYWAIRTR 
References fluorescense 
(5) 
(13,3I b) 
(31 b) 
(16) 
present paper 
present paper 
TABLE 4. Comparison of wild type and mutant HLA-B27-restricted CTL epitopes of 
influenza A virus nucleoprotein with those of the HIV-I gag protein. 
a "Mutations are shown in bold; bIn vitro generated mutant. 
The R384G mutation found in the influenza season 1993-1994 was 
accompanied with two other amino acid mutations in the NP, S259L and 
E375G. Also in the Japanese strains containing the R384G mutation (see 
above) the same accompanying mutations were found, which may indicate a 
more global spread of these viruses. The S259L mutation is only six aa N 
terminal of the HLA-A3 epitope ILRGSVAHK and, therefore, could have 
affected processing of tlus peptide. However, our results show that this 
mutation did not have an effect on MHC class I presentation of the HLA-A3 
epitope. Although a G at position 384 was always accompanied with a L at 
position 259 and a G at position 375, the latter two amino acids have 
previously also been found with an R at position 384, indicating that the 
R384G mutation is not forced by the other two mutations or vice versa and 
that the mutations observed are not mutually compensatory. In addition, in the 
influenza season 1989-1990 we obtained a virus isolate having a G at position 
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375 and an R at position 384 of the NP. 
The consequence of a mutation at the anchor residue with respect to virus 
escape from immunesurveillance by CTLs has been demonstrated 
previously13. The R264K mutation in the HIV-I Gag HLA-B27 epitope 
KRWIILGLNK (263 to 272) was accompanied with progression to AIDS in 
HIV -I-infected patients wich showed strong CTL responses against the 
nonmutated epitope. Although the role of CTLs in protection from influenza 
vims infection is still controversial, CTLs are likely to contribute to virus 
clearance and inhibition of viIus spread (40). Therefore, mutations at the 
anchor residue of the influenza A virus NP epitope SRYWAIRTR may have 
implications for HLA-B27 positive influenza virus-infected patients. At tllis 
point, it is not clear what the consequences of the R384G mutation are with 
respect to MHC class I bindiIlg and/or recognition by CTLs of the HLA-B8 
epitope. 
The observation that the R384G mutation was conserved in all sequenced 
influenza A (H3N2) viruses isolated after 1993 in The Netherlands suggests 
that this mutation is advantageous to the virus. We did not find differences 
between a wild-type virus and an R384G mutant virus with respect to 
replication properties in vitro. In addition, in transfection experiments, we 
have shown that an RNA molecule that resembles an influenza A vims gene 
segment was equally well transcribed and translated in the presence of wild-
type and mutant NP. Since the R384G mutation completely abrogates the 
recognition of the HLA-B27 epitope by specific CTLs, influenza A viruses 
harbouring this mutation may escape from immunity mediated by virus-
specific CTLs. HLA-B27 positive individuals constitute approximately 8% 
of the Caucasian population, which is predominant in The Netherlands. The 
immune pressure mediated by CTLs in these individuals, which recognize 
the wild-type HLA-B27 epitope in the NP, may have contributed to the 
emergence and continued circulation of escape mutant viruses. The mutant 
virus may have emerged from the quasispecies of influenza viruses in HLA-
B27 positive individuals. Since the R384G mutation did not impose 
functional constraints on the NP, a selective pressure in 8% of the 
individuals may have been sufficient to drive the selection process. At 
present, it is unknown whether the HLA-B27 epitope is immunodominant. 
Conceivably, this would favour the emergence of the R384G mutant virus. 
Little is known about the in vivo rate of attack of target cells by specific 
CTL: an infected cell may be recognized by one CTL but not by another at 
the same time, allowing the virus to escape from the action of one CTL 
clone. Once emerged into the human population, viruses with the R384G 
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mutation are fully replication competent and ultimately have replaced the 
original virus having the non mutated epitope. 
In contrast to the HLA-B8 and -B27 epitope, the HLA-A3 epitope proved to 
be conserved; we found only three silent mutations out of 162 sequenced 
influenza A (H3N2) vhuses isolated over 10 years despite a higher 
prevalence of the HLA-A3 allele in the human population. With the 
exception of one virus having a I265V mutation42, influenza virus sequence 
database searches (including HIN1, H2N2 and H3N2 viruses isolated over a 
period of more than 60 years) also did not reveal amino acid mutations 
within this epitope. A possible explanation is that mutations in this region of 
the NP are not or are less well tolerated by the virus because of functional 
constraints. For example, an R267 A mutation in the HLA-A3 epitope has 
been shown elsewhere to affect RNA binding by the NPII. Recently, a 
second HLA-B27 epitope in the NP (174 to 184) has been described17. 
However, a sequence database search revealed that this HLA-B27 epitope is 
completely conserved. 
CTL escape mutants have been shown to arise in individuals persistently 
infected with virus, e.g. HIV, as a result of continuous immune pressure 
mediated by CTLs. Influenza A viruses cause acute infections, affecting a 
large percentage of individuals each year, and therefore may be considered 
as persisting in the human population. We have provided epidemiological 
and immunological evidence for antigenic drift in the influenza A virus NP, 
possibly as a result of immune pressure mediated by CTLs. Thus, in 
addition to the introduction of mutations in the surface glycoproteins 
allowing escape from antibody-mediated immunity, the introduction of 
mutations in CTL epitopes may be a strategy exploited by influenza A 
viruses to escape from CTL-mediated immunity. Tills would be the first 
example of CTL-mediated antigenic drift in a virus that causes an acute 
infection. 
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SUMMARY 
The nucleoprotein genes of influenza virus AlNetherlands/O 18/94 (H3N2) and 
influenza virus BIHarbinl7/94 were cloned into the bacterial expression vector 
pMalC to yield highly purified recombinant influenza virus A and B nucleop-
roteins. With these recombinant influenza nUcleoproteins, enzyme-linked 
inllllunosorbent assays (ELISAs) were developed for the detection of 
influenza virus A- and B-specific immunoglobulin A (lgA) and IgG serum 
antibodies. Serum samples were collected at consecutive time points after the 
onset of clinical symptoms 11'0m patients with confinued influenza virus A or 
B infections. Nucleoprotein-specific IgA antibodies were detected in 41.2% of 
influenza virus A-infected patients and in 66.7% of influenza virus B-infected 
patients on day 6 after onset of clinical symptoms. In serum samples taken on 
day 21 (influenza virus A-infected patients) or day 28 (influenza virus B-
infected patients), nucleoprotein-specific IgA antibodies could be detected in 
58.8 and 58.3% of influenza virus A- and B-infected patients, respectively. At 
the same time, IgG antibody rises were detected in 88.2% of influenza virus 
A-infected patients and in 95.8% of influenza virus B-infected patients. On 
comparison, hemagglutination inhibition assays detected antibody titre rises in 
81.3 and 72.7% of patients infected with influenza virus A and B, respectively. 
In contrast to the detection of nucleoprotein-specific IgG antibodies or 
hemagglutination inhibiting antibodies, the detection of nucleoprotein-specific 
IgA antibodies does not require paired serum samples and therefore can be 
considered an attractive alternative for the rapid serological diagnosis of 
influenza. 
INTRODUCTION 
Influenza viruses (fanlily Ol'lholllyxovil'idae) are the causal agents of recurrent 
epidemics of acute respiratory disease in man. For the laboratory diagnosis of 
influenza vhus infections, several methods which detect either viral antigens 
or antigen-specific serum antibodies are used. For the quantification of 
influenza virus-specific serum antibodies, the hemagglutination inhibition (HI) 
assay and complement fixation (CF) assay are routinely used. However, these 
assays suffer from some disadvantages. They are laborious to pelform, 
difficult to incorporate into automated procedures and require a continuous 
source of the appropriate erytln·ocytes. Alternatively, enzyme-linked 
inlluunosorbent assays (ELISAs) have been used for the detection of influenza 
virus-specific antibodies. ELISAs measuring influenza vh1ls-specific sel1\lU 
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IgG antibodies have been shown to be more sensitive than the HI or the CF 
1101113,172223 I dd" ELISA bl I d ' f 'b d' f assay' " ", n a Itlon, s ena e t le etectlon 0 anti 0 les 0 
different isotypes3,6,18,19, For example, the demonstration of virus-specific IgA 
antibodies after influenza virus infections has been shown to be of diagnostic 
value5,6,19, The preparation of viral antigens to be used in these ELISAs 
usually requires the concentration and purification of virus conventionally 
propagated in embryonated chicken eggs or cell culture, However, ELISAs 
with purified (recombinant) viral proteins have also been described8,9,12,2o, In 
the present paper we describe the production of recombinant nucleoproteins 
(NPs) of influenza vimses A and B as a virtually unlimited source of viral 
antigen, By using highly purified recombinant NPs of influenza viruses A and 
B, ELISAs were developed for the detection of virus-specific iunl1unoglobulin 
A (IgA) and IgG senUl1 antibodies, With serum samples obtained from 
patients with confilmed influenza virus A and B infections, the value of these 
recombinant NP-based ELISA systems was demollstrated, 
MATERIALS AND METHODS 
Cloning of the NP genes of influenza viruses A and B 
The influenza vimses AINetherlands/018194 (H3N2) and B/Harhin17194 were obtained ft'orll 
the repository of the Dutch National Influenza Centre. Viral RNA was extracted ITom these 
vimses as described previously'. A reverse transcriptase (RT) reaction was performed to obtain 
single,stranded DNA copies of gene segment 5, which encodes the NP. To 10 ftl of viral RNA 
2 ftl forward primer (10 pmoVftl) was added and the mixture was incubated at 80'C for 2 min, 
followed by 5 min of incubation on ice. 111en, deoxynucleoside triphosphates (0.5 mM each), 
dithiothreitol (10 mM), RNasin (40 U) and Moloney murine lenkemia vims RT (200 U) were 
added in a total volume of25 ftl of I x RT buffer followed by incubation at 42'C for 45 min. 
The reaction was stopped by heating the mixture to 95'C for 3 min. 11le DNA obtained was 
used as a template in a PCR. Besides the DNA, the PCR mixture contained 20 pmol of forward 
and 20 pmol of reverse primer, deoxynucleoside triphosphates (0.2 mM each), and Pfit 
polymerase (5 units) in a total of 100 fllix Pfit buffer. 111e PCR cycles consisted of I min at 
94'C, 2 min at 52'C, and 4 min at noc for a total of 40 cycles. Primer sequences were based 
on the consensus sequence of the NP genes of recent influenza vil11s A and B strains obtained 
from the Wisconsin Sequence Analysis Package and designed in such a way that the ultimate 
PCR product contained an £CoRI (influenza vims A) or Xbal (influenza vims B) restriction 
endonuclease recognition sequence upstream of the stmt codon and a SalI restriction endonu-
clease recognition sequence downstream of the stop codon of the NP genes. The PCR products 
of the NP gene of both vimses were cloned into the bacterial expression vector pMalC (New 
England Biolabs) in frame with the gene encodhlg the maltose binding protehl (MBP) by using 
the EcoRl or Xbal and Sail sites in the multiple c10nhlg site of this plasmid. Resh'iction 
122 
Chapter 6 
endonuclease digestion, ligation, transfollllation in Escherichia coli (E. colt) DH5a, plasmid 
DNA isolation and agarose gel electrophoresis were perfonned by standard procedures21 
Production, isolation and purification of recombinant NP 
A total of 500 ml of SOB medium21 containing ampicillin (50 ~Iglml) and supplemented with 
glucose (2g/L) was inoculated with 5 ml of an ovemight culture of recombinant E. coli, and 
incubated at 37"C in a shaking incubator. TIle optical density at wavelength 600 Illll was 
monitored, and at a value between 0.5 and 0.6 I mM isopropyl fl-D-thiogalactopyranoside was 
added to induce expression of the fusion gene. Four hours after induction, the bacteria were 
pelleted by centrifugation, resuspended in 25 ml column buffer (20 mM Tric-CI pH 7.4, 200 
mM NaCI, I mM EDTA) containing Pefablock protease inhibitor (Boehringer Mannheim), 
and lysed by sonication. TIle lysate was diluted to 100 ml in column buffer and 11m through an 
amylose resin column (New England Biolabs). After extensive washing of the column, 
recombUlant protein was eluted with colunlllbuffer containing 25 mM maltose. Peak fl'actions 
were pooled and the purified proteins were stored at -70°C until use. Protein concentrations 
were detenllined using the Bradford reagent'. TIle procedure was carried out for recombulant 
E. coli carryulg the pMalC plasmid without cloned sequences to obtain recombinant MEP 
(rMBP) and for recombinant E. coli canyulg the pMalC plasmid in which the NP gene of 
influenza vims A or B was cloned to obtain recombulant fusion proteins consisting of MBP 
and ulfluenza virus A NP (rNPA) or ulfluenza vims B NP (rNPB), respectively. 
SDS-PAGE and Westel'll blotting 
Sodium dodecylsulfate-polyaclylamide gel electrophoresis (SDS-PAGE) and Western blotting 
were perfonned accordulg to standard procedures2l • Blots were incubated with blocking buffer 
(2% nonfat milk powder, 0.05% Tween 20 in phosphate-buffered salule [PBS] for I h, 
followed by I h of incubation with I: I 00 diluted polyclonal rabbit antisera specific for 
influenza vims A or B. After washing the blots with PBS, the blots were incubated for I h with 
1 :500 diluted horse radish peroxidase (HRP)-Iabeled swine-anti-rabbit IgG antibodies (Dako, 
Glostmp, Denmark). TIlen, the blots were washed with PBS followed by incubation in 
diaminobenzidinelH,O, in PBS (250 fIg diaminobenzidine/ml, 0.002% H,O,). TIle reaction 
was stopped with H20 when protein bands became visible. 
Sel'a 
Influenza vims A- and B-specific polyclonal rabbit and fenet antisera were obtained from 
rabbits injected with sucrose gradient-purified influenza vims AlHong Kongl2/68 (H3N2) or 
BlHarbin17 /94 and from fenets experimentally ulfected with influenza vims AlNether-
lands/O 18/94 (H3N2) or BlHarbinl7l94. 
Human sera were obtained from adult patients with acute influenza vims B (n'"24) and 
influenza virus A (HINI; n~2, H3N2; n~15) infection; the patients were enrolled in clinical 
studies during the respiratory season in March 1995 and December 1995, respectively. 
Influenza vil1ls infection was confmned by an immunofll1oresence test or by vims isolation 
fl'om cell culture. Sera were collected on the day of onset of clinical symptoms (day I) and at 
several time points thereafter. For the influenza virus A-infected patients, additional selUll1 
samples collected on days 6, 21, and 60 were available. For the patients with influenza vims B 
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infection, additional semm samples collected on days 6 and 28 were available. Sera were 
stored at -20°C until use. 
Hemagglutination inhibition assay (HI assay) 
One volume of senllll was mixed with five volumes of cholera filtrate, and the mixhlre was 
incubated at 37°C for approximately 16 h, followed by I h of incubation at 56'C. To 50 fll of 
twofold dilution series of semm in PBS, 25 ftl of a solution of influenza vims 
NSingaporef6f86 (H I N I), NJohannesburgf33f94 (H3N2), or BfHarbinf7f94 containing 4 
hemagglutinating units (HAU) was added, and the mixture was incubated at 37°C for 30 min. 
Then, 25 fll of a I % turkey elythrocyte suspension in PBS was added, followed by I h of 
incubation at 4'C. Subsequently, the hemagglutination pattem was examined and expressed as 
the reciprocal value of the highest senllu dilution inhibiting hemagglutination. A fourfold titer 
rise for paired serum samples was considered indicative of a recent influenza virus infection. 
Enzyme-linked immunosorbent assay (ELISA) 
ELISA for detection of IgA serum antibodies (capture IgA NP-ELISA) 
Ninety-six-well plates coated with rabbit anti-human IgA antibodies (Meddens Diagnostics, 
Bnllumen, The Netherlands) were washed with demineralized H20 containing 0.05% Tween 
80, followed by incubation with patient sera diluted I: I 00 in ELISA buffer (Meddens Diagnos-
tics). After I h of incubation at 37'C, the plates were washed and incubated with rNPA or 
rNPB, which were conjugated with HRP by previously described methods (24). Following I h 
of incubation at 37'C, the plates were washed again and incubated with tetramethylbenzidine 
substrate (Meddens Diagnostics) for 10 min. The reaction was stopped with 2M H2S04, and 
the 00 was measured at 450 nm. NP-specific reactivities were expressed as the following 
ratio: OD45Onm for patient serum/OD45Onm for negative control senllll. TIle negative control 
serum consisted ofa pool of sera negative for influenza vims A- and B-specific IgA antibodies. 
Ratios greater than 2.0 were considered positive. 
ELISA for detection ofIgG serum antibodies (indirect IgG NP-ELISA) 
For rabbit and ferret sera, 96 wells plates were coated overnight at room temperature with 50 
ng rNPA or rNPB in 100 ~I 0.1 M sodium carbonate buffer (pH 9.6). TIle plates were washed 
with demineralized H20 containing 0.05% Tween 80. Influenza VinlS A- and B-specific rabbit 
and ferret antisera were twofold diluted from I: I 00 to I :6,400 in ELISA buffer. A total of 50 
fll of each dilution was incubated in the recombinant NP-coated plates for I h at 37'C. After 
washing of the plates, 50 fll of 1:500 diluted goat anti-fen'et IgO antibodies (Kirkegaard & 
Peny) or I :500 diluted swine anti-rabbit IgO antibodies (Dako, Olostrnp, Denmark) 
cOluugated with HRP was added, and incubated for 1 hour at 37'C. The plates were washed 
agalll and ll!Cubated with 50 ftl of teo'aIuethylbenzidine substrate for 10 min. The reaction was 
stopped by adding 50 fll of 2M H2S04, and the 00450 was measured. 
For llUmaIl sera, ELISA was perfonned as described above. Human sera were diluted 
1:100,000 and IgO antibodies were detected with 1:5,000-diluted HRP-Iabeled goat anti-
human IgO antibodies (Biosource Europe, Fleums, Belgium). In addition to reactivities with 
rNPA and rNPB, the reactivity of human sera with rMBP was also measured. NP-specific 
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reactivities were expressed as the following ratio: OD'50 measured with rNP A or rNPB/OD"o 
measured with rMBP. An "lCreaSe in this ratio for paired serum samples of at least a factor 2.0 
was considered indicative ofa recent influenza vims infection. 
RESULTS 
Recombinant NPs of influenza viruses A and B 
After induction of expression and purification by affinity chromatography, the 
recombinant proteins rNPA and rNPB were analyzed by SDS-PAGE. As 
shown in figure lA, highly purified protein preparations with molecular 
masses of 100 kD for rNP A and 107 kD for rNPB (including 40 kD for MBP) 
were obtained. The difference in the molecular masses between rNP A and 
rNPB is in accordance with the difference in the lengths of the coding 
sequences for both proteins (1,494 bp for the NP of influenza virus A and 
1,680 bp for the NP of influenza virus B). The identities of rNPA and rNPB 
were confirmed by Western blot analysis. Rabbit antiserum raised against an 
influenza virus A reacted only with rNP A and not with rNPB, whereas a rabbit 
antiserum directed against an influenza virus B showed reactivity with rNPB 
but not with rNPA (Figure 1B and C, respectively). The identities of the 
recombinant proteins were fmiher confirmed in indirect ELISAs with rabbit 
and ferret antisera raised against influenza viruses A and B which showed 
reactivity only with the homologous rNPA and rNPB, respectively (Figure 2). 
Detection oflgA antibodies in patient sera by capture IgA NP ELISA 
Serum samples collected at consecutive time points from patients with 
confirmed influenza virus A and B infections were analyzed for the presence 
of NP-specific IgA antibodies. For the group of patients infected with 
influenza virus A, an IgA response against the NP of influenza virus A but not 
influenza virus B was measured (Figure 3A). The IgA response peaked at day 
21 and subsequently declined. Sera from 10 of 17 patients (58.8%) showed 
reactivity with rNPA at day 21, while serum from only 1 patient (5.9%) 
showed reactivity with rNPB at this time point (Figure 4A). For the group of 
patients infected with influenza virus B, a type-specific IgA response against 
NP was observed. The response showed a peak 6 days after the onset of 
clinical symptoms and slowly declined by day 28 (Figure 3B). For tlllS group 
of patients, sera from two patients (8.3%) showed reactivity with rNPB on day 
1 (Figure 4B). TillS Illunber increased until sera from 16 patients (66.7%) 
showed reactivity by day 6. Sera from four patients (16.7%) showed reactivity 
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with rNP A on day I but tillS number did not increase during the course of 
infection. 
2 3 2 3 2 3 
100kD __ 
A B c 
Figure 1. Analysis of rNPA and rNPB by SDS-PAGE and Westem blot. rMBP (lane I), 
rNPA (lane 2) and rNPB (lane 3) were separated on a 10% SDS-PAGE gel and stained with 
Coomassie Brilliant Blue (A) or transferred to nitrocellulose membranes which were 
incubated with a rabbit sennn specific for influenza virus A (B) or influenza vims B (C). 
Detection ofIgG antibodies in patient sera by indirect IgG NP ELISA 
The same serum samples were also analyzed for NP-specific IgG antibodies. 
For the group of patients infected with influenza virus A, a type-specific IgG 
response against NP was observed (Figure 3C). No reactivity was measured 
with the heterotypic rNPB. The NP-specific IgG response reached a maximum 
at 21 days after the onset of clinical symptoms and subsequently declined. For 
sera from 15 of 17 patients (88.2%) an increase in reactivity with rNPA was 
observed on day 21, whereas sera from none of these patients showed 
reactivity with rNPB (Figure 4A). In the influenza vinls B-infected patients, a 
strong IgG response against the homologous NP was observed, and this 
response increased at least until day 28 after the onset of clinical symptoms 
(Figure 3D). For this group, sera from 23 of 24 patients (95.8%) showed an 
increase in reactivity with rNPB on day 28, while only 3 patients (12.5%) 
showed an increase in reactivity with rNPA (Figure 4B). In addition to rNP A 
and rNPB, the reactivities of sera with rMBP were also measured. The 
reactivity with MBP did not change during the time course of influenza virus 
A or B infection (data not shown). 
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Figure 2. Confumation of the identity of rNPA and rNPB in indirect IgO NP-ELISA's. Plates 
were coated with rNPA (A and C) or rNPB (B and D) and incubated with ferret (A and B) or 
rabbit (C and D) antisera raised against influenza vims A (solid circles) or influenza vims B 
(open circles). 
Compat'ison of the indirect IgG NP ELISA and the HI assay 
In the ill assay, 13 of 16 (81.3%) patients infected with influenza virus A 
showed a fourfold rise in sel1lm antibody titer (between day I and day 21) 
against influenza vil1ls A, wlnle 88.2% showed an NP-specific IgO response 
(Figure 4A). Three patients who showed NP-specific IgO responses did not 
show a titer rise in the ill assay, whereas in two patients a rise in the HI titer 
was observed but no NP-specific IgO response was observed. None of the 
influenza virus A-infected patients showed an influenza virus B NP-specific 
IgO response, whereas by the ill assay the senUll of one patient showed a rise 
in titer against influenza virus B. Among the patients infected with influenza 
virus B, the sera of 16 of 22 (72.7%) patients showed rises in titers against 
influenza virus B (between day 1 and day 28) by the ill assay, while the sera 
of 95.8% showed NP-specific IgO responses (Figure 4B). For five patients, 
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IgG responses against NP were observed in the absence of at least fourfold 
rises in titer by the HI assay. The serum of one patient did not show an NP-
specific IgG response and no rise in titer by the ill assay. The sera of three 
patients showed influenza virus A and B NP-specific IgG responses. Serum 
from one of those tluee patients and sera from another two patients showed 
rises in titer to influenza viruses A and B by the ill assay. 
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Figure 3. IgA (A and B) and IgG (C and D) responses in influenza vims A (A and C) or B (B 
and D) -infected patients as measured by capture IgA NP-ELISA's and indirect IgG NP-
ELISA's using rNPA (solid circles) and rNPB (open circles). In the capture IgA NP-ELISA's, 
sera were measured against rNPA and rNPB and NP-specific reactivities expressed as the ratio: 
OD"~m' patient senull/OD"Onm negative control senUll. In the indirect IgG NP-ELISA's, sera 
were measured against rMBP, rNPA and rNPB and NP-specific reactivities expressed as the 
ratio: OD"Onm measured on rNPA or rNPB/OD4SO,,, measured on rMEP. 11,e mean values of 
the influenza vims A (n~17) and B (n~24) -infected patients on each time point are presented 
(+/- SEM). 
128 
Chapter 6 
,1 
A b::"' B I _2117 ." m, 
7117 ~, 
." 16124 
gA Np·ElISA 
" 
10/17 
..... 4124 ~i17 H/24 " 
4117 -~, I 9G NP-ELISA 
"" 
,W, 
15/17 -~, 
" (1;17 
23!"l4 
13116 )IaI= 
Pl1l6 "m " 
HI assay 
o 20 40 60 80 o 20 40 60 80 100 
percentage positives 
Figure 4. Percentages influenza vims A (A) or influenza vims B (B) -infected patients 
showing NP-specific antibody responses as measured by the captnre IgA NP-ELISA's and 
indirect IgG NP-ELISA's, and percentages infected patients showing titre rises in the HI assay. 
Results of sera si (day i), s2 (day 6) and s3 (day 2i for influenza vims A-infected patients and 
day 28 for influenza vims B-infected patients) are sholVn for the capture IgA NP-ELISA's. For 
the indirect IgG NP-ELISA's, resuits of paired sampies (s2 and s3 compared to si) are 
shown. In the HI assays 83 was compared to s 1. Sera were measured against influenza virus 
type A (solid bars) and influenza vims type B (open bars). 
DISCUSSION 
In the present paper, recombinant NPs of influenza viruses A and B were used 
for the development of ELISA systems which can detect vims-specific IgA 
and IgG semm antibodies. By using serum samples fi-om laboratory animals 
experimentally immunized with influenza viruses A and B and from humans 
with confirmed influenza virus A or B infections, the specificities of these 
ELISAs were confirmed. In the majority of the patients with influenza, virus 
type-specific antibodies were detected, demonstrating the diagnostic value of 
these recombinant NP-based ELISAs. These assays may replace the 
commonly used ill and CF assays for the serodiagnosis of influenza vil'lls 
infections and can be performed when respiratory specimens are not available 
or to confirm results obtained by culture procedures with respiratOlY 
specimens. 
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Capture IgA NP-ELISAs were developed for the detection of influenza virus 
A and B NP-specific IgA senUll antibodies with virus type-specific 
recombinant NP directly labeled with HRP. IgA responses were detected 
within 21 days after the onset of clinical symptoms in 5S.S% of the influenza 
virus A-infected patients and 66.7% of the influenza virus B-infected patients. 
These perecentages are comparable to the percentages of patients with virus-
specific IgA responses repot1ed in other studies (3,6, IS). The sera of four 
patients with confn'l1led influenza virus B infections had IgA antibodies 
directed to influenza virus A fi'Oll1 the fll'st day of clinical onset onward. These 
patients may have suffered fi'om a recent infection with an influenza A virus. 
Since influenza viruses of type A have also circulated in the 1994 and 1995 
influenza season, tllis is a likely explanation. Since the level of preexisting 
influenza NP-specific IgA antibody levels is low, the capture IgA NP-ELISAs 
do not require paired serum samples and, therefore, allow rapid serodiagnosis 
of influenza virus infections. Tllis ELISA can be considered an alternative to 
assays that measure IgG serum antibodies when only one serum sample is 
available. 
In addition to the capture IgA NP-ELISAs, virus type-specific recombinant 
NP was also used for the detection of influenza vil1ls A and B NP-specific IgG 
serum antibodies in indirect IgG NP-ELISAs. By these ELISAs, IgG antibody 
rises could be detected in almost all of the influenza vil1ls A and B-infected 
patients. Although in these ELISAs serum antibodies were measured against 
influenza vims NP, while in the HI assay serum antibodies directed against the 
hemagglutinin (HA) were measured, the results of both assays were compared 
to evaluate the diagnostic value ofthe IgG NP-ELISAs. The results of the IgG 
NP-ELISAs for the detection of influenza virus A-specific antibodies 
compared well with the results obtained by the HI assay. The IgG NP-ELISA 
for the measurement of influenza vil1ls B-specific antibodies, however, 
detected a hlgher percentage of patients with increased antibody titers than the 
HI assay, which is in agreement with the results of earlier studies2,11,14,16,17,22,2J. 
In contrast to antibodies of the IgA and IgG isotypes, the diagnostic value of 
IgM antibodies in influenza vil1ls infection seems to be limited. Although the 
measurement of IgM responses has been shown to be of diagnostic value in 
primmy influenza infection3,18, IgA and IgG antibody responses predominate 
in influenza vims-infected patients5,7,1I. Therefore, the measurement of IgG 
and IgA antibody responses is preferred for the serologic confn'11lation of 
influenza virus infections. 
The division of influenza A and B viruses is based on antigenic differences in 
the NPs and matrix proteins. Indeed, no rises in influenza virus B NP-specific 
IgG antibody titers were measured in the influenza vil1ls A-infected patients. 
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However, rises in influenza vil11s A and B NP-specific IgG antibodies titers 
were measured in 12.5% of the influenza vil11s B-infected patients. A recent 
influenza virus A infection or simultaneous infection with influenza viruses A 
and B may explain tllis observation. 
Since the NP is well conserved within the influenza A viruses, the IgG NP-
ELISA enables the detection of antibodies induced by influenza A viruses of 
both circulating subtypes (HIN 1 and H3N2). Fmihermore, tllis assay does not 
require the atmual adjustment of the viral antigen preparations, in contrast to 
the HI assay, which measures antibodies against the llighly variable 
hemagglutinin. Two of the influenza virus A-infected patients seemed to be 
infected with an HINI virus since in the HI assay only rises in titer against an 
HINI virus were measured (data not shown). Rises in NP-specific IgG 
antibody levels could be measured in these individuals, even though the 
recombinant NP used in the IgG NP-ELISA was derived from an H3N2 virus. 
Although the reactivities with MBP differed between patients, none of them 
showed increases in MBP-specific IgG antibody levels during the time course 
after the infection. Thus, it does not seem to be necessary to measure MBP 
antibody titers separately to be able to detect rises in the levels of influenza 
virus-induced antibodies in the IgG NP-ELISAs. 
In conclusion, recombinant influenza vil11s NPs were produced in virtually 
unlimited quantities and were purified to a lligh degree. These bacterially 
expressed viral atltigens proved to be valuable reagents for the development of 
ELISA systems for tile detection of vil11s-specific IgA and IgG antibodies 
which can be used for tile serodiagnosis of influenza vil11s type A and B 
infections. Especially for the detection ofNP-specific IgA antibodies, the IgA 
NP-ELISA proved to be valuable since it allows early diagnosis and does not 
require paired serum samples. 
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Influenza viruses continue to be a major pathogen to man affecting a 
considerable percentage of the human population every year. While most 
influenza virus infected individuals completely recover from infection, 
infection with influenza virus can be accompanied with severe 
complications which even may result in death. This is especially true for 
people belonging to influenza risk groups. Vaccination remains the major 
means to prevent infection or to reduce influenza-associated illness in these 
people30 • The currently used influenza vaccines are trivalent, i.e. contain 
representatives of influenza virus A HINI and H3N2 as well as influenza 
virus B and are administered as inactivated whole virus, as split virus or as 
purified haemagglutinin (HA) and neuraminidase (NA). Due to antigenic 
drift of influenza viruses, influenza vaccines need to be reformulated 
regularly to ensure a close match between the viruses represented in the 
vaccine and those circulating in humans. Partly as a result of tlus antigenic 
drift, vaccination needs to be repeated annually. Influenza vaccines are 
produced using embryonated chicken eggs and the vaccine viruses usually 
are 'high-growth' reassoliant viruses. These reassOliant viruses are 
generated after dual infection of eggs with a selected vaccine strain and a 
virus adapted to replicate to high titers in eggs (a virus with a high-growth 
phenotype). Those reassortant viruses which contain the appropriate surface 
glycoproteins and display a high-growth phenotype are selected for vaccine 
production. 
The use of embryonated chicken eggs for vaccine production suffers from 
major disadvantages. Most importantly, virus production in eggs lacks 
flexibility. The use of eggs requires long-term plaruling by vaccine 
manufacturers and the availability of eggs may become a problem in case of 
a sudden need for large quantities of vaccine, for example in pandemic 
situations. One cannot just order chickens to lay more eggs! A more flexible 
source for production of influenza vaccines would thus be needed. The use 
of continuous cell lines for production of influenza vaccines may fulfil this 
need as they are easily maintained and their production can be scaled up in 
short periods of time, allowing vaccine production at any time in any 
quantities. Other advantages of the use of continuous cell lines would be 
that thus propagated influenza viruses usually more closely resemble the 
original human isolate than do viruses propagated in eggs. In general, they 
also constitute a more homogenous population of influenza viruses,7,39,4o,50, 
A disadvantage of most cell lines is the requirement to grow cells in the 
presence of fetal bovine serum which interferes with the activity of trypsin, 
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necessary for propagation of most influenza A viruses, and complicates 
standardization of culture conditions. A novel MDCK cell line, adapted to 
grow without serum, MDCK-SFl, has been developed and vaccine studies 
already have shown that MDCK-SFI cell-derived vaccines are equally 
efficient as egg-derived vaccines8•9,l!. Chapter 2 describes the use of these 
MDCK -SF 1 cells for generation and propagation of high-growth reassortant 
influenza A viruses as a possible alternative to the current influenza vaccine 
production procedure in embryonated chicken eggs. It was shown that with 
these cells, like with eggs, high-growth reassOitant influenza A viruses 
containing the appropriate surface glycoproteins can be generated relatively 
easily by infection of MDCK-SFI cells with a virus containing the desired 
surface glycoproteins and a second virus with a high-growth phenotype. The 
use of a HINI virus with a high-growth phenotype (AlPRJ8/34) in dual 
infections with H3N2 viruses for generation of high-growth H3N2 viruses, 
and, conversely, the use of a H3N2 high-growth virus (AlHKl2/68) in dual 
infections with HIN I viruses to yield high-growth HINI viruses, were 
shown to be advantageous with respect to both selection of reassOitant 
viruses containing the desired surface glycoproteins (using antisera raised 
against HINI and H3N2 viruses) and subsequent genetic characterization of 
these viruses. The origin of HA was determined in haemagglutination 
inhibition (HI) assays while the origin of the other gene segments was 
determined by RT-PCR and restriction enzyme analysis, both of which 
assays allow easy discrimination between viruses belonging to different 
subtypes. In this way, it was shown that reassortant viruses obtained from 
dual infections of MDCK-SFl cells with AlPRJ8/34 and H3N2 viruses 
contained the HA and NA of the H3N2 viruses while the matrix protein and 
polymerase P A protein-encoding gene segments were derived from the 
high-growth parent. Reassortant viruses obtained from dual infection of 
MDCK-SFl cells with AlHKl2/68 and HlNl viruses contained the HA and 
NA of the HINI viruses wllile the matrix protein and polymerase PBl 
protein-encoding gene segments originated from the high-growth parent. 
Reassortant viruses propagated in MDCK -SF 1 cells, in general, yielded 
higher amounts of haemagglutinating units (HAU) per volume than the 
corresponding non high-growth parent. The procedure described to generate 
and characterize high-growth reassortant influenza A viruses in combination 
with the advantages of a continuous cell line in general, as well as the ability 
to culture cells in the absence of serum in pmticular, makes the use of 
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MDCK-SFI cells an attractive alternative to the current vaccine production 
procedure in embryonated chicken eggs. 
A relatively novel method to generate reassortant influenza viruses is 
reverse genetics. By tltis method, RNP complexes (RNPs) are transfected to 
influenza virus-infected cells allowing reassortment between the gene 
segments of the virus and the gene segment(s) contained within the 
transfected RNPs. While in double infected eggs or MDCK-SFI cells in 
principle 256 (28) different combinations of gene segments can be made 
(and as many different viruses), by reverse genetics reassortment can be 
limited to the gene segments encoding HA and NA and this more controlled 
reassortment can be considered an advantage in the selection of reassortant 
viruses for vaccine purposes. However, infection of cells with a high-growth 
virus followed by transfection with RNPs containing the desired HA and 
NA gene segments only, may not always be suffcient to obtain (high-
growth) reassortant viruses. Indeed, results obtained from studies in which 
reassortant viruses were generated by dual infection suggest that there are 
limitations towards reassOlimentl2·19.42.52.lhl, Iho;l, and not all combinations of 
gene segments may yield viable viruses. If reverse genetics will prove to be 
a universally applicable method, then it may replace current procedures for 
generating high-growth reassOliant viruses for vaccine purposes. 
Besides studies aiming at improvement of current influenza vaccine 
production procedures, numerous studies are foccussing on novel influenza 
vaccines making use of several adjuvant formulations and antigen 
presentation forms. One antigen presentation form that has received 
considerable attention is the immune stimulating complex (ISCOM). 
ISCOM-based experimental vaccines have been shown to be potent inducers 
of both humoral and cellular immune responses which, in mtimal models, 
have been shown to confer protection against challenge infection36•37 , and 
ISCOM-based influenza vaccines are currently being evaluated in clinical 
phase III trials in humans' ·13•38• In addition, an ISCOM-based influenza 
vaccine has already been licensed for use in horses. ISCOMs were originally 
developed as an antigen presentation form for viral membrane proteins" and 
most studies concerning the development of ISCOM-based vaccines for 
influenza have focussed on the surface glycoprotein HA as a model antigen. 
HA is considered the most important influenza virus antigen with regard to 
protection and, due to its highly hydrophobic membrane-spanning region, is 
incorporated well into the ISCOM structure. This feature is thought to be 
essential for optimal induction of immune responses. Incorporation of less 
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hydrophobic antigens usually requires modification of the antigen with 
hydrophobic sequences which can be achieved by coupling fatty acids to the 
antigen or by recombinant DNA technology. In chapter 3, this latter 
possibility was explored. The necessity of a hydrophobic sequence and 
incorporation into the ISCOM structure for ISCOM-facilitated entry of 
antigen into the MHC class I processing and presentation pathway was 
evaluated using the influenza virus A matrix Ml protein. Recombinant Ml 
protein (rMA) was modified with the transmembrane region of HA to yield 
rMAHA protein. rMAHA protein seemed to incorporate better into ISCOM 
than rMA protein and in vitro analysis of MHC class I presentation of the 
Ml protein-derived, HLA-A2-restricted, peptide GILGFVFTL (aa 58 to 66) 
showed that the addition of the transmembrane region of HA to the Ml 
protein favoured MHC class I presentation to specific cytotoxic T 
lymphocytes (CTL). To determine whether or not for this purpose 
incorporation into the ISCOM structure was essential, pre-formed 'empty' 
ISCOMs were mixed with the respective proteins. MHC class I processing 
and presentation was observed for both rMA and rMAHA protein mixed 
with empty ISCOMs indicating that incorporation of antigen is not 
necessary for its delivelY into the MHC class I pathway. In fact, MHC class 
I presentation of both antigen preparations was more efficient than rMAHA 
protein incorporated into ISCOMs and was best for rMAHA protein mixed 
with empty ISCOMs. FUl1hermore, it was shown that mixing of the 
respective proteins with empty ISCOMs was necessary for ently of the 
proteins into the MHC class I pathway, since pre-incubation of cells with 
empty ISCOMs followed by washing the cells and subsequent incubation 
with the proteins did not result in MHC class I presentation. Thus, 
presumably rMA and lMAHA protein associate with empty ISCOMs and 
the presence of the transmembrane region of HA added to this. In another 
experiment using recombinant nucleoprotein (rNP) it was found that rNP 
mixed with empty ISCOMs was processed for MHC class I presentation of 
the HLA-A3-restricted peptide ILRGSVAHK (aa 265 to 273) equally well 
as rNP incorporated into ISCOMs (unpublished data). These results seem to 
conflict with those obtained with the measles virus fusion (F) protein which 
was shown to be processed for MHC class I presentation when it was 
incorporated into ISCOMs but not after mixing with empty ISCOMs'. This 
discrepancy most likely reflects differences in the preparation and nature of 
the antigens. The results of the studies with recombinant matrix protein and 
NP strongly suggest that incorporation of antigen into ISCOMs per se is not 
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necessary for ISCOM-facilitated entry into the MHC class I pathway and 
implicates that the use of ISCOM as an antigen presentation form, for the 
induction of humoral and cellular immune responses, is not restricted to 
antigens containing highly hydrophobic sequences like membrane-spanning 
envelope proteins. 
The observation that ISCOMs facilitate the processing of matrix protein and 
NP for MHC class I presentation to specific CTL in vitro, indicates that 
ISCOM-based vaccines may be used to induce in vivo CTL responses 
against these proteins, which are the most abundant viral antigens and 
important targets for CTL6.15.25.26.'7,53. Since the matrix protein and NP are 
relatively well conserved, vaccines based on these proteins would not suffer 
from the necessity of regular reformulation as is the case for the currently 
used vaccines. However, although experimental NP-based vaccines have 
been shown to induce CTL which conferred protective immunity in animal 
models",4'·',·51, it is generally believed that in humans protective immunity 
is primarily mediated by virus-neutralizing antibodies raised against HA and 
NA, and that CTL merely contribute to the clearance of virus-infected cells 
and reduce spread of virus1.2.10.'3.'6. Thus, ISCOM-based vaccines aiming at 
the induction of CTL responses against conserved influenza virus antigens 
only, probably would not suffice to establish long-lasting immunity against 
influenza in humans. ISCOM-based vaccines containing matrix protein and 
NP in addition to the influenza virus surface glycoproteins may be useful for 
the induction of both CTL and virus-neutralizing antibody responses against 
the major influenza virus antigens. 
The conventional MHC class I processing and presentation pathway usually 
requires endogenous protein synthesis. In vil'lls-infected cells, viral proteins 
produced in the cytoplasm are degraded by the proteasome to yield peptides 
which are transpOlied to the ER by TAP. In the ER, the peptides associate 
with MHC class I molecules and the resulting complexes traverse the Golgi 
system to be presented at the cell surface for recognition by specific CD8+ 
CTL. However, numerous studies have already shown that exogenous 
proteins, which normally are processed in endosomes for MHC class II 
presentation to CD4+ Th cells, can be processed for MHC class I 
presentation to CD8+ CTL as well, and several alternative mechanisms for 
MHC class I processing and presentation have been proposed,s.".'1,45.5'. 
These studies mainly focussed on macrophages and dendritic cells and the 
antigen used was often particulate (e.g. bacteria or antigen coupled to 
beads). MHC class I processing and presentation by B-Iymphoblastoid cell 
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line (B-LCL) cells has been described for exogenous proteins incorporated 
into or associated with ISCOM7"h;, th";,, Alternatively, exogenous proteins 
have been shown to enter the MHC class I pathway of B-Iymphocytes by 
receptor-mediated endocytosis",,20,23, Chapter 4 describes MHC class I 
processing and presentation of exogenous protein by B-LCL cells not 
attributable to these mechanisms. MHC class I presentation of exogenous 
rNP by B-LCL cells was demonstrated in CTL assays and lymphocyte 
stimulation tests (LST) using HLA-A3 and HLA-B27-restricted CTL with 
specificity for the NP-derived epitopes ILRGSVAHK (aa 265 to 273) and 
SRYWAIRTR (aa 383 to 391), respectively. HLA-B27-associated 
presentation required low amounts of protein (as little as 0.2 ~lg/ml was 
sufficient) and was demonstrated for rNP containing the proper epitope but 
not for rNP with a mutated epitope, for rNP of influenza virus B or for 
control rMBP. MHC class I presentation associated with HLA-A3 required 
significantly higher doses of protein and, like HLA-B27, was observed only 
for rNP containing the appropriate epitope. Using inhibitors of the 
conventional MHC class I pathway (the proteasome inhibitor lactacystin and 
the ER transport inhibitor brefeldin A), and inhibitors of proteolysis in 
endosomes (chloroquine and NI-I,CI), it was demonstrated that processing 
and presentation of rNP most likely followed the conventional MHC class I 
pathway. In contrast, results obtained with cells lacking a functional TAP 
suggested alternative mechanisms for MHC class I processing and 
presentation. Processing of rNP in endosomes and loading of recycled MHC 
class I molecules with peptide in these compartments may be a major route 
exploited by these cells. The results of this study thus not only demonstrate 
that B-LCL cells can process exogenous rNP for presentation to CTL but 
also that multiple pathways may exist for MHC class I processing and 
presentation of exogenous proteins. 
Although NP is relatively well conserved, mutations in this protein do 
OCCUI'. Since NP harbours many CTL epitopes (at least eight epitopes are 
known), amino acid mutations in this protein may affect processing and 
presentation of these epitopes andlor recognition by specific CTL. In 
chapter 5, the effect of mutations, found within a CTL epitope of the 
influenza virus A NP, with respect to MHC class I presentation and 
recognition by specific CTL was studied. Part of the NP gene, containing 
four different CTL epitopes, of influenza A H3N2 viruses isolated from 
1989 to 1999 in The Netherlands was sequenced. A R384K mutation in the 
HLA-B8 and HLA-B27-restricted CTL epitopes ELRSRYWAI (aa 380 to 
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388) and SRYWAIRTR (aa 383 to 391), respectively, was found in part of 
the influenza A viruses isolated in the influenza season 1989-1990, but not 
in the influenza A viruses isolated in later seasons. This mutation has 
previously been described for two viruses isolated in 1971 and 1972". In the 
influenza season 1993-1994, another mutation at the same position 
(R384G), that did not occur before 1993, was found in all sequenced 
isolates of this season and showed to be conserved. Indeed, this mutation 
was found in all sequenced influenza A viruses isolated from 1993 onwards, 
and has also been found in viruses isolated in Japan after 199324 • In contrast 
to the HLA-B8 and HLA-B27 epitopes, no mutations were found that 
affected the other two CTL epitopes (HLA-A3 and HLA-B37) present in the 
sequenced NP region. In CTL assays, it was shown that B-LCL cells 
infected with mutant influenza viruses or recombinant vaccinia virus 
expressing NP with a R384G mutation, or B-LCL cells pulsed with a 9-mer 
peptide (representing the epitope) containing the R384K or R384G mutation 
were no longer recognized by HLA-B27-restricted CTL. Exactly the same 
type of mutations (R264K and R264G) have been associated with loss of 
recognition of the HLA-B27-restricted HIV-l Gag epitope KRWIILGLNK 
(aa 263 to 272) by specific CTL29. Thus, a mutation at the second residue of 
HLA-B27-restricted epitopes, which is a critical anchor residue position, 
completely abrogates MHC class I presentation and subsequent recognition 
by HLA-B27-restricted CTL. 
The introduction of mutations in CTL epitopes as a possible mechanism to 
escape CTL-mediated immunity has thus far only be described for viruses 
causing persitent infections, like HIV-l, and a mutation in a HLA-B27-
restricted epitope of the HIV -I Gag protein has been associated with 
progression to AIDS"·I6·,,·27.33.3'. It has been questioned whether such a 
mechanism could be exploited by influenza viruses". First, influenza 
viruses cause acute infections in immunocompetent individuals and, as a 
result, there may be little time for evolution of influenza viruses and the 
emergence of CTL escape mutants within an individual. Second, most of the 
currently known CTL epitopes are located within NP. This protein plays a 
crucial role in transcription and replication of the virus and mutations at a 
certain position will not be tolerated because of functional constraints, again 
limiting the oppertunities for the emergence of CTL escape mutants. The 
fact that we did not find any amino acid mutations in the HLA-A3- and 
HLA-B37-restricted epitopes may reflect this limitation. Nevertheless, the 
results of our study suggest that mutations introduced in CTL epitopes 
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within NP, that do not impose functional constraints on NP, are selected for 
by influenza virus to allow escape from CTL-mediated immunity. In 
support of this, CTL escape mutant viruses with amino acid changes in a 
CTL epitope of NP have been isolated recently from influenza virus-
infected mice transgenic for a NP-specific T cell receptor". Although it is 
unknown from where the R3840 mutant virus originated, it may have 
emerged in HLA-B27 positive individuals which constitute approximately 
8% of the Caucasian population. The immune pressure mediated by HLA-
B27-restricted CTL in these individuals may have been sufficient to drive 
the selection process. Since the R3840 mutation did not have a negative 
effect on virus replication, the mutant viruses may have spread in the human 
population ultimately replacing viruses containing the intact epitope. 
In addition to studies related to vaccine development and to MHC class I 
processing and presentation of influenza virus antigens, one chapter deals 
with influenza serology. Chapter 6 describes the development of ELISAs for 
detection of NP-specific antibodies of the IgA and IgO isotypes in sera of 
influenza virus A or B-infected patients using rNP derived from 
NNetheriandsl18/94;H3N2 and B/Harbin!7l94. Both the IgA and IgO 
ELISA were shown to be specific and the IgO ELISA compared well with 
the commonly used HI assay. Wllile in the HI assay serum antibodies 
against the highly variable HA are measured, the IgO ELISA measures 
antibodies against the relatively well conserved NP. The use of NP in 
ELISAs can be considered an advantage since these ELISAs, in contrast to 
the HI assay, do not require annual adjustments of the antigen used. 
Moreover, these ELISAs can be used to measure NP-specific antibodies in 
patients infected with either of the currently circulating influenza virus A 
subtypes (HINI and H3N2), while in the HI assay representatives of both 
these subtypes need to be included. In addition, there are some practical 
advantages of the NP-based ELISAs over the HI assay. The recombinant 
NPs of influenza virus A and B can be produced in large quantities with 
high purity and the amount of antigen used can be defined accurately. In 
contrast, in the HI assay whole virus and erythrocytes are uscd of which the 
quality may vary and the appropriate amount of antigen used is more 
difficult to determine since it is related to the amount of haemagglutinating 
units (HAU). Also, the read out ofELISAs, unlike that of HI assays, can be 
incorporated easily into automated procedures. While for influenza 
serology, NP-based ELISAs may be a useful alternative to the currently 
used HI assays, the latter still will be required for influenza virus subtype-
144 
Chapter 7 
specific surveillance purposes. Indeed, unlike the NP-based ELISAs, the HI 
assay can be used to discriminate between influenza virus A subtypes and 
variants of influenza virus A subtypes as well as influenza virus B and thus 
provide information about antigenic properties of the circulating influenza 
viruses. 
In conclusion, the studies described in this thesis have largely focussed on 
vaccine development and on MHC class I processing and presentation of 
influenza virus antigens. It was shown that a continuous cell line offers 
opportunities to improve current vaccine production procedures and that the 
main goal of current vaccines, the induction of virus-neutralizing antibodies 
against the surface glycoproteins HA and NA, may be extended to the 
induction of CTL responses against the internal matrix protein and NP by 
using ISCOM as an antigen presentation form. The observation that 
incorporation of these influenza virus antigens in the ISCOM structure is 
not a prerequisite for entry into the MHC class I pathway adds value to the 
use of ISCOMs as the basis of alternative influenza vaccines. The efficacy 
of vaccines aiming at the induction of virus-neutralizing antibodies and CTL 
responses, however, would not only depend on the antigenic match between 
the surface glycoproteins contained within the vaccine virus and those of 
the circulating viruses, but also on the match of CTL epitopes between these 
viruses. Indeed, like mutations in HA and NA allowing escape from 
antibody-mediated immunity, mutations in CTL epitopes may allow escape 
from CTL-mediated immunity and the emergence of CTL escape mutant 
viruses in the population may limit the efficacy of such vaccines. Thus, in 
developing influenza vaccins aiming at the induction of both virus-
neutralizing antibodies and CTL responses one has to take into account both 
antigenic drift of HA and NA and the possibility of CTL escape mutants. 
Although the variability of influenza viruses will remain and will continue 
to limit the efficacy of vaccination against influenza, the development of 
novel generations of influenza vaccines as well as alternative production 
procedures undoubtedly will contribute to the prevention and control of 
influenza. 
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Influenza A en B virussen zijn de veroorzakers van een acute respiratoire 
infectieziekte bekend als influenza of griep. Influenza A virussen worden 
onderverdeeld op basis van de typen oppervlakteglycoproteinen 
haemagglutinine (HA) en neuraminidase (NA) waarvan respectievelijk IS 
(HI tim HIS) en 9 typen (NI tim N9) kUlmen worden onderscheiden. Op dit 
moment komen bij mensen, naast influenza virus B, de influenza virus A 
subtypen HINI en H3N2 voor. Het continu veranderen van influenza 
virllssen door introductie van mutaties in HA en NA (antigene drift) is de 
drijvende kracht achter de jaarlijks in de winter terugkerende 
griepepidemieen. HoeweI de meeste mensen zonder blijvende schade 
herstellen van griep, kan infectie met het influenzavirus gepaard gaan met 
complicaties met verstrekkende gevolgen, met name bij mensen die tot de 
influenzarisicogroepen gerekend worden zoals 65+ -ers, diabetici, mensen 
met chronische hart of luchtwegaandoeningen en mensen met een 
venninderde werking van het inunuunsysteem. Om de ernst en het 
voorkomen van infectie met het virus te voorkomen en eventuele 
complicaties te venninderen, wordt vaccinatie als preventieve maatregel 
aanbevolen. Thans gebruikte influenzavaccins bevatten geinactiveerd virus 
of virale antigenen (HA en NA) en zijn trivalent, dat wil zeggen dat de 
beide typen influenza A virussen (HINI en H3N2) en influenzavirus B er in 
vertegenwoordigd zijn. De in dit proefschrift besclueven studies zijn in de 
meest algemene zin gerelateerd aan vaccinontwikkeling met speciale 
aandacht voor MI-IC klasse I-gerestricteerde processing en presentatie van 
virale antigenen. Een hoofdstuk is gewijd aan serologische diagnostiek van 
influenzavirusinfectie. 
Influenzavirussen die in het vaccin worden opgenomen worden 
geproduceerd in geembryoneerde kippeneieren. Hiervoor worden veelal 
'high-growth' reassortant influenza A virus sell gebruikt die zich tot hoge 
titers vermeerderen. Deze virus sen worden verkregell door dubbelinfectie 
van geembryoneerde kippeneieren met het virus waartegen bescherming 
moet worden opgewekt (vaccinvirus) en een virus met een high-growth 
fenotype, en die reassortant virussen welke de oppervlakteglycoproteinen 
(HA en NA) van het vaccinvirus en een high-growth fenotype bezitten 
worden geselecteerd voor vaccinproductie. Het gebruik van kippeneieren 
voor de productie van influenzavaccins kent een aantal nadeIen wam'van het 
gebrek aan flexibiliteit, met als consequentie een noodzakelijke lange-
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tenuijn plmming, de belangrijkste is. Hoofdstuk 2 besclu'ijft het gebruik van 
een continue cellijn, geadapteerd aan groei in serum-vrij medium (MDCK-
SF 1), als mogelijk alternatief voor de tl13ns toegepaste influenzavaccin-
productieprocedure in kippeneieren. Analoog aan de methode in 
kippeneieren werden reassortant influenza A virussen gegenereerd in 
MDCK-SFI cell en door dubbelinfectie met geselecteerde HINI of H3N2 
vaccinvirussen en H3N2 ofHINI high-growth virussen. De origine van elk 
van de gensegmenten van de reassOliantvirussen alsmede hun 'groei-
eigenschappen' in MDCK-SFI cellen werden bepaald. Uit deze studie is 
gebleken dat reassortant influenza A virussen in deze cellen, net als in 
kippeneieren, gegenereerd kunnen worden door dubbelinfectie, dat de 
genetische samenstelling van deze virussen vrij eenvoudig en snel kan 
worden bepaald, en dat de aldus verkregen reassortant virus sen, die allemaal 
het MA eiwit coderende RNA segment van het high-growth virus bezitten, 
meestal tot hogere virusproduktie leiden. 
Naast studies gericht op het verbeteren van huidige vaccinproductie-
procedures, wordt veel aandacht besteed aan de ontwikkeling van 
alternatieve influenzavaccins waarbij gebruik wordt gemaakt van 
verschillende adjuvantia en antigeenpresentatievonuen. Een voorbeeld 
hiervan zijn vaccins gebaseerd op de zogenaamde immuunstimulerend 
complex (ISCOM) structUUl', opgebouwd uit lipiden, cholesterol en het 
adjuvans QuilA waarin virale eiwitten geYncorporeerd kUlmen worden. 
Talrijke studies met ISCOM-gebaseerde experimentele vaccins in 
dienuodellen hebben aangetoond dat zowel humorale als cellulaire 
inlluuumesponsen ge1nduceerd ktlmlen worden die meestal een excellente 
bescherming bieden tegen challenge infecties. Bovendien zijn ISCOM-
gebaseerde influenzavaccins reeds getest in fase III studies in mensen en is 
een ISCOM-gebaseerd influenzavaccin voor pam'den op de markt. De 
meeste studies met ISCOM-gebaseerde vaccins zijn uitgevoerd met virale 
envelopeiwitten (bijvoorbeeld influenzavirus HA en NA) omdat deze, 
dankzij de hydrofobe transmembraansequenties, gemakkelijk te 
incorporeren zijn in de ISCOM structuur. Incorporatie van de meer 
hydrofiele interne virale eiwitten is doorgaans aileen mogelijk na 
modificatie van het eiwit met hydrofobe sequenties bijvoorbeeld door 
koppeling van vetZUl'en aan het eiwit of door middel van recombinant DNA 
technologie. Hoofdstuk 3 bescluijft een studie waarbij deze laatste 
mogelijkheid werd onderzocht. ISCOMs werden gemaakt in aanwezigheid 
van recombinant matrixeiwit met (rMAHA) of zonder (rMA) 
transmembraansequentie van HA. De noodzaak van een hydrofobe 
sequentie en incorporatie in de ISCOM structUUl' van het matrixeiwit met 
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betrekking tot MHC klasse I processing en presentatie van het HLA-A2-
gerestricteerde epitoop GILGFVFTL (aminozlll'en 58 tim 63) werd 
onderzocht gebruikmakend van cytotoxische T lymphocyten (CTL) die dit 
epitoop herkennen. rMAHA leek betel' ge¥ncorporeerd te worden in 
ISCOMs dan rMA, en MHC klasse I presentatie aan specifieke CTL in vitro 
werd aileen waargenomen voor rMAHA-ISCOMs. Echter, MHC klasse I 
presentatie werd ook waargenomen voor rMA en rMAHA gemengd met 
ISCOMs, waarbij de combinatie van ISCOMs en rMAHA de beste bleek. 
De conclusie van deze studie is dat incorporatie van influenzavirus 
Illatrixeiwit in ISCOMs niet noodzakelijk is, maar dat associatie met 
ISCOMs voldoende is voor ISCOM-gemedieerde processing en presentatie 
via de MHC klasse I pathway. Het feit dat incorporatie niet noodzakelijk is 
betekent dat het gebruik van ISCOMs als antigeenpresentatievorm niet 
gerestricteerd is tot de hydrofobe oppervlakteglycoprote¥nen HA en NA, 
maar ook toegepast zou kunnen worden voor het induceren van 
imll1uunresponsen tegen de ll1eer hydrofiele interne influenzaviruseiwitten 
zoals matrixeiwit en het nUcleoproteine (NP) welke waarschijnlijk 
belangrijke targets zijn voor CTL responsen. Theoretisch zou incorporatie 
van dergelijke eiwitten in ISCOM-gebaseerde influenzavaccins een bredere 
beschenning kunnen geven en wellicht zelfs de jaarlijkse aanpassing aan 
circulerende stannnen mindel' noodzakelijk Illaken. 
Processing van eiwitten voor MHC klasse I-gerestricteerde presentatie aan 
CTL vereist in het algell1een eiwitsynthese in het cytoplasma van cellen. 
Echter, exogene eiwitten (niet gesynthetiseerd door de cel), welke nonnaal 
worden geprocessed voor MHC klasse II -gerestricteerd presentatie aan T 
helpercellen, kUlmen via alternatieve routes geprocessed worden voor MHC 
kIasse I-gerestricteerde presentatie. Hoofdstuk 4 beschrijft MHC klasse I 
processing en presentatie van exogeen recombinant influenzavirus A NP 
(rNP) door B-lymphoblastoide cellijnen (B-LCL). MHC klasse I presentatie 
van het HLA-A3-gerestricteerde epitoop ILRGSVAHK (265 tim 273) en 
het HLA-B27-gerestricteerde epitoop SRYWAIRTR (383 tim 391) werd 
aangetoond gebruikmakend van specifieke CTL clones. HLA-A3-
geassocieerde presentatie vereiste ongeveer 100 maal hogere concentraties 
exogeen rNP dan HLA-B27-geassocieerde presentatie. De route waarlangs 
exogeen rNP werd geprocessed voor MHC klasse I presentatie we I'd 
onderzocht gebruiklllakend van remmers van de conventionele MHC klasse 
I processing en presentatie pathway (lactacystine en brefeldine A), remmel'S 
van processing in endosomen (chloroquine en NH4CI) en een cellijn zonder 
een functionele transporter geassocieerd met antigeenprocessing (TAP). De 
resultaten die hiennee werden verkregen duiden erop dat in normale B-LCL 
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cellen processing en presentatie voornamelijk ver/oopt via de conventionele 
MHC klasse I pathway en dat in cellen zonder functioneel TAP processing 
van rNP en associatie van peptiden met MHC klasse I moleculen in 
endosomen waarschijnlijk de meest belangrijke route is. 
De invloed van een mutatie in een CTL epitoop met betrekking tot MHC 
klasse I presentatie en herkenning door specifieke CTL is beschreven in 
hoofdstuk 5. Van 162 influenza A (H3N2) virussen die hlssen 1989 en 1999 
in Nederland werden gelsoleerd, werd van een deel van het NP gen dat vier 
CTL epitopen bevat, de aminozuurvolgorde bepaald. Een deel van de 
influenzavirussen uit het seizoen 1989-1990 bevatte een R384K mutatie in 
het HLA-B8-gerestricteerde epitoop ELRSRYWAI (380 t/m 388) en het 
HLA-B27-gerestricteerde epitoop SRYWAIRTR (384 t/m 391). Deze 
R384K mutatie werd niet meer aangetroffen bij influenzavirussen 
gelsoleerd na 1990. Een andere mutatie op dezelfde positie, R384G, werd 
gevonden in aile influenza A H3N2 virussen gelsoleerd vanaf het seizoen 
1993-1994 en leek dus geconserveerd. Geen aminozuunnutaties werden 
aangetroffen in de HLA-A3 en HLA-B37-gerestricteerde epitopen aanwezig 
in het NP. In CTL assays werd getoond dat cellen gelnfecteerd met 
influenza A virussen of recombinant vacciniavirus welke mutant NP tot 
expressie brengen, of gelncubeerd waren met mutante peptides, niet herkend 
werden door HLA-B27-gerestricteerde CTLs. Het introduceren van 
mutaties in CTL epitopen is een strategie die gebruikt word door vil'l1ssen 
die persistente infecties veroorzaken (bv. HIV) om CTL-gemedieerde 
i1l11l1uniteit te omzeilen en mutaties op het tweede aminozuUJ' (ankerresidu) 
van een HLA-B27 epitoop van het HIV -I Gag eiwit zijn in verband 
gebracht met verlies van specifieke CTL activiteit en progressie naar AIDS. 
De resuItaten van deze studie suggereren eenzelfde strategie voor 
influenzavirussen. Dit zou betekenen dat net zoals de continue introductie 
van mutaties in de oppervlakteglycoprotelnen HA en NA influenzavirussen 
de mogelijklleid bieden antilichaam-gemedieerde im1l1uniteit te omzeilen, 
mutaties in CTL epitopen influenzavil'l1ssen in staat stellen te ontsnappen 
aan CTL-gemedieerde immuniteit. 
Tenslotte beschrijft hoofdstuk 6 de ontwikkeling van enzyme-linked 
im1l1unosorbent assays (ELISAs) voor het meten van NP-specifieke IgA en 
IgG antistoffen in sera van influenzavil'l1s A of B-gelnfecteerde patienten 
gebl'l1ik1l1akend van rNP van influenzavirus A en B. Zowel de IgA als de 
IgG ELISA bleken antistoffen zeer specifiek te kunnen aantonen en de 
resultaten van de IgG ELISA verhielden zich goed tot de thans toegepaste 
haemagglutinatie-inhibitie (HI) test, die HA-specifieke antistoffen meet. 
NP-gebaseerde ELISAs zijn voor bepaalde doeleinden dus een bl'l1ikbaar 
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alternatief voor de HI test en hebben daarnaast nog een aantal voordelen. 
NP is een relatief geconserveerd eiwit en derhalve is het niet nodig om NP 
regelmatig te vervangen en kan in het geval van influenza A Vil'llSSen 
hetzelfde NP gebruikt worden voor het ll1eten van antistoffen geYnduceerd 
door zowel influenza A HINI en H3N2 virussen. Bovendien kan 
recombinant NP in ongelill1iteerde hoeveelheden en met een constante 
kwaliteit worden geproduceerd. Bovendien en is het aflezen van ELISAs 
eenvoudiger en ll1eer objectief dan het aflezen van de HI test. 
Samenvattend kan gesteld worden dat de studies beschl'even in dit 
proefschrift hebben getoond dat het gebrllik van een continue cellijn goede 
mogelijkheden biedt als alternatief voor de huidige vaccinproductie-
procedure in kippeneieren en dat een mogelijke nieuwe generatie 
influenzavaccins gebaseerd op de ISCOM structuur de mogelijkheid biedt 
CTL activiteit te induceren tegen de interne virale antigenen. Hoewel deze 
antigenen relatief goed geconserveerd zijn, dient bij de ontwikkeling van 
influenzavaccins gericht op het induceren van CTL responsen rekening te 
worden gehouden met de mogelijkheid op het ontstaan van CTL escape 
mutanten. Ondanks dat influenzavirussen continu veranderen en dit de 
ontwikkeling van een uniform vaccin moeilijk, zo niet olUllogelijk, maakt, 
zullen nieuwe vaccinproductieprocedures en nieuwe genel'aties 
influenzavaccins bijdragen aan preventie en controle van influenza. 
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